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La schizophrénie est un désordre mental chronique et sévère avec une prévalence 
mondiale d’environ 1 %. Les premiers symptômes psychotiques de cette maladie 
apparaissent généralement à la fin de l’adolescence ou au début de la vie adulte. Les 
symptômes de la schizophrénie sont classés en symptômes positifs, négatifs et 
cognitifs. Les symptômes positifs tels que les hallucinations et délires correspondent à 
la phase psychotique de la maladie, alors que les symptômes négatifs de retrait social 
et diminution de l’expression des émotions sont constamment présents. Les causes de 
la schizophrénie proviennent d’une interaction entre facteurs génétiques et facteurs 
environnementaux, parmi lesquels l’usage du cannabis. 
Des études ont montré que l’utilisation du cannabis peut augmenter le risque 
de développer la schizophrénie en précipitant la maladie chez les individus qui 
présentent une vulnérabilité génétique aux désordres mentaux. Des recherches portant 
chez l’homme et l’animal indiquent que la neuréguline 1 (Nrg1) est un gène de 
susceptibilité à la schizophrénie. L’objectif de cette thèse a donc été d’examiner si un 
dérèglement du gène Nrg1 module les effets comportementaux et neuronaux des 
cannabinoïdes.  
Dans une première partie (Chapitre 2), les effets comportementaux de 
l’administration de Δ9-tétrahydrocannabinol (THC), le principal composant 
psychotrope du cannabis, ont été évalués. Les souris mutantes hétérozygotes pour le 
domaine transmembranaire de Nrg1 (Nrg1 HET) montrent des différences de 
comportement d'activité locomotrice, d’exploration et d’anxiété. D'une manière 
primordiale, les souris Nrg1 HET sont plus sensibles aux effets du THC sur la 
XIV 
suppression de l’activité locomotrice comparées aux souris sauvages. De plus, les 
souris Nrg1 HET expriment une plus grande augmentation du % d’inhibition par pré-
pulse (PPI) induite par le THC que les souris sauvages. Ces résultats indiquent pour la 
première fois que la perturbation d’un gène impliqué dans la susceptibilité à la 
schizophrénie module les effets des cannabinoïdes. 
Apres avoir démontré que les souris Nrg1 HET sont plus sensibles aux effets 
aigus du THC dans différents tests comportementaux y compris ceux qui modélisent 
des symptômes de la schizophrénie, nous avons mesuré les effets du THC sur 
l'activité neuronale chez les souris Nrg1 HET et sauvages en utilisant l’expression de 
c-Fos mesurée par immunohistochimie (Chapitre 3). Dans le septum latéral, le THC 
accentue l’expression de c-Fos uniquement chez les souris Nrg1 HET. De plus, le 
THC induit une augmentation de l'expression de c-Fos dans le noyau central de 
l'amygdale, le noyau du lit de la strie terminale et dans le noyau paraventriculaire de 
l'hypothalamus plus masquée chez les souris Nrg1 HET que chez les souris sauvage. 
Conformément à l’expression d’un phénotype associé à la schizophrénie chez les 
souris Nrg1 HET, ces animaux présentent une augmentation d’expression de c-Fos 
dans le septum latéral et la coquille du noyau accumbens. De plus, l’effet du génotype 
sur l’expression de c-Fos, sans drogue ou après exposition au THC, est observé 
seulement quand les animaux ont été soumis à des tests comportements avant d’être 
perfusés. Ceci suggère qu’un stress est nécessaire pour promouvoir ces effets. Ces 
données fournissent des corrélations neurobiologiques attestant l’augmentation de la 
sensibilité comportementale des souris Nrg1 HET au THC. Ces travaux rapportés 
dans le Chapitre 2 renforcent l’hypothèse de l'existence d’une interaction entre les 
cannabinoïdes et la neuréguline 1. 
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Comme le risque de développer la schizophrénie chez les individus 
vulnérables augmente avec la fréquence d’utilisation du cannabis, le Chapitre 4 évalue 
les effets de l’administration répétée de CP 55,940, un analogue synthétique du THC. 
Les tests comportementaux ont montré que la tolérance aux effets hypothermiques et 
hypolocomoteurs du CP 55,940 apparait plus rapidement chez les souris Nrg1 HET 
que chez les souris contrôles. Inversement, une tolérance à l'effet anxiogène du CP 
55,940 s’est développée chez les souris témoins, mais pas chez les souris Nrg1 HET. 
Dans la PPI, des effets opposés du CP 55,940 ont été observés lors du premier jour 
d'exposition, avec une facilitation de la PPI chez les souris Nrg1 HET souris et une 
diminution chez les souris contrôles. Toutefois, cet effet différentiel entre les souris 
Nrg1 HET et témoins ne se maintient pas avec la répétition des administrations de CP 
55,940, les deux génotypes devenant tolérants aux effets du cannabinoïde sur la PPI. 
En outre, une augmentation de l’expression de Fos B / ΔFos B, un marqueur des 
changements neuronaux à long terme, a été observée dans le septum ventrolatéral des 
souris Nrg1 HET après exposition chronique au CP 55,940 mais cet effet n’a pas été 
observé chez les souris contrôles. Ces résultats indiquent que le système de la 
neuréguline 1 est impliqué dans la réponse neuroadaptative à l'exposition répétée aux 
cannabinoïdes. 
Les déficits cognitifs figurent parmi les principaux endophénotypes observés 
dans la schizophrénie. Ainsi, le chapitre 5 propose une procédure qui permettrait 
d'évaluer les effets des cannabinoïdes sur les déficits de mémoire de travail chez la 
souris wild-type. Peu d'études se sont intéressées aux effets de l'exposition chronique 
aux cannabinoïdes sur la mémoire et ont examiné si une tolérance à ces effets se 
produit. Ici, nous avons étudié les effets de l'exposition répétée au THC sur la 
mémoire spatiale et l’expression de zif268, un autre gène de mesure d’activité 
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neuronale. Un groupe d'animaux n’a pas été prétraité avec du THC alors qu'un autre 
groupe a reçu 13 injections quotidiennes de THC (1mg/kg/jour; i.p.) avant d’être 
soumis aux tests de mémoire dans le labyrinthe aquatique de Morris. Les deux 
groupes ont reçu le THC durant toute la phase comportementale. Le THC a diminué la 
mémoire spatiale et la mémoire de travail, en particulier la flexibilité 
comportementale, même chez les animaux prétraités par le THC et qui étaient déjà 
tolérants à ses effets hypolocomoteurs. L’expression de zif268 a été significativement 
réduite dans l’aire CA3 de l'hippocampe et dans le cortex préfrontal seulement chez 
les animaux n’ayant pas reçu de prétraitement. Ceci suggère que la tolérance aux 
effets des cannabinoïdes apparait plus rapidement sur l'activité neuronale que sur les 
effets comportementaux, ces derniers persistant après 24 jours d'exposition. Cette 
étude montre que l’administration répétée de THC perturbe la flexibilité 
comportementale et que ces effets sont résistants au phénomène de tolérance. Il serait 
intéressant d’examiner si ces déficits de mémoire induits par les cannabinoïdes sont 
modifiés chez les souris Nrg1 HET par rapport aux souris contrôles. 
En conclusion, les résultats présentés dans cette thèse fournissent la première 
preuve que la suppression partielle d’un gène de susceptibilité de la schizophrénie, le 
Nrg1, module l'action comportementale et neurobiologique des cannabinoïdes 
administrés en traitement aigu ou chronique. Cette recherche met en évidence que les 
systèmes de la neuréguline et des cannabinoïdes interagissent dans le system nerveux 
central, et accroît nos connaissances sur la façon dont les facteurs génétiques 
augmentent la vulnérabilité d’un individu à la schizophrénie et à la psychose induite 
par le cannabis. 
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ABSTRACT 
 
 
Schizophrenia is a severe, chronic and disabling mental disorder with a worldwide 
prevalence of approximately 1 %. It is a lifelong illness characterized by psychotic 
symptoms which typically first appear in late adolescence/early adulthood. The 
symptoms of schizophrenia are usually categorized as positive (hallucinations and 
delusions), negative (blunted affect and poverty of speech) and cognitive (memory, 
attention and executive function impairments). Schizophrenia is thought to arise from 
an interaction between several susceptibility genes and environmental factors, one of 
them being the use of cannabis, the most widely used illicit drug in the world. Human 
population studies show that cannabis use is associated with schizophrenia, and it is 
now well recognised that cannabis use increases the risk of developing schizophrenia 
by approximately twofold. 
The reasons for the association between cannabis and schizophrenia remain 
controversial and different theories have been proposed to explain the nature of this 
relationship. According to the self-medication hypothesis of schizophrenia, patients 
with psychotic disorders use cannabis to alleviate aversive symptoms of the disorder 
or the side effects associated with antipsychotic medications. Other theories posit that 
cannabis is a component cause contributing to the development of schizophrenia. 
Supporting this, an increasing body of evidence shows that cannabis use increases the 
incidence and severity of psychotic symptoms and that cannabis use most frequently 
precedes the onset of schizophrenia. As a large majority of cannabis users do not 
develop schizophrenia, a gene-environment interaction appears necessary for the 
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development of the disorder. That is, cannabis use may unmask latent schizophrenia 
in individuals that have a genetic predisposition to the disorder. 
Family studies provide strong evidence of a genetic contribution to the 
aetiology of schizophrenia. Several candidate genes are likely involved in the 
disorder, but this thesis will specifically focus on the neuregulin 1 (NRG1) gene. 
NRG1 was first proposed as a schizophrenia susceptibility gene in 2002 and linkage 
studies have since replicated this association in diverse populations around the world. 
In addition, changes in expression of Nrg1 isoforms and its receptor ErbB4 have been 
reported in the brain of schizophrenia patients. NRG1 polymorphism has also been 
associated with cognitive and behavioural differences in schizophrenia patients 
compared to healthy individuals. Collectively, NRG1 is now recognized as one of the 
most promising genes that confer an increased risk of developing schizophrenia 
The creation of knockout mice lacking a specific gene offers an exciting new 
approach in the study of mental disorders. While several mutant mice for Nrg1 and 
ErbB4 receptor have been developed, this thesis focussed on mice that are 
heterozygous for the transmembrane domain of the Nrg1 gene (named Nrg1 HET 
mice). These mice exhibit a schizophrenia-like phenotype including hyperactivity that 
can be used as a reflection of positive symptoms of schizophrenia. Furthermore, they 
display impairments in social recognition memory and prepulse inhibition (PPI), a 
model of attentional deficits observed in schizophrenia patients. In addition, the brains 
of Nrg1 HET contain fewer functional NMDA receptors and more 5-HT2A receptors 
than wild type-like (WT) animals which is consistent with the neurotransmitters 
imbalance observed in schizophrenic patients. The phenotype of Nrg1 HET mice is 
age-dependent, another aspect that mirror the late adolescent/early adulthood onset of 
schizophrenia symptoms. The present thesis aimed at developing an animal model of 
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genetic vulnerability to cannabinoid-precipitated schizophrenia by utilising Nrg1 HET 
mice to observe if these animals show an altered behavioural and neuronal response to 
cannabinoid exposure. We hypothesise that Nrg1 deficiency will alter the 
neurobehavioural responses of animals to cannabinoids.  
The experiments detailed within the first research chapter (Chapter 2) aimed at 
examining the behavioural effects of an acute exposure to the main psychoactive 
constituent of cannabis, Δ9-tetrahydrocannabinol (THC), in Nrg1 HET mice using a 
range of behavioural tests of locomotion, exploration, anxiety and sensorimotor 
gating. Relative to WT control mice, Nrg1 HET mice were more sensitive to both the 
locomotor suppressant action of THC, as measured in the open field test, and to the 
anxiogenic effects of THC in the light-dark test, although the effects in this procedure 
may be confounded by the drug-free hyperactive phenotype of Nrg1 HET mice. 
Importantly, Nrg1 HET mice expressed a greater THC-induced enhancement in PPI 
than WT mice. Taken together, the data presented in Chapter 2 show that a deficiency 
in a schizophrenia susceptibility gene Nrg1 enhanced the behavioural impact of THC. 
After having established a link between Nrg1 deficiency and increased 
sensitivity to the behavioural effects of cannabinoids in Chapter 2, Chapter 3 assessed 
the neuronal activity underlying the effects of an acute THC exposure on Nrg1 HET 
mice by using c-Fos immunohistochemistry. In the ventral part of the lateral septum 
(LSV), THC selectively increased c-Fos expression in Nrg1 HET mice with no 
corresponding effect being observed in WT mice. In addition, a non-significant trend 
for THC to promote a greater increase in c-Fos expression in Nrg1 HET mice than 
WT mice was observed in the central nucleus of the amygdala, the bed nucleus of the 
stria terminalis and the paraventricular nucleus of the hypothalamus. Consistent with 
Nrg1 HET mice exhibiting a schizophrenia-related phenotype, these mice expressed 
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greater drug-free levels of c-Fos in the shell of the nucleus accumbens and the LSV. 
Interestingly, the effects of genotype on c-Fos expression, drug-free or following THC 
exposure, were only observed when animals experienced behavioural testing prior to 
perfusion. This suggests that an interaction with stress was necessary for the 
promotion of these effects. 
As the risk of developing psychosis in vulnerable individuals increases with 
the frequency of cannabis use, Chapter 4 assessed the effects of repeated exposure to 
cannabinoids on Nrg1 HET mice. As THC was not available at the time, the synthetic 
analogue of THC, CP 55,940, was used in this experiment. Behavioural testing 
showed that tolerance to CP 55,940-induced hypothermia and locomotor suppression 
developed more rapidly in Nrg1 HET mice compared to WT mice. On the contrary, 
tolerance to the anxiogenic-like effect of CP 55,940 in the light-dark test was 
observed in WT mice, however no such tolerance occurred to this effect in Nrg1 HET 
mice. Similarly, no tolerance developed to CP 55,940-induced thigmotaxis in Nrg1 
HET mice as measured in the open field. For PPI, on the first day of exposure 
opposite effects were observed, with CP 55,940 treatment facilitating PPI in Nrg1 
HET mice and decreasing it in WT mice. However, the differential effect of CP 
55,940 on PPI was not maintained with repeated testing as both genotypes became 
tolerant to the effects of the cannabinoid on sensorimotor gating. In addition, a 
selective increase in Fos B/∆Fos B expression, a marker of longer-term neuronal 
changes, was observed in the LSV of Nrg1 HET mice following chronic CP 55,940 
exposure, with no corresponding effect seen in WT mice. These results collectively 
demonstrate that the neuregulin system is involved in the neuroadaptive response to 
repeated cannabinoid exposure. 
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One of the main schizophrenia endophenotypes observed in human studies are 
cognitive impairments of higher executive functions. Thus Chapter 5 aimed to 
develop a procedure to allow evaluation of cannabis-induced working memory 
deficits in mice. Few studies have investigated the effects of chronic cannabinoid 
exposure on memory performance and whether tolerance occurs to cannabinoid-
induced memory impairment. Here we studied the effects of repeated exposure to 
THC on spatial memory and the expression of the immediate early gene zif268 in 
mice. One group of animals were not pre-treated with THC while another group was 
given 13 daily injections of THC prior to memory training and testing in the Morris 
water maze. Both groups were administered THC throughout the memory training and 
testing phases of the experiment. THC decreased spatial memory and reversal 
learning, even in animals that received the THC pre-treatment and were tolerant to the 
locomotor suppressant effects of the drug. Zif268 immunoreactivity was reduced in 
the CA3 of the hippocampus and in the prefrontal cortex only in non pre-treated 
animals, indicating that while tolerance to the effects of cannabinoids on neuronal 
activity arose, cannabinoid-promoted memory impairment in these animals persisted 
even after 24 days of exposure. Taken together these data demonstrate that the spatial 
memory impairing effects of THC are resistant to tolerance following extended 
administration of the drug. Such a model could be applied to Nrg1 HET mice in future 
studies to observe if cannabinoid-induced working memory impairments and the 
development of tolerance to this effect are altered relative to WT mice. 
In conclusion, this thesis provides the first evidence that partial deletion of the 
schizophrenia susceptibility gene Nrg1 modulates the neurobehavioural actions of 
acutely and chronically administered cannabinoids. Nrg1 HET mice appear more 
sensitive to the acute neurobehavioural effects of cannabinoids. Notably, acutely 
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administered THC facilitated attentional function by increasing PPI in Nrg1 HET 
mice. However, with repeated cannabinoid administration this acute benefit was lost. 
The Nrg1 HET mice displayed a long-lasting anxiogenic profile that was resistant to 
tolerance. Conversely, Nrg1 HET mice developed tolerance to the locomotor 
suppressant and hypothermic effects of cannabinoids more rapidly than WT mice, 
indicating a distorted neuroadaptive response in these animals. Another major finding 
of this thesis is that the lateral septum appears to be an important brain region 
dysregulated by cannabinoids in Nrg1 HET mice. Cumulatively, this research 
highlights the fact that neuregulin 1 and cannabinoid systems appear to interact in the 
central nervous system. This may ultimately enhance our understanding of how gene-
environment interactions are responsible for cannabis-induced development of 
schizophrenia. 
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1. Schizophrenia 
1.1. Epidemiology 
Schizophrenia is a severe, chronic and disabling mental disorder. It was first described 
as specific brain pathology, “dementia praecox”, in 
the early 20th century by Emil Kraepelin, and then 
renamed “schizophrenia” (from the Greek roots 
schizein “to spilt” and phrēn “the mind”) by Eugen 
Bleuler (Black and Boffeli, 1989) (see Fig. 1). A 
recent epidemiological study indicates that about 7 
individuals per 1000 will develop schizophrenia during their lifetime (McGrath et al., 
2008), and data from the World Health Organization (WHO) report that 
approximately 25 million persons are suffering from this disorder in the world (WHO, 
2008). Schizophrenia is a lifelong illness with symptoms typically beginning in late 
adolescence/early adulthood, and males usually having an earlier onset than females 
(Jablensky, 2000). This disorder causes significant distress to the patient and also to 
the patient’s family and friends. Approximately 10 % of schizophrenia patients 
commit suicide (Meltzer, 2002). People with schizophrenia are often unemployed, 
poor and homeless with many spending long periods of time in mental health 
facilities. This incurs a major cost to society, where 2 % of Australia’s health and 
community expenditure is accounted for by this disorder (Carr et al., 2004) and the 
annual cost of medical management of schizophrenia in France is estimated to be 
billions of dollars (Rouillon et al., 1997). 
 
 
 
Figure 1. (A) Emil Kraepelin (1856-
1926) and (B) Eugen Bleuler (1857-
1939), were German and Swiss 
psychiatists. 
A B 
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1.2. Symptoms 
Many different types of psychotic disorders have been characterized and they are 
categorized by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 
as schizoaffective, schizophreniform, delusional, shared psychotic and brief psychotic 
disorders (DSM-IV). They all have a slightly different symptomatology but this thesis 
will focus specifically on schizophrenia. This disorder must last for at least 6 months 
to be classified as schizophrenia and include the presence of at least 2 of the 
characteristic symptoms of impaired contact with reality and evidence of social or 
occupational dysfunction (each of 1 month duration minimum). These symptoms 
should not be attributable to mood, medical and substance abuse disorders (DSM-IV). 
More specifically, the psychiatric symptoms of schizophrenia are usually classified as 
positive and negative. The positive symptoms reflect an excess or distortion of normal 
functions, and include psychotic symptoms such as distortion in perception 
(hallucinations) and thought content (delusions), disorganized speech and abnormal 
behaviours (DSM-IV). These positive symptoms are usually present at discrete 
periods in time which are often classified as “psychotic episodes”, while the negative 
symptoms of schizophrenia are present persistently during the course of the illness. 
Negative symptoms reflect a loss of normal functions and include decreased emotions 
(affective flattening/blunted affect) and pleasure (anhedonia), poverty of thought and 
speech (alogia) and lack of motivation (avolition/apathy) (DSM-IV). These symptoms 
are usually associated with a general intellectual decline with decreased performance 
in most cognitive functions like memory, attention and executive functions (Mitchell 
et al., 2001).  
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1.3. Treatments and early theories of schizophrenia  
The neuronal mechanisms that underline the symptoms of schizophrenia have been 
investigated for more than half a century, and are thought to arise from an imbalance 
of many different neurotransmitter systems. Advances in this area came from the 
introduction in 1952 of the first antipsychotic drug, chlorpromazine. The therapeutic 
actions of this neuroleptic were first observed by a French surgeon, Henri Laborit, 
who used the drug as a surgical anaesthetic because of its highly sedative and calming 
effects (Shen, 1999). It was then realized that these so-called classical or typical 
antipsychotic drugs like chlorpromazine or haloperidol are effective in reducing 
symptoms of schizophrenia, particularly positive symptoms such as hallucinations and 
delusions (Levinson, 1991).  
The observation that typical 
antipsychotic drugs are antagonists for 
dopamine D2 receptors, and that drugs 
such as amphetamine which enhance 
dopamine release may promote psychotic 
symptoms, led to the formulation of the 
“dopamine hypothesis” that positive 
symptoms of schizophrenia are 
attributable to a hyperactivity of dopamine 
function (Seeman, 1987). There are 4 
different dopaminergic pathways in the brain (Fig. 2) and the activation of the 
mesolimbic dopaminergic pathway that extends from cell bodies in the ventral 
tegmental area (VTA) to the nucleus accumbens (ventral striatum) is most likely 
dysregulated in schizophrenia. This pathway is involved in addiction and studies 
Figure 2. The different dopaminergic pathways 
in the brain. The location of the main groups of 
cell bodies and fibre tracts is shown in red. 
Pink areas show the location of dopaminergic 
terminals. (Ac, nucleus accumbens; Am, 
Amygdala; C, cerebellum; Hip, hippocampus; 
Hyp, hypothalamus; p, pituitary; sep, septum; 
SN, substantia nigra; Str, striatum; Th, 
thalamus). Adapted from Rang and Dale’s 
Pharmacology, 2007, Churchill Livingstone. 
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suggest that the elevated levels of dopamine in response to drugs accentuate the 
attribution of salience to stimuli and conditioned learning, inducing addictive 
behaviours (Volkow et al., 2007). Within the pathophysiological framework of 
schizophrenia, increased activity of this pathway could be responsible for the 
association of abnormal importance to internal or external stimuli, thus producing 
hallucinations and delusions (Stone et al., 2007, Murray et al., 2008). The strong 
dopamine D2 receptor antagonism of typical antipsychotic drugs renders them 
markedly efficient in reducing positive symptoms of schizophrenia.  
However typical antipsychotics are inefficient in reducing the negative and 
cognitive symptoms of schizophrenia and these drugs are associated with severe side 
effects. They are extremely sedative and induce weight gain, metabolic disorders or 
sexual dysfunction as well as the development of unwanted extrapyramidal motor 
symptoms (Levinson, 1991, Nikam and Awasthi, 2008). These Parkinson-like 
symptoms are thought to be caused by the dopamine antagonism of antipsychotic 
drugs that also block dopamine transmission in the nigrostriatal pathway (Fig. 2), a 
region known to regulate motor behaviour.  
The absence of effect of antipsychotic drugs on the negative symptoms of 
schizophrenia suggests that other neurotransmitter systems are involved in the 
disorder. Evidence of decreased glutamatergic levels in the cerebrospinal fluid (CSF) 
of schizophrenic patients led to the hypothesis of a dysfunction in glutamatergic 
function in schizophrenia (Kim et al., 1980). In addition, glutamate NMDA receptor 
antagonists, such as phencyclidine or ketamine, induce most of the positive, negative 
and cognitive symptomatic features of schizophrenia in healthy individuals and 
exacerbate psychosis in schizophrenic patients (Allen and Young, 1978, Coyle, 1996, 
Javitt, 2007). Clinical studies also showed that drugs which enhance NMDA receptor 
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function reduce negative and cognitive symptoms in schizophrenia patients. From 
these observations developed the theory that hypoglutamatergic neurotransmission in 
limbic and cortical regions such as frontal cortex and hippocampal formation might 
subserve the negative and cognitive symptoms of schizophrenia (Coyle, 1996, 
Mitchell et al., 2001).  
The diversity of the neurotransmitter systems involved in schizophrenia is also 
highlighted by the introduction in the 1970’s of the first atypical antipsychotic, 
clozapine. This provided a turning point in schizophrenia treatment as these drugs 
induce fewer extrapyramidal side-effects as they are weaker antagonists for the 
dopamine D2 receptor than typical antipsychotics. In addition, besides decreasing 
positive symptoms, atypical antipsychotics are also effective in reducing the negative 
symptoms of schizophrenia (Meltzer et al., 1989, Lindenmayer, 1995, Shen, 1999, 
Nikam and Awasthi, 2008). Even if all antipsychotic drugs available are dopamine D2 
antagonists, these atypical antipsychotic drugs have different selectivity for other 
dopamine receptor subtypes and they are known to interact with additional 
neurotransmitter receptors having particularly high affinity for serotonin 5-HT2 
receptors. This reinforces the notion that multiple neurotransmitters are involved in 
the pathophysiology of schizophrenia (Gerlach, 1991, Lindenmayer, 1995). 
The most recent theories of schizophrenia acknowledge that both genetic (see 
section 3) and environmental factors are involved in the pathogenesis of the disorder. 
The current theories within the literature posit that schizophrenia cannot be attributed 
to a single cause, but rather is a multifactorial neurodevelopmental disorder, involving 
the interaction of several susceptibility genes with environmental factors. This thesis 
will focus on modelling the interaction between genes and the environment. 
Environmental factors play an important role in triggering the development of 
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schizophrenia (Henquet et al., 2008). Examples of environmental factors associated 
with the disorder include pregnancy and delivery complications, exposure to viral 
infections or to stress during gestation or childhood, nutritional deficiencies or 
psychosocial deficiencies like low intelligence quotient, urban upbringing, being an 
immigrant, having an older father, low socioeconomic status and winter birth 
(Jablensky, 2000, Tandon et al., 2008). While all these factors may indeed play a role 
in the emergence of schizophrenia, this thesis is specifically concerned with the 
relationship between cannabis use and genetic vulnerability in the development of the 
disorder. 
 
2. The role of cannabis in the development of schizophrenia  
2.1. Cannabinoid pharmacology 
Extracts of the plant Cannabis sativa have been used for medicinal and recreational 
purposes for millennia, the first documented case dating back 5000 years ago in China 
(Mikuriya, 1969). It was introduced to the western world during the ninetieth century, 
and its recreational use has dramatically increased since the 1960’s. Today, it is 
estimated that about 147 million people consume cannabis, making it the most widely 
used illicit drug in the world (WHO, 2008). 
In the past 20 years extensive research has been undertaken to characterize 
cannabis pharmacology, as there is increasing interest in the use of this drug as a 
therapeutic agent. Cannabinoids promote analgesia and show potential in the 
treatment of neuropathic pain and inflammation associated with multiple sclerosis. 
Further, their antiemetic and appetite stimulant properties are potentially useful in 
treating patients with chemotherapy-induced nausea and vomiting (Hosking and 
Zajicek, 2008). In addition, blockade of cannabinoid CB1 receptors using rimonabant 
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(SR 141716) is effective in treating obesity, inducing weight loss via both central and 
peripheral mechanisms of action (Isoldi and Aronne, 2008). While rimonabant has 
recently been suspended for its use as an anti-obesity drug in Europe (Jones, 2008), it 
might also be developed for other applications, for example as an anti-craving 
compound against nicotine and alcohol dependence (Colombo et al., 2007, Le Foll et 
al., 2008). Interestingly, the USA’s Food and Drug Administration has been reticent 
to introduce rimonabant as a therapeutic agent given evidence that it might increase 
the risk of psychiatric disturbances in patients. The association between cannabinoids 
and mental disorder remains one of the major stumbling blocks for the introduction of 
cannabinoid-based therapies. 
Cannabinoid consumption produces a range of effects on the central nervous 
system (CNS) including euphoria, sensory magnification and impairment of short-
term memory, attention and motor function. Cannabis use also induces some 
peripheral effects such as tachycardia, vasodilatation of the eyes, reduction of 
intraocular pressure, bronchodilatation and immunosuppression (Abood and Martin, 
1992, Iversen, 2003). Cannabis is relatively safe in overdose, and does not induce 
death in itself. There are however a lot of adverse effects associated with the use of 
the drug. Even at low doses, cannabis produces drowsiness and confusion, sometimes 
accompanied by anxiety, panic attacks, paranoia, hallucinations and 
depersonalisation. Cannabis also decreases motivation promoting a so-called 
amotivational syndrome that resembles the negative symptoms of schizophrenia 
(Manzanares et al., 2004). Further, the long-term exposure to the drug is associated 
with the development of tolerance and dependence, and also induces long term 
cognitive deficits in attention, memory and executive functions (Hall and Solowij, 
1998).  
Chapter 1: Cannabis use and schizophrenia 
9 
Cannabis extracts from the plant contain more than 60 cannabinoid 
compounds that are highly lipid soluble (Di Marzo and Petrocellis, 2006). These 
phytocannabinoids include the main psychoactive constituent of cannabis, Δ9-
tetrahydrocannabinol (THC), and cannabidiol, a major non-psychotropic constituent 
of cannabis that may possess antipsychotic actions (Zuardi et al., 2006). From these 
chemical structures, synthetic cannabinoids have been developed such as CP 55,940, 
WIN 55,212-2 and HU 210 (Di Marzo and Petrocellis, 2006, Pertwee, 2008). The 
existence of an endocannabinoid system was discovered by the isolation of the 
endogenous ligands anandamide (Devane et al., 1992) and 2-arachidonoylglycerol 
(Mechoulam et al., 1995), that are chemically distinct from the phytocannabinoids and 
synthetic cannabinoids (see Fig. 3).  
 
Figure 3. Cannabinoid ligands. 
Δ9-tetrahydrocannabinol 
Cannabidiol 
Phytocannabinoids 
Endocannabinoids 
2-Arachidonoylglycerol (2-AG) 
Anandamide 
WIN 55,212-2 
CP 55,940 
HU-210 
Synthetic cannabinoids 
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As their high lipophilicity allows passage across the blood brain barrier to the 
CNS, all cannabinoids affect brain functioning. They exert their effects by binding to 
the cannabinoid CB1 receptor, which was first isolated in 1988 (Devane et al., 1988). 
A cannabinoid CB2 receptor has also been isolated and is mainly present in the 
periphery where it is located predominantly on immune cells (Pertwee, 2008). 
However, CB2 receptors have recently been shown to be also present in the brain 
where they may be involved in depression and substance abuse (Onaivi et al., 2006). 
In addition, a growing body of evidence suggests the presence of an additional 
cannabinoid receptor (CB3) that is yet to be cloned (Di Marzo et al., 2000, Fride et 
al., 2003).  
The CB1 receptor is one of the 
most abundant G-protein-coupled receptors 
in the CNS. CB1 is coupled to Gi/o proteins 
that inhibit adenylate cyclase activity thus 
decreasing cAMP production and Ca2+ ion 
channel activity (see Fig 4). The activation 
of CB1 receptors also increases K+ 
conductance and increases mitogen-
activated protein kinase (MAPK) activity 
(Howlett et al., 2004). CB1 receptors are 
predominantly localized presynaptically, 
exerting inhibitory effects on synaptic 
transmission (Di Marzo and Petrocellis, 2006). Endocannabinoids are synthesized and 
released on demand and appear to act as retrograde messengers that modulate the 
release of various neurotransmitters implicated in the aetiology of schizophrenia, 
Figure 4. Intracellular pathway of CB1 
receptor activation.  CB1 receptor activation 
inhibits neurotransmitter release via 
inhibition of Ca2+ entry and 
hyperpolarisation due to activation of 
potassium channels. It also alters gene 
expression. (GIRK, G-protein-responsive 
potassium channel; MAPK, mitogen-
activated protein kinase; PKA, protein 
kinase A; VOC, voltage-operated calcium 
channel). Adapted from Rang and Dale’s 
Pharmacology, 2007, Churchill Livingstone. 
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including GABA, glutamate and dopamine (van der Stelt and Di Marzo, 2003). Some 
of the highest densities of CB1 receptors are found in brain regions implicated in 
schizophrenia that regulate diverse functions affected by cannabinoids. Specifically, 
CB1 receptors are localised in the hippocampus (memory), the amygdala (emotion), 
the cerebellum and the substantia nigra (motor function), the hypothalamus 
(hypothermia), the pituitary gland (hormone secretion), as well as in the cortex 
(alteration of higher cognitive function) (Herkenham et al., 1990, Abood and Martin, 
1992).  
Consistent with the localisation of the CB1 receptor in the brain, the effects of 
cannabinoids on humans are mirrored in animals. The administration of cannabinoids 
in rodents produces a characteristic combination of four symptoms: hypothermia, 
analgesia, hypoactivity, and catalepsy (Chaperon and Thiebot, 1999). The effects of 
cannabinoids on general reduction of spontaneous locomotor activity are widely 
reported and involve modulation of dopamine transmission in the basal ganglia where 
the levels of CB1 receptors are the highest in the brain (Giuffrida et al., 1999). When 
injected with high doses of cannabinoids, a state of hyper-reflexia can be observed 
where sedated mice jump in response to auditory or tactile stimuli producing a 
“popcorn effect” that is due to the depressant effects of the drug (Dewey, 1986). 
Catalepsy is another classic type of motor depression observed in rodents following 
high dose cannabinoid administration (Dewey, 1986).  
Administration of exogenous cannabinoids in animals bidirectionally 
influences anxiety. While low doses have anxiolytic properties, high doses of 
cannabinoids induce anxiogenic responses in animal models of anxiety correlating 
with activation of the hypothalamo-pituitary axis (HPA) and the release of stress 
hormones such as ACTH and corticosterone (Valjent et al., 2002, Valverde, 2005). 
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Anxiety can also be measured as decreased social interaction in animals, a behaviour 
that is decreased by cannabinoids (Genn et al., 2004). However unlike in humans, 
cannabinoids exposure normally decreases food intake in laboratory animals 
(Valverde, 2005). In addition they modulate reward-related behaviours such as 
intracranial self stimulation or conditioned place aversion (Chaperon et al., 1998, 
Arnold et al., 2001a), and modulate cognitive processes such as memory (Riedel and 
Davies, 2005), attention (Solowij and Michie, 2007) and executive functions (Pattij et 
al., 2008).  
 
2.2. The endogenous cannabinoid system and schizophrenia 
The cannabinoid system and schizophrenia have neuronal, functional and 
psychological similarities, and there is increasing evidence that the endogenous 
cannabinoid system may in itself be dysfunctional in schizophrenia and other 
psychoses. In 1997, the cannabinoid hypothesis of schizophrenia was proposed 
(Emrich et al., 1997). The authors suggested that some schizophrenia symptoms may 
be related to a dysregulation of the endogenous cannabinoid system because normal 
healthy volunteers intoxicated with THC exhibited strong neuropsychological 
similarities to schizophrenia patients. Association between schizophrenia and a 
polymorphism for the gene that encodes the CB1 receptor, CNR1, has been delineated 
(Ujike et al., 2002). Interestingly, this association was only observed for the 
hebephrenic type of schizophrenia. This type of schizophrenia is characterized 
predominantly by negative symptoms that resemble the “amotivational syndrome” 
that can develop following chronic cannabis use (Campbell, 1976), genetically 
supporting that altered cannabinoid system may be involved in the pathogenesis of 
hebephrenic schizophrenia.  
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Neuroanatomical studies have analysed the levels of CB1 receptors and 
endocannabinoids in the brain of schizophrenia patients. Using autoradiography, a 
significant increase of CB1 receptor binding was found in the dorsolateral prefrontal 
cortex (PFC) (Dean et al., 2001), as well as in the posterior (Newell et al., 2006) and 
anterior (Zavitsanou et al., 2004) cingulate cortex in post mortem brains from 
patients. Decreased gray matter density in the right posterior cingulate cortex was also 
observed in cannabis-abusing first episode schizophrenia patients compared to non 
using schizophrenia patients (Bangalore et al., 2008). These data suggest that 
modulation of the endocannabinoid system in the cingulate cortex and the PFC may 
play a role in the impairments of higher cognitive functions observed in schizophrenia 
patients (Schlosser et al., 2008).  
An imbalance of the endocannabinoid system has also been linked to 
schizophrenia, as the concentration of endocannabinoids were elevated in the blood 
(De Marchi et al., 2003) and the CSF of schizophrenic patients (Leweke et al., 1999). 
An 8-fold increased anandamide level in the CSF was observed specifically in non-
medicated first episode paranoid type schizophrenia patients (Giuffrida et al., 2004). 
Interestingly, this alteration was absent in schizophrenia patients treated with typical 
antipsychotic drugs which predominately antagonise dopamine D2 receptors. 
Paranoid schizophrenia is characterized mainly by positive symptoms which are 
thought to arise from increased levels of dopamine (Oades et al., 2002). Thus acute 
psychotic episodes likely involve increased dopamine levels which trigger 
anandamide release as a homeostatic mechanism to counter excessive dopamine 
levels in the brain. Indeed, the increased anandamide level in schizophrenia patients 
was inversely correlated with psychotic symptoms (Giuffrida et al., 2004). Further, 
this fits with endocannabinoids acting as retrograde transmitters which inhibit the 
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release of dopamine, a phenomenon that has been demonstrated in the dorsal striatum 
(Giuffrida et al., 1999). In another study from the same group, increased CSF 
anandamide level was only observed in low-frequency cannabis users-schizophrenia 
patients, but was absent if these patients had high-frequency level of cannabis use or 
in healthy controls (Leweke et al., 2007). This suggests that the frequent use of 
cannabis may down-regulate anandamide signalling thereby removing the 
homeostatic role such signalling has in schizophrenia patients leading to uninhibited 
dopamine release and the precipitation of psychosis.  
 
2.3. Association between cannabis and schizophrenia 
Epidemiological studies show that there exists significant comorbidity between 
cannabis abuse disorders and schizophrenia with the rate of cannabis use among 
patients with schizophrenia being about twice as high than among the general 
population (Degenhardt et al., 2001). Although the association between cannabis and 
psychosis is well supported, the exact nature of this relationship is controversial with 
often polarized viewpoints being offered to interpret the association.  
 Some posit that schizophrenia causes cannabis abuse/dependence. For 
example, a polymorphism in the CB1 receptor gene might increase the risk of 
substance abuse in schizophrenia patients (Leroy et al., 2001). This is consistent with 
the view that the relationship between cannabis abuse and schizophrenia may be 
explained by a common brain circuitry subserving these disorders. Therefore, 
schizophrenia patients exhibit an enhanced vulnerability to addictive behaviour as a 
part of the disorder’s symptomology (Chambers et al., 2001). At face value this 
appears compelling as the mesolimbic dopamine system is involved in both 
schizophrenia and drug addiction.  
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The self-medication hypothesis provides another explanation consistent with 
the notion that schizophrenia causes cannabis abuse. According to this, patients with 
psychotic disorders use cannabis to alleviate aversive symptoms of the disorder or the 
side effects associated with antipsychotic medications (Peralta and Cuesta, 1992, 
Khantzian, 1997, Chambers et al., 2001). However, there is now a growing body of 
evidence highlighting the limitations of this theory. One compelling argument against 
the self-medication hypothesis is that the initiation to substance use often precedes the 
first episode of psychosis (Hall, 1998). In addition, the effects of cannabis can often 
be unpleasant (e.g. increased anxiety and sedation), and may also exacerbate cognitive 
and attentional dysfunction in schizophrenia patients (D'Souza et al., 2004).  
The opposing viewpoint is that cannabis use causes schizophrenia. This 
originates from reports of cannabis-induced psychotic episodes in individuals using 
high doses of cannabis. Indeed, the symptoms of cannabis intoxication resemble those 
of schizophrenia leading some to believe it provides a model state for the study of this 
disorder (D'Souza et al., 2004). However, most cases of cannabis psychosis are 
reversible with many patients remitting following the cessation of drug use. In this 
sense “cannabis psychosis” refers only to an acute, toxic reaction to heavy cannabis 
use that can be distinguished from persistent schizophrenia-like psychotic reactions 
that have a more prolonged time course (Hall et al., 2004b, Leweke et al., 2004).  
Be that as it may, epidemiological studies strongly support that cannabis may 
play a component causal role in the development of schizophrenia with a meta-
analysis showing that cannabis use increases the risk of developing schizophrenia by 
approximately twofold (Henquet et al., 2005). The argument that cannabis causes 
schizophrenia is compelling as it meets many of the criteria for causality in 
epidemiology. For example, the relationship is dose-dependent, with a greater risk of 
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schizophrenia in people who use cannabis more frequently than those that rarely use 
the drug (Andreasson et al., 1987, Henquet et al., 2005, Moore et al., 2007). Further, 
the relationship between cannabis and psychosis shows directionality as demonstrated 
by the association being maintained even when controlling for many of the potential 
confounding variables that could explain the association (D'Souza, 2007). In addition, 
studies have also shown that temporality exists in the association with cannabis use 
pre-dating or coinciding with the onset of schizophrenia symptoms (Allebeck et al., 
1993, Linszen et al., 1994, Hambrecht and Hafner, 2000, Arseneault et al., 2002). 
However, the view that cannabis use is necessary and sufficient to cause 
shizophrenia is undermined by the fact that the vast majority of people that use 
cannabis do not develop schizophrenia. This has led to the theory that cannabis is a 
component cause in the development of schizophrenia that might interact with 
vulnerability factors to promote schizophrenia. Supportive of this view is that 
cannabis use is associated with an earlier onset of symptoms (Barnes et al., 2006, 
Mauri et al., 2006) and an increased incidence and severity of psychotic symptoms in 
schizophrenia patients at high risk of developing the disorder (Johns, 2001, Miller et 
al., 2001, Degenhardt and Hall, 2002, D'Souza et al., 2005, Hides et al., 2006) 
Here we specifically hypothesise that cannabis might unmask latent 
schizophrenia in individuals that have a genetic predisposition to the disorder (Caspi 
et al., 2005). This is consistent with the neurodevelopmental theory of schizophrenia 
which postulates that gene-environment interactions are required for the development 
of this debilitating mental disorder (Bayer et al., 1999).  
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3. Neuregulin 1 gene and schizophrenia 
3.1. Genetic factors and susceptibility to schizophrenia 
Family studies provide strong evidence that genetic predisposition is involved in the 
aetiology of schizophrenia. These studies report that the estimate risk for acquiring 
schizophrenia is 6-13 % for first-degree relatives like parents or siblings and 3-6 % 
for second-degree relatives (Faraone et al., 2002, Tandon et al., 2008). If both parents 
are affected, the risk of the offspring developing schizophrenia is more than 40 %. 
Twin studies showed that the risk is at least 50 % for monozygous twins that share 
100 % of their genetic material, while it is around 15 % for dizygotic twins that only 
share 50 % of their genetic material like for siblings (Faraone et al., 2002). The 
heritability of schizophrenia is estimated at 80 % (Faraone et al., 2002, Tandon et al., 
2008). However this hereditary factor is incomplete, which supports the 
neurodevelopmental theory of schizophrenia of the need of environmental factors like 
cannabis to trigger the development of the disorder. Expression of schizophrenia is 
likely to involve interaction of multiple susceptibility genes of small effects with non-
genetic factors to modulate susceptibility to the disorder. 
To identify the genes involved in the vulnerability to schizophrenia, genetic 
linkage and association studies have isolated several specific susceptibility genes 
including neuregulin 1 (NRG1) from chromosome 8p21 and DTNBP1 (dysbindin) 
from chromosome 6p22 (Owen et al., 2005), that both influence glutamatergic 
transmission (Sawa and Snyder, 2003). Another strong candidate gene for 
schizophrenia is DISC-1 (disrupted-in-schizophrenia 1) from chromosome 1q42, that 
interacts with cytoskeletal proteins which might affect neuronal migration (Owen et 
al., 2005). The chromosome 22q11 is also reported to be a particular susceptibility 
locus for schizophrenia risk (Owen et al., 2005) and two genes from this chromosome 
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have been identified as candidate genes for schizophrenia. COMT (catechol-O-
methyltransferase) is one of the main enzymes that degrade catecholamines thus 
decreasing dopamine levels especially in the PFC (Sawa and Snyder, 2003). The 
second gene isolated is PRODH (proline dehydrogenase), a precursor of glutamate 
and a neuromodulator of glutamatergic transmission (Sawa and Snyder, 2003).  
Other promising susceptibility genes have been implicated in schizophrenia, 
but the evidence of their role is not yet compelling (Owen et al., 2005). They include 
G72 (D-amino-acid oxidase activator) from chromosome 13q34 that activates D-
amino acid oxidase, the enzyme that catabolizes D-serine, the glial neuromodulator of 
glutamatergic NMDA receptors (Sawa and Snyder, 2003), or RGS4 (regulator of G-
protein signalling 4) from chromosome 1q22 that modulates G-protein signalling. 
Interestingly, most of these genes influence neurotransmission and especially the 
glutamatergic pathway, including NMDA receptors, that is deficient in schizophrenia. 
Although the association of these genes with schizophrenia is sometimes contentious 
(Sanders et al., 2008), their identification is essential in understanding the 
pathogenesis of schizophrenia.  
 
3.2. Association between neuregulin and schizophrenia 
Schizophrenia is a multifactorial polygenic disorder, and one of its most promising 
susceptibility genes is NRG1. Neuregulins are a family of growth and differentiation 
factors that are encoded by 4 genes (NRG1-4), with NRG1 being the most 
characterized. It is a huge gene of around 1.4 megabases that generates 6 types of 
protein, and more than 31 isoforms (Fig. 5). Nrg1 contains an epidermal growth factor 
(EGF)-like domain that activates ErbB receptor tyrosine kinases. There are 4 ErbB 
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receptors (ErbB1-4) but Nrg1 binds predominantly to ErbB4 in the CNS (Falls, 2003, 
Mei and Xiong, 2008). 
The possible linkage of schizophrenia to the chromosome 8p has been 
postulated since 1995 (Pulver et al., 1995, Kendler et al., 1996) and Stefansson and 
colleagues first associated NRG1 with schizophrenia in 2002 (Stefansson et al., 2002). 
Since that time associations between NRG1 and schizophrenia have been replicated in 
diverse Caucasian (Stefansson et al., 2002, Stefansson et al., 2003, Williams et al., 
2003, Bakker et al., 2004, Corvin et al., 2004, Petryshen et al., 2005, Thomson et al., 
2007, Georgieva et al., 2008), Asian (Yang et al., 2003, Li et al., 2004, Tang et al., 
2004, Zhao et al., 2004, Fukui et al., 2006, Kim et al., 2006) and African American 
(Lachman et al., 2006) populations. However, some negative findings have also been 
reported (Hall et al., 2004a, Hong et al., 2004, Iwata et al., 2004, Kampman et al., 
2004, Thiselton et al., 2004, Ingason et al., 2006). A meta-analysis of these data 
indicates that the problems associated with replication of findings lie in the 
heterogeneity of these studies in their methods, markers, sample ancestry and 
phenotype definition (Munafo et al., 2008). An association between NRG1 with 
schizotypal personality has also been shown (Lin et al., 2005) further supporting the 
Figure 5. The different types of neuregulin 1. The 6 types of neuregulin 1 (NRG1) isoforms are 
classified according to their distinct amino-terminal sequences. In the type III isoforms, this 
sequence contains a cysteine-rich domain (CRD) that has a transmembrane domain (TMn). All six 
types of NRG1 isoforms have an epidermal growth factor (EGF)-like domain. Types I, II, IV and V 
have an immunoglobulin (Ig)-like domain between the N-terminal sequence and the EGF domain, 
with or without the spacer region (S), whereas the N-terminal-specific region of types III and VI is 
connected directly to the EGF domain.Variants are also generated by splicing in the linker regions 
and the C-terminal regions. Between the two regions is a C-terminal transmembrane domain (TMc). 
Adapted from Mei, L. and Xiong, W. C., 2008. Neuregulin 1 in neural development, synaptic 
plasticity and schizophrenia. Nat Rev Neurosci. 9, 437-452. 
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role of this gene in schizophrenia. In addition, the Nrg1 receptor ErbB4 has also been 
associated with schizophrenia (Nicodemus et al., 2006, Norton et al., 2006, Silberberg 
et al., 2006, Law et al., 2007).  
Together with these linkage studies, gene expression evidences also support a 
role of NRG1 in schizophrenia. A first report showed an increase in Nrg1 isoform 
type I expression mRNA levels and a decrease in type II/type I and type II/type III 
ratios in the dorsolateral PFC of patients with schizophrenia (Hashimoto et al., 2004). 
However, more recent studies revealed a decreased Nrg1 isoform type I and an 
increased type II in the PFC (Parlapani et al., 2008) and a decreased Nrg1 isoform α 
in the PFC of schizophrenic patients (Bertram et al., 2007). At the protein level, 
elevated Nrg1 and ErbB4 have also been observed in the PFC of schizophrenia 
patients (Chong et al., 2008). In the hippocampus, increased levels of Nrg1 isoform 
type I has also been observed post mortem in patients (Law et al., 2006) and NRG1 
genetic variation is associated with hippocampal volume reduction in patients with 
schizophrenia and their relatives (Gruber et al., 2008). Taken together, these results 
show that abnormal expression of Nrg1 isoforms in the foremost brain regions 
implicated in schizophrenia might be one of the features that induce susceptibility to 
schizophrenia.  
On a behavioural level, NRG1 is also associated with psychoaffective and 
cognitive aspects of schizophrenia. NRG1 is associated with personality difference in 
healthy individuals (Krug et al., 2008), and with increased reactivity to psychosocial 
stress in schizophrenic patients (Keri et al., 2008). Among the number of symptoms of 
schizophrenia, deficits in PPI and working memory are part of the main 
endophenotypes of the disorder. Interestingly, NRG1 polymorphism has been 
associated with both deficits in prepulse inhibition (PPI) in schizophrenia and healthy 
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populations (Hong et al., 2008) and with cognitive deficits seen in schizophrenia and 
development of psychotic symptoms (Hall et al., 2006). These cognitive disruptions 
associated with NRG1 polymorphism have been linked to impaired frontal and 
temporal lobe activation (Hall et al., 2006). NRG1 is also associated with 
hyperactivation of the superior frontal gyrus during performance of a working 
memory task in healthy individuals (Krug et al., 2008) and with disruption in neural 
connectivity that, by leading to a slower speed of cognitive processing, may 
contribute to cognitive impairments observed in schizophrenia (Bramon et al., 2008). 
These associations of NRG1 with schizophrenia shows that it is one of the main 
susceptibility genes for the disorder, however the mechanism by which NRG1 
signalling may influence the disorder remains largely unknown.  
 
3.3. Functional role of neuregulin in schizophrenia 
Nrg1-ErbB4 signalling plays essential roles in neurodevelopment, neurotransmission 
and synaptic plasticity that could influence the development of of psychiatric and 
neurological disorders such as schizophrenia (Mei and Xiong, 2008). Evidence now 
suggests that schizophrenia arises from disconnection between different brain regions, 
and the disruption of this circuitry could underlie the disturbed behaviours and 
perceptions observed in schizophrenia (Mitchell et al., 2001). Cognitive impairments 
of executive function subserved by the PFC can be considered as an endophenotype 
of schizophrenia (Wobrock et al., 2008), and it was recently shown that there is an 
abnormal activation in the dorsolateral PFC and in the anterior cingulate cortex of 
schizophrenia patients during working memory and executive processing (Schlosser 
et al., 2008). ErbB4 is associated with variation in fronto-temporal structural 
connectivity that is correlated with working memory (Konrad et al., 2008), and NRG1 
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gene variation is also associated with changes in medial frontal white matter structural 
integrity (Winterer et al., 2008). Further it has been reported that Nrg1-induced cell 
migration is impaired in schizophrenia (Sei et al., 2007). Thus, deficiency in Nrg1-
ErbB4 function could subserve the deficits observed in schizophrenia. 
Neuregulins are important regulators of glial cells including oligodendrocytes 
and myelination (Mei and Xiong, 2008). It is suggested that altered fronto-temporal 
connectivity could result from disruption in oligodendrocyte function in schizophrenia 
as altered expression of genes involved in myelination were observed in the 
postmortem dorsolateral PFC of schizophrenia patients (Hakak et al., 2001). 
Reduction of oligodendrocytes in the PFC (Vostrikov et al., 2008) and of key 
oligodendrocyte-related and myelin-related genes (Tkachev et al., 2003) as well as 
abnormalities of myelination (Flynn et al., 2003) were also observed in schizophrenia 
patients. Furthermore, it has recently been proposed that an increased risk of 
developing schizophrenia could result from inherited genetic variation that would 
affect oligodendrocyte development and myelination and that could also lead to a 
deficiency in dopaminergic functioning (Feng, 2008). In summary these studies 
suggest that deficits in Nrg1-ErbB4 signalling may contribute to the risk of 
schizophrenia by altering neuronal myelination and synaptic plasticity during brain 
development, resulting in defects in brain circuitry maturation. This would result in 
disruption of synaptic connectivity and subsequently lead to abnormal information 
processing in the brain that could contribute to the behavioural perturbation observed 
in schizophrenia. 
Nrg1 is expressed in the adult human brain like the dorsolateral PFC, the 
hippocampal formation or the cerebellum (Law et al., 2004), regions of the brain that 
have been implicated in schizophrenia (Mitchell et al., 2001, Baldacara et al., 2008, 
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Segarra et al., 2008). Abnormalities in NRG1 signalling might also influence 
schizophrenia susceptibility by altering the expression and function of 
neurotransmitter receptors, including glutamate receptors (Ozaki et al., 1997). 
Interestingly, NRG1-ErbB4 signalling is involved in glutamatergic NMDA receptor 
hypofunction in the PFC (Gu et al., 2005, Hahn et al., 2006) and the NMDA receptor 
is altered in the PFC of postmortem schizophrenia brain (Woo et al., 2008), consistent 
with the glutamatergic hypothesis of schizophrenia. NRG1 also regulates other 
neurotransmitters systems, including dopamine (Yurek et al., 2004), GABA (Woo et 
al., 2007), acetylcholine (Mathew et al., 2007) and serotonin (Dean et al., 2008) which 
is of particular interest given that these neurotransmitters are involved in 
schizophrenia and modulated by atypical antipsychotics (Gray and Roth, 2007, Huang 
et al., 2008). Finally, ErbB4 signalling is also involved in the neuroendocrine control 
of puberty (Ma et al., 1999), which is important as the age of onset of the first episode 
of schizophrenia is usually associated with the post-pubertal period corresponding to 
sexual maturation (Stevens, 2002, Walker and Bollini, 2002). Thus, defects in Nrg1 
signalling could disrupt hormonal changes associated with neurodevelopmental 
processes and neuroendocrine maturation underlying abnormal brain development 
(Walker and Bollini, 2002).  
 
3.4. Animal models in schizophrenia research 
A wide range of pharmacological, lesion and developmental manipulations 
have been developed to replicate some of the features of schizophrenia as modelled in 
animals. Pharmacology-based models have frequently been used since it was 
discovered that drugs which enhance dopamine function like amphetamine or 
antagonise NMDA receptor function like PCP promote psychotic symptoms in 
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humans (Gainetdinov et al., 2001). These drugs induce hyperlocomotion and 
stereotypy in animals, but glutamate hypofunction additionally induces negative 
symptoms like deficits in social interaction that can be reversed by atypical 
antipsychotic drugs (Corbett et al., 1995). In an attempt to model the 
neurodevelopmental theory of schizophrenia, aetiological models have been 
developed. For example, disrupted neurogenesis using X-ray or toxin exposure during 
gestation promote morphological changes in the hippocampus, frontal and entorhinal 
cortices as well as behavioural alterations such as hyperactivity, cognitive 
impairments and PPI and latent inhibition (LI) deficits (for a review, see Lipska and 
Weinberger, 2000). Similar changes are observed using other models including 
neonatal hippocampal lesions and early stress exposure like maternal separation or 
social isolation (Lipska and Weinberger, 2000).  
The creation of knockout mice lacking a specific gene offers an exciting new 
approach in the study of mental disorders, especially schizophrenia which is partly 
genetically determined. Genetic animal models using mutations of dopamine 
transporter or NMDA receptor subunits have been reported (for a review, see 
Gainetdinov et al., 2001), but mutations of specific schizophrenia susceptibility genes 
provide particularly relevant animal models. Such genetic models of schizophrenia 
offer valuable tools in investigating the neurobiological basis and potential therapeutic 
targets of schizophrenia.  
Given the complex nature of schizophrenia, animal research is limited to 
modelling specific schizophrenia-like symptoms and may not approximate all aspects 
of the disorder (Geyer, 2008). Modelling such aspects requires the need for 
appropriate endophenotypic measures. Endophenotypes are measurable components, 
unseen by the unaided eye, which are determined by an underlying genotype related 
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to a disease/disorder state. Such endophenotypes include behavioural, 
neuroanatomical, biochemical and cognitive measures (Gottesman and Gould, 2003). 
Some endophenotypes of schizophrenia can be directly reproduced in animal 
research. The most relevant example is deficits in PPI. This phenomenon is the 
decreased startle response produced by a prepulse stimulus, and reflects deficits in 
sensorimotor gating (Swerdlow et al., 1994). PPI is impaired in schizophrenia patients 
and can be reproduced in animals (Swerdlow et al., 1994). LI that is defined as the 
poorer conditioning to a previously irrelevant stimulus, is another model that 
measures the capacity of an organism to ignore irrelevant stimuli (Lubow and Moore, 
1959). Importantly, LI is impaired in schizophrenia (Gray et al., 1995) providing 
support for its use in animal modelling of psychosis (Lubow, 2005). Schizophrenia is 
also characterized by social withdrawal in humans, a key component of negative 
symptoms (DSM-IV). This effect can be studied in animals as social interaction (SI), 
as developmental models such as neonatal hippocampal lesion and prenatal stress, and 
pharmacological models of schizophrenia using PCP induce deficits in SI in rat 
(Sams-Dodd et al., 1997, Sams-Dodd, 1999, Lee et al., 2007). Other negative 
symtoms of schizophrenia such as anhedonia can also be modelised in animals using 
reward sensitivity, a behaviour that is reduced in adult rats that received neonatal 
ventral hippocampal lesions (Le Pen et al., 2002). 
While positive and negative symptoms have long been considered as 
hallmarks of schizophrenia, cognitive impairments are now considered as core 
features of the disorder (Elvevag and Goldberg, 2000). Working memory deficits are 
the most consistently observed cognitive symptoms in schizophrenia patients (Park et 
al., 1999) and antipsychotic drugs reverse working memory impairments (Weinberger 
and Gallhofer, 1997). The measurement of working memory provides an additional 
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endophenotype that can be discerned in animals. Interestingly, animal working 
memory deficits are subserved by dysfunctional dopamine and glutamate signalling in 
the prefrontal cortex (for a review, see Castner et al., 2004), areas thought to underlie 
cognitive impairments seen in schizophrenia patients. In addition to behavioural 
changes, endophenotypes might take the form of underlying anatomical or 
neurochemical changes in animals that parallel those observed in schizophrenia 
patients. For example, enlarged ventricles are consistently observed in schizophrenia 
patients and their relatives (McDonald et al., 2006) and thus provide a potential 
morphometric endophenotype of schizophrenia which might be reproduced in animal 
models of the disorder (Hikida et al., 2007, Pletnikov et al., 2008, Verma et al., 2008). 
Further, alteration in levels of neurotransmitters or receptors implicated in 
schizophrenia such as dopamine or NMDA receptors might also provide an 
endophenotypic measure in animal studies.  
Of course reproducing the characteristic positive symptoms of schizophrenia 
such as hallucinations and delusion in animals is more difficult and subject to 
anthropomorphism. However, the positive symptoms might be modelled by increased 
locomotor activity as this is usually subserved by increased dopamine release, a 
proposed feature of schizophrenia neurochemistry. Indeed, drugs like amphetamine 
that increase psychotic symptoms in humans induce hyperactivity in rodents, and this 
effect is reversed by antipsychotic drugs (Ellison and Eison, 1983, Gleason and 
Shannon, 1997, Millan et al., 1999). 
 
3.5. Nrg1 HET mice as an animal model for schizophrenia  
In the last decade mutant mice have been developed to disrupt Nrg1 signalling in an 
attempt to model schizophrenia. The behavioural and neuronal manifestations of such 
Chapter 1: Cannabis use and schizophrenia 
27 
genetically modified mice are summarized in Table 1. Overall, the different 
manipulation of genes encoding for the different isoforms of Nrg1 and ErbB4 
receptors reproduce many of the important endophenotypes relevant to animal 
modelling of schizophrenia. The present thesis will concentrate on studying mutant 
mice heterozygous for the transmembrane domain of Nrg1 gene, as this is the best 
characterised neuregulin 1-ErbB system genetic model. Further, a mutation of the 
transmembrane domain of the Nrg1 gene has been specifically associated with 
schizophrenia in human populations (Walss-Bass et al., 2006). Interestingly, Nrg1 
knockout mice were originally developed to better understand cardiac development, 
and Nrg1 homozygous knockout animals die embryonically due to heart defects 
(Meyer and Birchmeier, 1995). Mice heterozygous for Nrg1 (Nrg1 HET) are viable 
and fertile and have since been behaviourally characterised as an animal model of 
schizophrenia. These mice provide a very promising phenotype for the study of 
schizophrenia displaying hyperlocomotion that can be reversed by the antipsychotic 
drug clozapine, PPI deficits and a reduction in NMDA receptors (Stefansson et al., 
2002). They also show a retarded exploratory habituation profile in a novel 
environment and impairments in social recognition memory (O'Tuathaigh et al., 2006, 
O'Tuathaigh et al., 2007). In addition, Nrg1 HET mice show an age-dependent 
phenotype where the hyper-locomotor and hyper-exploratory behaviours of Nrg1 
HET mice is only seen in animals older than 4 months, which somewhat models the 
post-pubescent onset of schizophrenia (Karl et al., 2007). More recently these mice 
have been shown to have increased serotonin 5-HT2A receptor levels in the brain 
(Dean et al., 2008) – this receptor is thought to be involved in hallucination as 
hallucinogenic drugs such as lysergic acid diethylamide (LSD) and psilocybin target 
5-HT receptors (Gonzalez-Maeso et al., 2007). 
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Table 1. The different animal models of Nrg1 deficiency 
Gene dysfunction Study Behaviour modified 
TM Nrg1 (Stefansson et al., 2002) Hyperactivity, reversed by clozapine 
PPI impairments  
Reduction of functional NMDA receptors 
(O'Tuathaigh et al., 2006) Hyperactivity and increased rearing 
Decreased habituation to exploration 
(Karl et al., 2007) Hyperactivity and increased exploration 
Moderate anxiolytic-like effect 
Age-dependent phenotype  
Environment enrichment-dependent phenotype 
(O'Tuathaigh et al., 2007) Hyperactivity 
Impairments in social novelty 
(O'Tuathaigh et al., 2008) Hyperactivity 
Increased aggressive behaviour 
(Dean et al., 2008) Increased serotonin 2A receptor and serotonin 
transporter
EGF-like Nrg1 (Gerlai et al., 2000) Hyperactivity 
(Duffy et al., 2008) Hyperactivity 
Increased habituation to new environment 
Moderate impairment in PPI following NMDA 
antagonism 
immunoglobulin 
(Ig)-like Nrg1 
(Rimer et al., 2005) Clozapine-induced decreased exploration 
Latent inhibition deficit
type III Nrg1 (Chen et al., 2008) Enlarged ventricles 
Hypofunction of the PFC, hippocampus and 
subiculum 
Reduced spine density 
Memory deficits 
PPI impairments 
BACE1 (Savonenko et al., 2008) Hyperactivity, reversed by clozapine 
Social impairment 
Cognitive deficits 
PPI impairments 
Hypersensitivity to NMDA receptor antagonist 
Reduced spine density 
Aph1B/C (Dejaegere et al., 2008) PPI impairments, reversed by antipsychotics 
Memory deficits
ErbB4 (Stefansson et al., 2002) hyperactivity 
CNS-specific 
ErbB4 null 
(Golub et al., 2004) Decreased locomotion  
Disrupted cue use in memory test 
ErbB signalling in 
oligodendrocytes 
(Roy et al., 2007) Decreased locomotion 
Social impairment 
Anxiety-like behaviour 
increased levels of dopamine receptors and 
transporters 
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4. Aims of the current thesis 
The work described in this thesis aims at examining if vulnerability to cannabinoid-
induced effects could represent an additional phenotype of schizophrenia reproduced 
by Nrg1 HET mice. While human population studies indicate that a gene-environment 
interaction is likely required for the development of schizophrenia they are restricted 
in the mechanistic detail they can provide. Indeed epidemiologists have made a call to 
basic scientists to assist in the quest to delineate the exact genetic and 
neuropharmacological bases for cannabis-induced schizophrenia (Henquet et al., 
2005). Therefore, the present thesis attempts to answer such a call by examining the 
role of Nrg1 in the neurobehavioural actions of cannabinoids.  
Chapter 2 aimed to examine the behavioural effects of acute exposure to THC, 
the main psychoactive constituent of cannabis, in Nrg1 HET mice and their control 
wild-type-like (WT) littermates. This study focussed on testing the animals in a wide 
range of behavioural domains such as locomotion, exploration, anxiety and 
sensorimotor gating using a multi-tiered behavioural phenotyping strategy. Here we 
hypothesised that deficiency in Nrg1 would modulate the behavioural effects of acute 
THC exposure. 
In Chapter 3 we aimed to assess the underlying neuronal changes that might 
subserve any distinct behavioural effects of acute THC administration on Nrg1 HET 
mice observed in Chapter 2. To achieve this Nrg1 HET mice and WT were exposed to 
THC before their brains were retained for c-Fos immunohistochemical analysis. C-
Fos is a marker of neuronal activity as it is rapidly and transiently expressed to novel 
stimuli. Further, Chapter 3 also aimed to investigate whether the stress of behavioural 
testing contributed to any differential effect of THC observed on Nrg1 HET mice.  
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As the relationship between cannabis and schizophrenia increases with the 
frequency of drug use, chronic cannabis consumption is more reliably associated with 
precipitating psychosis. Thus Chapter 4 aimed to assess the effect of chronic 
cannabinoid exposure on the neurobehavioural responses of Nrg1 HET and WT mice. 
It was hypothesised that repeated cannabinoid exposure might induce altered 
neuroadaptive responses as measured by Fos B/∆Fos B expression in Nrg1 HET 
compared to WT mice which might correlate with altered effects of the drug as 
measured on the behavioural level. 
One of the main schizophrenia endophenotypes observed in human studies are 
cognitive impairments of higher executive functions. However, behavioural 
phenotyping in animal models of schizophrenia does not provide enough cognitive 
testing to evaluate higher functional deficits. Importantly, it is difficult to assess the 
cognitive effects of cannabinoids as these drugs are highly sedative and produce 
tolerance to their effects. Thus Chapter 5 aimed at setting up a procedure that would 
allow evaluating cannabis-induced behavioural flexibility deficits that could be 
extended to phenotyping cognitive deficits in Nrg1 HET and WT animals in the 
future.   
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Summary of the main results at the end of Chapter 2 
 
 
Chapter 2 examined the behavioural effects of THC (10 mg/kg) on WT and Nrg1 
HET mice. Two groups of animals have been tested in either the open field test (30 
min), followed by the hole board test (7 min) and the elevated plus maze (5 min), or 
in the light dark test (10 min), followed by social interaction (10 min) and prepulse 
inhibition (30 min), animals returning to their home cage for 5 min between the 
different tests. The main results obtained from this experiment are summarised in 
Table 3 and show that Nrg1 HET mice are more sensitive to the effects of THC on 
locomotor activity and prepulse inhibition. 
 
Table 3. Summary of main results form Chapter 2. 
 
Test 
 
Chapter 2 
Effect of THC (10 mg/kg) 
Locomotor activity in the open field 
 
Hypolocomotion more important in Nrg1 HET mice than 
WT mice  
Anxiety in the light dark  
 
 
Decreased time spent in the light compartment only in 
Nrg1 HET mice 
Social interaction Decreased social interaction in both WT and Nrg1 HET 
mice similarly 
Prepulse inhibition 
 
Facilitation only in Nrg1 HET mice 
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Summary of the main results at the end of Chapter 3 
 
 
Chapter 3 examined the neurobiological effects of THC (10 mg/kg) on c-Fos 
expression using immunohistochemistry on WT and Nrg1 HET mice. The main 
results obtained from this experiment are summarised in Table 3 and show that Nrg1 
HET mice are more sensitive to the effects of THC on c-Fos expression in the 
ventrolateral septum (LSV). In addition, this effect is dependent on the stress induced 
by behavioural testing. 
 
Table 3. Summary of main results form Chapter 2 and 3. 
 
Test 
 
Chapter 2 
Effect of THC  
(10 mg/kg) 
Chapter 3 
Effects of THC  
(10 mg/kg) 
Locomotor activity in the open field 
 
Hypolocomotion more 
important in Nrg1 HET mice 
than WT mice  
 
Anxiety in the light dark  
 
 
Decreased time spent in the 
light compartment only in 
Nrg1 HET mice 
 
Social interaction Decreased social interaction 
in both WT and Nrg1 HET 
mice similarly 
 
Prepulse inhibition 
 
Facilitation only in Nrg1 HET 
mice 
 
Immunohistochemistry 
 
 Increased c-Fos expression 
in the LSV of Nrg1 HET 
mice dependent on 
behavioural testing 
 
 
 
 
 
 
 
  
 
Chapter 4 
 
 
 
DIFFERENTIAL NEUROBEHAVIOURAL EFFECTS 
OF REPEATED CANNABINOID TREATMENT ON 
HETEROZYGOUS NEUREGULIN 1 MICE 
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1. Introduction 
Cannabis is the most widely used illicit drug in the world. Evidence suggests that 
cannabis exposure may precipitate schizophrenia in individuals that are genetically 
vulnerable to this disorder (Bayer et al., 1999). One of the most promising 
susceptibility genes for schizophrenia is neuregulin 1 (NRG1) (Stefansson et al., 
2002) and animal studies have shown that mutant mice heterozygous for the 
transmembrane domain of Nrg1 (Nrg1 HET mice) exhibit a schizophrenia-related 
phenotype. Specifically, these animals develop an age-dependent phenotype, an 
increased sensitivity to environmental factors, hyperlocomotion, abnormalities in 
social behaviour and sensorimotor gating deficits (Stefansson et al., 2002, 
O'Tuathaigh et al., 2006, Boucher et al., 2007a, Karl et al., 2007). In addition to these 
behavioural defects, neurobiological changes have been reported where Nrg1 HET 
mice displayed increased levels of serotonergic 5-HT2A receptors (Dean et al., 2008) 
and an increased baseline c-Fos expression in brain areas implicated in schizophrenia 
such as the ventrolateral septum (LSV) and the shell of the nucleus accumbens (NAS) 
(Boucher et al., 2007b).  
We have previously reported that Nrg1 HET mice have an increased 
sensitivity to the acute neurobehavioural effects of cannabinoids (Boucher et al., 
2007a, b). For example, the administration of the main psychoactive constituent of 
cannabis, Δ9-tetrahydrocannabinol (THC), selectively facilitated prepulse inhibition 
(PPI) in Nrg1 HET mice (Boucher et al., 2007a). We also showed that unlike WT 
animals, Nrg1 HET mice show increased sensitivity to THC-induced c-Fos expression 
as measured in the LSV, and that these differential effects were dependent upon 
behavioural testing (Boucher et al., 2007b). Therefore, this phenomenon appears to be 
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dependent on a 3-way interaction between Nrg1 deficiency, stress and cannabinoid 
administration. 
As Nrg1 HET mice are more sensitive to the neurobehavioural effects of THC, 
this study aims to investigate whether these animals adapt differently than their wild 
type-like (WT) littermates to the chronic administration of a cannabinoid receptor 
agonist. This is particularly relevant, as chronic, high dose cannabis exposure is more 
strongly linked to the development of schizophrenia (Linszen et al., 1994). It is a 
common phenomenon that animals develop tolerance to the behavioural effects of 
cannabinoids after repeated administration (Costa et al., 1996, Lichtman and Martin, 
2005). This phenomenon is partly explained by the development of neuroadaptative 
processes that act to counteract the acute action of the drug. For example, 
desensitization and/or down regulation of cannabinoid CB1 receptors in the brain may 
subserve tolerance to cannabinoids. Interestingly, tolerance arises to different 
behavioural effects at differing rates, for example reduced sensitivity to cannabinoid-
induced hypothermia occurs more rapidly than cannabinoid-promoted locomotor 
suppression (Gonzalez et al., 2005).  
As neuregulins are neurodevelopmental factors involved in synaptogenesis, 
neuronal migration, glial differentiation, myelination and neurotransmitter receptor 
expression (Corfas et al., 2004), we aim in the present study to assess if Nrg1 HET 
mice display altered neuroadaptive responses to chronic cannabinoid exposure. To 
achieve this, we observed the effects of repeated exposure to the synthetic analogue of 
THC, CP 55,940 on various physiological (body temperature), behavioural 
[locomotor activity, exploration, social interaction, anxiety and PPI] and 
neurobiological (c-Fos and Fos B/∆Fos B expression) measures.  
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2. Methods 
2.1. Animals 
Male adult (22 to 25 weeks) group-housed Nrg1 HET mice generated from a 
C57BL/6 background strain were provided by Prof Richard Harvey (Victor Chang 
Cardiac Research Institute, Sydney Australia) as previously described (Karl et al., 
2007). Nrg1 HET mice and their control wild-type like littermates (WT) were pair-
housed under a 12:12 h normal light:dark schedule [light phase: white light 
(illumination: 80 lx) - dark phase: red light (illumination: <2 lx)] with food and water 
available ad libitum. Microbiological monitoring revealed no infection of the SPF 
facility holding room - with the exception of the pathogens commonly found in 
commercial and research facilities, Pasteurella pneumotropica and Helicobacter spp. 
Male adult (age-matched ±7 days) group-housed A/J mice (Animal Resources Centre, 
Canning Vale, Australia) were used as standard opponents in the social interaction 
test. All research and animal care procedures were approved by the "Garvan Institute / 
St Vincent's Hospital Animal Experimentation Ethics Committee" and were in 
agreement with the "Australian Code of Practice for the Care and Use of Animals for 
Scientific Purposes".  
 
2.2. Drug treatments 
CP 55,940 (Tocris, Ellisville, USA) was dissolved in 4% ethanol, 1% Tween 80, and 
95% saline. CP 55,940 or vehicle (VEH) were administered intraperitoneally (i.p.) at 
0.4 mg/kg in a volume of 10 ml/kg of body weight, 30 min prior to behavioural 
testing.  
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2.3. Experimental procedure 
Animals were treated once daily for 15 days. Thirty min after the injection, mice were 
tested for body temperature (BT) and locomotor activity in the open field (OF) every 
second day. Mice were additionally tested for social interaction (SI), light-dark (LD) 
and PPI on days 1, 7 and 15. The order of the test was always the same and separated 
by a 5 min rest time in the animals’ home cage. For habituation purposes all test 
animals were transported to the testing room 1 h prior to behavioural testing (holding 
and test room were part of the same facility having therefore identical light, air 
pressure, and temperature conditions). Environmental odours were removed from the 
different test apparatus by cleaning the equipment after each trial with a 30% ethanol 
solution. 
BT: Rectal temperature was measured in each mouse using a mouse rectal 
temperature probe (ADInstruments, Bella Vista, Australia) attached to a thermocouple 
(Dicksmith electronics). The probe was placed 3 cm into the rectum of the mice for 
approximately 5 s until the temperature was constant. BT was recorded immediately 
prior to, and 30 min after, the injection. Data were expressed as difference in BT 
between the baseline BT and BT + 30 min.  
OF: Locomotor activity and explorative-like tendencies were evaluated by 
placing the mouse into an infrared photobeam-controlled (x-, y-, and z-axis) open 
field activity test chamber (43.2 cm x 43.2 cm; MED Associates Inc., USA, 
Vermont). Animals were tested for 10 min (illumination at floor level: 20 lx), and the 
total distance travelled (horizontal activity: x- and y-axis) and the vertical activity (z-
axis) were recorded automatically (software settings: box size: 3; ambulatory trigger: 
2; resting delay: 1000 ms; resolution: 100 ms) in the central and peripheral areas.  
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PPI: Patients with schizophrenia show impaired sensorimotor gating. PPI is 
the operational measure of sensorimotor gating, in which a weak pre-stimulus 
(prepulse) attenuates the startle response (Wang et al., 2003). PPI was tested in two 
startle chambers (SR-Lab: San Diego Instruments, San Diego, USA). Animals were 
habituated to the test device for three consecutive days (Day 1: 5 min; Day 2-3: 10 
min) before being tested 24 h later. The protocol used was adapted from methods 
developed by Geyer and Swerdlow (Geyer and Swerdlow, 1998). After a 5 min 
acclimation period with a 70 dB background noise each session of approximately 30 
min consisted of 115 trials in a pseudorandomised order: A block of 5 x 120 dB trials 
was presented at the beginning and end of each test session in order to observe 
habituation of the startle response and to scale down the initial startle response to a 
stable plateau. The remainder of the session consisted of the following trials of stimuli 
presented in a pseudorandomized order: 5 trials of startle alone trials for different 
startle stimuli (70 / 80 / 100 / 120 dB) and 5 trials of prepulse-startle stimulus (120 
dB) trials for a variety of prepulse intensities (PI: 4, 12 or 16 dB above background 
noise) and intratrial intervals (prepulse-pulse intervals of 32, 64, 128, 256 or 512 ms). 
We chose a variable intertrial interval of averaged 15 s (range 10–20 s), prepulse 
duration of 20 ms and startle duration of 40 ms. Startle response was measured as the 
average mean amplitude. Percentage of PPI (%PPI) was calculated as [(startle 
response 120 dB – PPI response) x 100 / startle response 120 dB]. We also analysed 
the mean %PPI of all summed prepulse responses (averaged over PI and intratrial 
intervals) for each group. 
SI: This pharmacologically validated model is widely used to measure 
anxiety-like behaviours (File, 1988, Kask et al., 2001). Test animals were placed 
together with an unfamiliar A/J standard opponent into the OF activity test chamber 
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(in opposite corners), where they were allowed to explore the arena and each other 
freely for 10 min. The behaviour of the test mouse was recorded online. The total 
duration in the active socio-positive behaviours such as general sniffing, anogenital 
sniffing, allogrooming, following and crawling over/under were recorded. Active 
social interaction (SI) time is inversely related to the anxiety of rodents, which is 
confirmed by the observation that the maximum active SI time is found when rodents 
are tested in a familiar test arena with a low level of illumination (File and Hyde, 
1978).  
LD: This paradigm mimics the natural conflict between the tendency of mice 
to explore a novel environment and to avoid an exposed open area (DeFries et al., 
1966, Crawley, 1985). Test animals were placed into the open field chamber, which 
was equipped with a dark box insert for mice (covering half the area of the chamber: 
MED Associates Inc.). An opening located in the centre of the partition connected 
light (illumination: 20 lx) and dark (illumination: <2 lx) compartments. At the start of 
the experiment mice were placed into the bright compartment, facing the dark one. 
The time spent in the light compartment was recorded during a 10 min session and 
was used as a measure of anxiety (Costall et al., 1989, Crawley, 1999). Animals that 
did not explore the dark chamber for more than 10 % of the total time on day 1 were 
excluded from the analysis (1 Nrg1 HET-VEH, 1 WT-VEH and 1 WT-CP 55,940). 
 
2.4. Immunohistochemistry 
We used c-Fos and Fos B/∆Fos B immunohistochemistry in diverse brain regions to 
assess changes in neuronal activity following repeated CP 55,940 exposure. While c-
Fos is rapidly and transiently expressed with novelty and acute drug exposure, ∆Fos B 
accumulates in the brain and persists for a long period of time as it is extremely 
Chapter 4: Neurobehavioural effects of repeated CP 55,940 treatment on Nrg1 HET mice 
64 
stable, therefore reflecting long term molecular changes indicating of neuroadaptation 
processes (Nestler et al., 1999). However, the anti-Fos B antibody used here is not 
specific to ∆Fos B, a product of the Fos B gene, but recognizes the full-length Fos B 
isoform that is not specific to long term neuronal changes. Therefore we also 
measured the expression of c-Fos to assess if any Fos B/∆Fos B expression would 
appear without concomitant expression of c-Fos, thus supporting that the Fos B/∆Fos 
B expression could be due to long term changes induced by ∆Fos B (Berton et al., 
2007). 
Immediately after behavioural testing was completed and approximately 90 
minutes after the final injection of either VEH or CP 55,940 (day 15), mice were 
anaesthetized with halothane and perfused transcardially with 0.9% saline followed 
by 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer saline. The brains were 
removed and postfixed overnight in fresh PFA at 4°C before being incubated in 15% 
sucrose, followed by 30% sucrose for cryoprotection. The brains were then placed in 
the cryostat for slow freezing at -17°C and the entire brain was sliced at 40 μm in the 
coronal plane. Brain slices were placed sequentially into three vials containing 
phosphate buffer (PB). Tissues were stored in freezing solution (ethanediol/glycerol) 
at -15°C until needed. Free floating sections were washed three times in PB then 
placed in a 1% hydrogen peroxide solution for 30 min and then placed in 3% normal 
horse serum for 30 min. Sections were then placed in vials with 3 ml of primary c-Fos 
antibody (Santa Cruz Biotechnology, rabbit polyclonal; reacts with c-Fos p62 of 
mouse and non-cross reactive with FosB, Fra-1 or Fra-2) diluted 1:10 000 in 
phosphate buffered horse serum (PBH) (0.1% bovine serum albumin, 0.2% Triton X-
100, 2% normal horse serum) for 3 days at 4°C. Another vial was prepared in the 
same way as above, but stained with the Fos B/∆Fos B primary antibody (Santa Cruz 
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Biotechnology, rabbit polyclonal) diluted in 1:2000 in PBH overnight at 4°C. 
Afterwards, both sets of tissue were washed in PB and then incubated for 1 h in 
biotinylated anti-rabbit IgG secondary antibody (Vector Laboratories, Burlingame, 
CA) diluted 1:500 in PBH. Sections were washed again before being incubated in 
ExtrAvidin peroxidase (Sigma, diluted 1:1000 in PBH) for 2 h. After three washes in 
PB, peroxidase activity was visualised by placing the tissue in nickel 
diaminobenzidine (0.05% diaminobenzidine tetrahydrochloride, 0.004% ammonium 
chloride, 0.02% nickel ammonium sulphate, 0.2% D-glucose) and glucose oxidase 
(Sigma, 1:1000) and the reaction was terminated after 10 min by washing in PB. 
Sections where stored in PB at 4°C before being mounted onto gelatinized slides, 
dehydrated, xylene cleared and coverslipped. Fos immunoreactive cells (black and 
dark brown) were quantified by a rater blind to treatment with reference to the mouse 
brain atlas of Paxinos and Franklin (Paxinos and Franklin, 2000) as previously 
described (McGregor et al., 1998, Arnold et al., 2001b, Boucher et al., 2007b). 
 
2.5. Data analysis 
For each behavioural model, we first analysed the overall effects using repeated 
measures two-way analysis of variance (ANOVA). The two factors were genotype 
(WT and Nrg1 HET mice) and treatment (VEH and CP 55,940) and the repeated 
measure was test day. When needed, we evaluated the development of tolerance in CP 
55,940-treated animals or habituation to behavioural testing in VEH-treated animals, 
by using repeated measures two-way ANOVA split by the corresponding factor. Then 
when focusing on each day separately, we investigated the specific effects of the 
treatment and/or of the genotype using two-way ANOVA split by the corresponding 
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factor. In the OF, the total distance travelled was further analyzed as a % of VEH 
using one-way ANOVA to reveal any genotype difference on this measure.  
Fos counts in each brain region were analysed using two-way ANOVA 
followed by Tukey’s post-hoc test for within group comparisons. A significance level 
of P<0.05 was chosen for all comparisons. In the graphs and tables, data are presented 
as means ± standard error of the mean (SEM) and the post hoc effects are reported 
with symbols when appropriate (see legends). 
 
3. Results 
3.1. Body temperature and locomotor activity 
The results from locomotor activity in the OF and BT are shown in Fig. 1. Repeated 
CP 55,940 treatment produced an overall decreased BT [Treatment: F(1,35) = 79.22, 
P < 0.001] (Fig. 1A). Trends for an effect of the genotype [F(1,35) = 3.54, P = 0.07] 
and for a genotype by treatment interaction [F(1,35) = 3.42, P = 0.07] were observed. 
An effect of test day [F(7,245) = 16.89, P < 0.001] and treatment by test day 
[F(7,245) = 18.47, P < 0.001] and genotype by treatment by test day [F(7,245) = 2.46, 
P < 0.05] interactions were also observed. When separating by treatment, no test day 
effect was observed in VEH-treated animals but a genotype by test day interaction 
was revealed [F(7,126) = 2.32, P < 0.05]. Tolerance to the effects of the drug on BT 
was highlighted by a test day effect in CP 55,940-treated WT and Nrg1 HET animals 
[F(7,119) = 27.94, P < 0.001] and a difference between CP 55,940-treated Nrg1 HET 
and WT mice was also observed over days [genotype: F(1,17) = 4.64, P < 0.05]. To 
assess the difference in development of tolerance between Nrg1 HET mice and WT 
mice, we analysed genotype effects in CP 55,940-treated animals on the different days 
(Fig. 1A). No difference was observed between CP 55,940-treated Nrg1 HET and WT 
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mice on day 1. Interestingly, a genotype effect was observed in CP 55,940-treated 
animals on days 3 [F(1,17) = 11.31, P < 0.01] and 5 [F(1,17) = 5.83, P < 0.05]. This 
highlights that while CP 55,940 promoted equivalent hypothermia in Nrg1 HET and 
WT mice on day 1, the drug reduced BT less in Nrg1 HET mice than WT mice on 
days 3 and 5. 
In the OF, repeated exposure to CP 55,940 promoted an overall decreased 
distance travelled [treatment: F(1,35) = 8.15, P < 0.01] and Nrg1 HET mice exhibited 
an overall higher locomotor activity [genotype: F(1,35) = 6.77, P < 0.05] (Fig. 1B). 
An effect of test day [F(7,245) = 9.13, P < 0.001] and a treatment by test day 
interaction [F(7,245) = 22.64, P < 0.001] were also observed. When separating by 
treatment, VEH-treated animals habituated to the OF [test day: F(7,126) = 8.88, P < 
0.001] and a strong trend for a genotype effect was observed [F(1,18) = 4.38, P = 
0.05]. A test day effect was observed in CP 55,940-treated animals [F(7,199) = 17.66, 
P < 0.001] showing that tolerance developed to the effect of the drug in the OF. When 
assessing genotype effects in VEH-treated animals on the different days, although no 
significant hyperactivity of Nrg1 HET mice compared to WT mice was observed on 
day 1, a genotype effect was revealed on days 9 [F(1,18) = 6.54, P < 0.05], 11 
[F(1,18) = 4.55, P < 0.05] and 15 [F(1,18) = 7.28, P < 0.05]. Interestingly, when 
analysing the % of change of locomotor activity between day 1 and day 15, VEH-
treated Nrg1 HET mice showed a strong trend for reduced habituation to the OF 
compared to WT mice (a 6.35 % versus 37.89 % reduction respectively) [F(1,18) = 
4.36, P = 0.05]. This suggests that hyperactivity was unmasked when VEH-treated 
WT mice habituated to the OF. 
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Figure 1: Tolerance to the effects of CP 55,940 (0.4 mg/kg) compared to vehicle (VEH) on (A) BT 
and (B) locomotor activity in the OF of WT and Nrg1 HET mice (WT VEH, n = 12; WT CP 55,940, n 
= 11; Nrg1 HET VEH, n = 8; Nrg1 HET CP 55,940, n = 8). Data are presented as means ± SEM. 
Significant effects of Nrg1 HET mice compared to WT mice in CP 55,940-treated animals are 
indicated by Ì (P < 0.05), ÌÌ (P < 0.01) and ÌÌÌ (P < 0.001).  Significant effects of Nrg1 HET 
mice compared to WT mice in VEH-treated animals in the OF are indicated by # (P < 0.05). 
 
 
Like for BT, we assessed differential development of tolerance between Nrg1 
HET mice and WT mice by evaluating any genotype difference within CP 55,940-
treated animals on the different days. CP 55,940-induced locomotor suppression was 
less important in Nrg1 HET mice than in WT mice as revealed by treatment effects on 
days 1 [F(1,17) = 5.53, P < 0.05], 3 [F(1,17) = 16.62, P < 0.001] and 5 [F(1,17) = 
5.23, P < 0.05] (Fig. 1B). As there was a marginal difference between Nrg1 HET 
mice and WT mice on day 1, we examined the rate of induction of tolerance by 
analysing the effect of CP 55,940 on total distance travelled as a % of the VEH group 
for each genotype using one-way ANOVA. No difference between Nrg1 HET mice 
and WT mice was found on day 1, showing that the animals were equally affected by 
the drug and only travelled for 6.47 % and 2.62 % of the distance travelled by VEH-
treated animals respectively. However on day 3 CP 55,940-treated Nrg1 HET mice 
travelled significantly more than WT mice (51.64 % versus 17.99 % of distance 
travelled by VEH) [treatment: F(1,17) = 10.72, P < 0.01]. This indicates that on day 3 
Nrg1 HET mice displayed a more rapid decline in the effect of CP 55,940 on 
locomotor activity than WT mice. Complete tolerance developed to CP 55,940-
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induced decreased locomotor activity in the OF, as treatment effects were only 
observed for 3 days in Nrg1 HET mice [day 1: F(1,14) = 38.51, P < 0.001, day 3: 
F(1,14) = 10.95, P < 0.01] and 5 days in WT mice [day 1: F(1,21) = 74.39, P < 0.001, 
day 3: F(1,21) = 37.42, P < 0.001, day 5: F(1,21) = 9.6, P < 0.01].   
 
3.2. Prepulse inhibition 
In the PPI paradigm (Fig. 2A) no overall effect of the genotype, treatment or test day 
was observed. However, genotype by treatment [F(1,35) = 4.49, P < 0.05] and 
genotype by treatment by test day [F(2,70) = 5.42, P < 0.01] interactions were 
observed. When analysed by days of treatment, a genotype difference was observed in 
VEH-treated animals, with a decreased %PPI of Nrg1 HET mice compared to WT 
mice on day 1 [F(1,18) = 4.79, P < 0.05], but not on days 7 and 15. An effect of CP 
55,940 was observed on day 1 as the drug decreased %PPI in WT mice [F(1,21) = 
5.83, P < 0.05] while it increased % PPI in Nrg1 HET mice [F(1,14) = 4.95, P < 
0.05]. However, no effect of CP 55,940 on %PPI in WT mice or in Nrg1 HET mice 
was observed on days 7 and 15. 
 
Figure 2: Tolerance to the effects of CP 55,940 (0.4 mg/kg) compared to vehicle (VEH) on (A) % 
PPI (mean of the different prepulse intensities) and (B) startle response of WT and Nrg1 HET mice 
(WT VEH, n = 12; WT CP 55,940, n = 11; Nrg1 HET VEH, n = 8; Nrg1 HET CP 55,940, n = 8). Data 
are presented as means ± SEM. Significant effects of CP 55,940 compared to VEH within the same 
genotype group are indicated by Ì (P < 0.05) and ÌÌÌ (P < 0.001). Significant effects of Nrg1 
HET mice compared to WT mice in VEH-treated animals are indicated by # (P < 0.05) and # # (P < 
0.01). 
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During the PPI test we also measured the startle response of the animals (Fig. 
2B). Over days, CP 55,940 administration decreased startle response [treatment: 
F(1,35) = 4.2, P < 0.05]. No effect of the genotype was observed but a significant 
genotype by treatment interaction was revealed [F(1,35) = 4.14, P < 0.05]. An effect 
of test day [F(2,70) = 20.67, P < 0.001] and a treatment by test day interaction 
[F(2,70) = 21.03, P < 0.001] were also reported. Tolerance to the reduced startle 
response was observed in CP 55,940-treated animals [test day: F(2,34) = 36.3, P < 
0.001]. On the different days independently, genotype difference in VEH-treated 
animals was observed on day 1 where Nrg1 HET mice showed a decreased startle 
response compared to WT mice [F(1,18) = 8.93, P < 0.01]. Treatment with CP 55,940 
decreased startle response in Nrg1 HET mice and WT mice on day 1 [F(1,14) = 5.95, 
P < 0.05 and F(1,21) = 57.04, P < 0.001 respectively], with no effect seen on days 7 
and 15.  
 
3.3. Social interaction and rearing frequency 
The results from the total time in SI are shown in Fig. 3A. Repeated administration of 
CP 55,940 produced an overall decreased time spent in SI [F(1,35) = 107.18, P < 
0.001] and the effect of the drug was in interaction with the test day [F(2,70) = 11.11, 
P < 0.001]. No overall genotype difference was observed over days. Depending on 
the treatment, we observed habituation to SI over the days in VEH-treated animals 
[test day: F(2,36) = 6.11, P < 0.01] and development of tolerance to the effect of the 
drug on SI in CP 55,940-treated mice [test day: F(2,34) = 12.38, P < 0.001]. On the 
different days separately, no genotype differences were observed in VEH-treated 
animals on any days. The development of tolerance to CP 55,940-induced decreased 
SI was not complete, as a significant treatment effect was observed on all days for 
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both WT [day 1, F(1,21) = 95.35, P < 0.001; day 7, F(1,21) = 49.19, P < 0.001; day 
15, F(1,21) = 9.87, P < 0.01] and Nrg1 HET mice [day 1, F(1,14) = 23.21, P < 0.001; 
day 7, F(1,14) = 21.17, P < 0.001; day 15, F(1,14) = 7.35, P < 0.05].  
 
 
Exploration-like behaviour of Nrg1 HET and WT mice was recorded as the 
rearing frequency of the animals during the SI test (Fig. 3B). When repeatedly 
administered, CP 55,940 induced an overall decreased rearing frequency [F(1,35) = 
130.6, P < 0.001]. Trends for a genotype effect [F(1,35) = 3.47, P = 0.07] and a 
genotype by treatment interaction [F(1,35) = 3.28, P = 0.08] were observed. 
Interestingly a significant test day effect was observed [F(2,70) = 10.19, P < 0.001] 
and treatment by test day [F(2,70) = 6.3, P < 0.01], genotype by test day [F(2,70) = 
3.56, P < 0.05] and genotype by treatment by test day [F(2,70) = 3.34, P < 0.05] 
interactions were reported. In VEH-treated animals, an effect of test day [F(2,36) = 
9.01, P < 0.001] and importantly a genotype by test day interaction [F(2,36) = 3.82, P 
< 0.05] were observed showing a differential habituation to rearing of VEH-treated 
Nrg1 HET mice compared to VEH-treated WT mice. No test day effect was observed 
in CP 55,940-treated animals, showing that both WT and Nrg1 HET mice did not 
Figure 3: Tolerance to the effects of CP 55,940 (0.4 mg/kg) compared to vehicle (VEH) on (A) SI 
and (B) rearing frequency of WT and Nrg1 HET mice (WT VEH, n = 12; WT CP 55,940, n = 11; 
Nrg1 HET VEH, n = 8; Nrg1 HET CP 55,940, n = 8). Data are presented as means ± SEM. 
Significant effects of CP 55,940 compared to VEH within the same genotype group are indicated by 
Ì (P < 0.05), ÌÌ (P < 0.01), and ÌÌÌ (P < 0.001). Significant effects of Nrg1 HET mice compared 
to WT mice in VEH-treated animals are indicated by # (P < 0.05). 
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develop tolerance to the drug-induced suppression of decreased rearing. When 
analysed on the different days, genotype differences were revealed in VEH-treated 
animals as Nrg1 HET mice exhibited an increased rearing frequency compared to WT 
mice on days 7 [F(1,18) = 4.95, P < 0.05] and 15 [F(1,18) = 4.77, P < 0.05]. CP 
55,940 decreased rearing frequency on all days for both WT [day 1, F(1,21) = 100.55, 
P < 0.001; day 7, F(1,21) = 47.61, P < 0.001; day 15, F(1,21) = 57.6, P < 0.001] and 
Nrg1 HET mice [day 1, F(1,14) = 29.97, P < 0.001; day 7, F(1,14) = 45.85, P < 
0.001; day 15, F(1,14) = 51.36, P < 0.001]. Similar results were also observed on 
vertical activity in the OF, another measure of rearing (data not shown).  
 
3.4. Anxiety in light-dark and open field tests 
The results from the anxiety-related behaviours are shown in Fig. 4. The measure of 
the time spent in the light compartment of the LD (Fig. 4A) revealed that repeated CP 
55,940 treatment decreased the time spent in the light over days [F(1,32) = 17.02, P < 
0.001]. An effect of test day was also observed [F(2,64) = 6.55, P < 0.01] as well as 
trends for genotype by treatment [F(1,32) = 3.78, P = 0.06], genotype by test day 
[F(2,64) = 2.97, P = 0.06] and genotype by treatment by test day [F(2,64) = 2.95, P = 
0.06] interactions. However, no overall genotype effect was observed. Over days, 
VEH-treated animals habituated to the LD independently of the genotype [test day: 
F(2,32) = 8.62, P < 0.01] and a trend for a test day effect was observed in CP 55,940-
treated animals [F(2,32) = 3.03, P = 0.06]. Interestingly, a genotype by test day 
interaction was observed in CP 55,940-treated animals [F(2,32) = 3.33, P < 0.05] 
showing that tolerance to the anxiogenic-like effect of the drug in the LD did not 
appear similarly in Nrg1 HET mice compared to WT mice. On the different days 
separately, no genotype difference between WT and Nrg1 HET mice was observed in 
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VEH-treated animals on any days. Interestingly, CP 55,940 decreased the time spent 
in the light of Nrg1 HET mice on days 1 [F(1,13) = 9.78, P < 0.01], 7 [F(1,13) = 
26.57, P < 0.001] and 15 [F(1,13) = 28.79, P < 0.001], while it only decreased time in 
the light on day 1 in WT mice [F(1,19) = 67.72, P < 0.001].  
 
 
We also analysed the time spent in the peripheral area of the OF 
(“thigmotaxis”) as another indicator of anxiety-related behaviour (Simon et al., 1994) 
(Fig. 4B). No overall effect of treatment or genotype was revealed over days, but a 
genotype by treatment interaction [F(1,35) = 6.73, P < 0.05] was observed. In 
addition a trend for an effect of test day [F(2,70) =2.97, P = 0.06] was also reported. 
Independently of their genotype, VEH-treated animals showed an increased time 
spent in the periphery of the OF over days [test day: F(2,36) = 8.04, P < 0.01]. No 
tolerance was reported to the effect CP 55,940 as shown with no effect of test day and 
no genotype by test day interaction in CP 55,940-treated animals. Interestingly an 
effect of the genotype was observed [F(1,17) = 4.94, P < 0.05] showing that CP 
55,940-treated Nrg1 HET mice exhibited an increased thigmotaxis compared to CP 
55,940-treated WT mice that was constant over days. When analysing the different 
Figure 4: Tolerance to the effects of CP 55,940 (0.4 mg/kg) compared to vehicle (VEH) on (A) the 
light dark test (WT VEH, n = 11; WT CP 55,940, n = 10; Nrg1 HET VEH, n = 7; Nrg1 HET CP 
55,940, n = 8) and (B) the OF in WT and Nrg1 HET mice (WT VEH, n = 12; WT CP 55,940, n = 11; 
Nrg1 HET VEH, n = 8; Nrg1 HET CP 55,940, n = 8). Data are presented as means ± SEM. 
Significant effects of CP 55,940 compared to VEH within the same genotype are indicated by Ì (P < 
0.05), ÌÌ (P < 0.01), and ÌÌÌ (P < 0.001). The doted line shows the total time spent in the OF. 
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days separately, no genotype difference between WT and Nrg1 HET mice was 
observed in VEH-treated animals on any day. Consistent with the increased 
thigmotaxis of CP 55,940-treated Nrg1 HET mice reported over days, CP 55,940 only 
increased the time spent in the periphery of the OF in Nrg1 HET mice on every day 
[day 1, F(1,14) = 64.98, P < 0.001; day 7, F(1,14) = 19.58, P < 0.001; day 15, F(1,14) 
= 7.53, P < 0.05] but not in WT mice.  
 
3.5. Fos immunohistochemistry 
Table 1 shows c-Fos and Fos B/∆Fos B counts in diverse brain areas. The regions 
where no significant genotype or treatment effects and no genotype by treatment 
interaction were found on Fos expression included the medial prefrontal cortex (PFC), 
the shell and core of the nucleus accumbens (NAC), the central and dorsolateral 
caudate putamen (CPU), the lateral and ventromedial hypothalamus (HT), the ventral 
tegmental area (VTA) and the ventrolateral periaqueductal gray (PAG) (see Table 1). 
CP 55,940 increased Fos B/∆Fos B expression in two regions, the paraventricular 
nucleus of the thalamus (PVT) [F(1,35) =15.7, P < 0.001] and in the central nucleus 
of the amygdala (CEA) [F(1,34) = 9.2, P < 0.01]. Interestingly, in the LSV there was 
a significant genotype by treatment interaction [F(1,34) = 5.6, P < 0.05] and post-hoc 
analysis revealed that chronic CP 55,940 treatment increased Fos B/∆Fos B 
expression in the LSV in Nrg1 HET mice (P < 0.01) but not in WT mice (Fig. 5).   
Repeated CP 55,940 exposure decreased c-Fos expression in four brain 
regions; the medial caudate putamen (CPUm) [F(1,35) = 7.8, P < 0.01], the bed 
nucleus of the stria terminalis (BNST) [F(1,15) = 12, P < 0.01] and two hippocampal 
areas, the CA1 [F(1,31) = 4.4, P < 0.05] and CA3 region [F(1,31) = 6.3, P < 0.05]. CP 
55,940 treatment also increased c-Fos expression in the paraventricular nucleus of the 
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hypothalamus (PVN) [F(1,32) = 4.2, P < 0.05] and in the PVT [F(1,34) = 4.5, P < 
0.05].  
 
Region Bregma Marker 
WT Nrg1 HET 2-way 
ANOVA VEH CP 55,940 VEH CP 55,940 
PFC medial +1.98 Fos B 22.3±3.2 24.4±3.8 22.1±3.4 21.7±4.1  c-Fos 29.5±6.3 22.6±4.8 24.1±6.7 12±2.7  
NAC shell +0.98 Fos B 47.5±9.4 41.5±10.9 50.4±6.2 55.3±10.8  c-Fos 13.8±3.7 9.7±2.3 12.9±4 11.6±5.3  
NAC core +0.98 Fos B 56.4±13.4 50.6±9.3 53.4±6.1 59.6±14.9  c-Fos 5±1.7 2.3±0.8 3.6±1.5 3.1±1.8  
CPU medial +0.98 Fos B 41.8±13.3 39.3±6.2 36.9±6.5 52.25±11.5  c-Fos 17.75±4.3 8.5±2 25.6±8.9 7.25±3.7 t 
CPU central +0.98 Fos B 7.7±2.7 3.4±1.4 8.5±4.7 8.3±6.3  c-Fos 3.7±1.2 3.6±1.8 4.4±2.6 3±2.1  
CPU 
dorsolateral +0.98 
Fos B 2.1±1.2 0.8±0.3 0.8±0.6 2.3±1  
c-Fos 1.6±0.5 2.2±0.9 1±0.7 1.9±1.3  
LSV  +0.98 Fos B 56.8±5.5 53.7±7.3 41.6±4.7 69.1±7 i c-Fos 67.5±9.5 86.1±10 69.75±8.5 67.1±9.1  
BNST 
dorsolateral +0.26 
Fos B 6.25±1.2 4.75±1.9 7.5±3.2 7.5±1.8  
c-Fos 5.5±2.3 1.25±0.9 5.6±1 1.3±0.5 t 
PVN -0.94 Fos B 6.9±1.8 16.9±5.6 4.6±0.8 7.4±1.6  c-Fos 19.5±3.8 38.4±9.9 11.9±4.4 22.1±7.2 t 
PVT -0.94 Fos B 0.75±0.5 6.2±1.4 1.9±0.6 4.5±1.1 t c-Fos 39.1±6.9 84.1±17.6 41.7±9.5 53.9±14.4 t 
CEA -1.34 Fos B 14.9±2.7 29.3±5.5 14.3±3.2 25.5±3.3 t c-Fos 6.8±1.4 7.7±1.4 3.4±1.3 6.6±2.1  
HT lateral -1.58 Fos B 2.2±0.6 3.1±0.7 1.3±0.6 2±1.1  c-Fos 10.4±2.3 12.7±2.6 8.1±3 9.6±3.6  
HT 
ventromedial -1.58 
Fos B 0.8±0.3 1.9±0.7 0.1±0.1 0.4±0.4  
c-Fos 0.7±0.4 0.3±0.2 0.7±0.4 0.3±0.3  
CA1 -1.58 Fos B 0.1±0.1 0.1±0.1 0±0 0±0  c-Fos 2.2±0.7 1.4±0.4 3.3±2 0±0 t 
CA3 -1.58 Fos B 1.5±0.7 0.9±0.5 1.6±0.5 0.5±0.4  c-Fos 5.5±1.1 1.4±0.7 4±1.7 2.2±1 t 
VTA -3.28-3.40 
Fos B 0.1±0.1 0.7±0.3 0.7±0.4 0.8±0.3  
c-Fos 3.1±0.8 5.5±1.4 3±1.5 2.5±1.3  
PAG 
ventrolateral -4.60 
Fos B 4.3±1.1 6.4±0.8 4.1±1.2 6.1±1.3  
c-Fos 19±3.9 23.6±4.4 16±2.8 14.5±3.3  
Fos B/∆Fos B and c-Fos counts following 15 days repeated treatment with CP 55,940 (0.4 mg/kg) or 
vehicle (VEH) in WT and Nrg1 HET mice (WT VEH, n = 12; WT CP 55,940, n = 11; Nrg1 HET VEH, n = 
8; Nrg1 HET CP 55,940, n = 8). Data are presented as means ± SEM. Significant effect with 2-way 
ANOVA for treatment and interaction are indicated by t and i, respectively.  
 
 
 
 
 
 
Table 1. Fos B/∆Fos B and c-Fos expression.
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4. Discussion 
The present results show that mice heterozygous for the Nrg1 gene display distinctive 
neurobehavioural responses to repeated cannabinoid exposure over days. Tolerance to 
CP 55,940-induced hypothermia and hypolocomotion developed more rapidly in Nrg1 
HET mice compared to WT mice. Enhanced development of tolerance was not 
observed for all measures, with Nrg1 HET mice maintaining a consistent anxiogenic-
like response to CP 55,940 over days, unlike WT control mice, as assessed by the 
time spent in the light compartment of the light dark test and the time spent in the 
periphery of the open field. Conversely, in both genotypes very little or no tolerance 
was observed to the effects of CP 55,940 in tests of SI or rearing frequency, while 
complete tolerance was evident within one week of cannabinoid treatment on startle 
response and PPI. The most striking neurobiological correlate of chronic cannabinoid 
treatment was that Fos B/∆Fos B was selectively increased in the LSV of Nrg1 HET 
mice but not WT mice. 
VEH-treated Nrg1 HET mice displayed an overall hyperactivity that is 
consistent with previous studies on these mice (Stefansson et al., 2002, Boucher et al., 
2007a, Karl et al., 2007). Interestingly, the hyperactivity of VEH-treated Nrg1 HET 
Figure 5: Fos B/∆Fos B-labelled neurons within the LSV in representative sections from 
Nrg1 HET mice treated with VEH or CP 55,940 (0.4 mg/kg). The lateral ventricle (lv) and 
anterior commissure (ac) are also indicated. Scale bar = 300 µm. 
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mice was not present on the first day of testing, but was unmasked with repeated 
testing as VEH-treated WT mice habituated to the OF more than Nrg1 HET mice. 
These results show that Nrg1 HET mice are deficient in habituation to the OF over 
days. In addition, we observed an increased rearing frequency in VEH-treated Nrg1 
HET mice compared to WT mice on days 7 and 15 in the SI tests. This shows that no 
habituation to such exploration-related behaviour occurred and rearing frequency 
even intensified in Nrg1 HET mice over days. Taken together, these results suggest a 
deficit in between sessions habituation to exploration in Nrg1 HET mice which is 
consistent with reduction in within session habituation showed by previous research 
(O'Tuathaigh et al., 2006). 
Acute administration of CP 55,940 strongly decreased BT and locomotor 
activity of both WT and Nrg1 HET mice. After repeated administration these classical 
effects of cannabinoids became less marked as tolerance developed (Little et al., 
1988, Oliva et al., 2004). Interestingly, here we observed that tolerance to the 
locomotor suppressant and hypothermic effects of CP 55,940 developed more rapidly 
in Nrg1 HET mice than in WT mice. Tolerance is a homeostatic mechanism that 
attempts to counter the imbalance engendered by excessive exposure of the brain to a 
drug. Indeed, high cannabinoid doses administered at frequent intervals will more 
rapidly promote tolerance than lower doses of these drugs administered less often 
(McKinney et al., 2008). Here we hypothesised that the more rapid tolerance 
induction to the locomotor suppressant and hypothermic effects of cannabinoids in 
Nrg1 HET mice might be explained by their enhanced acute cannabinoid-sensitivity 
as highlighted by our previous findings (Boucher et al., 2007a, b). That is, Nrg1 HET 
mice might invoke a more marked counteradaptive response to lessen the greater 
impact that the cannabinoids have on these mice acutely compared to WT mice. 
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Future studies could address the underlying mechanisms responsible for this. For 
example, cannabinoid tolerance is primarily explained by cannabinoid receptor 
downregulation and desensitization (see review by Gonzalez et al., 2005), therefore it 
would be interesting to observe if repeated cannabinoid exposure has a differential 
effect on these processes in Nrg1 HET and WT mice. 
Nrg1 and its receptor ErbB4 regulate many neurotransmitter receptors, 
including NMDA, dopamine and GABA receptors (Ozaki et al., 1997, Yurek et al., 
2004, Woo et al., 2007). In our prior research showing that Nrg1 HET mice are more 
sensitive to the acute neurobehavioural effects of cannabinoids, we postulated that 
partial deficiency of NRG1 could have engendered a reorganisation of the brain 
during development that may have increased the expression or efficacy of CB1 
receptors. In the present study, the increased development of tolerance to CP-55,940-
induced hypothermia and locomotor suppression in Nrg1 HET mice further 
emphasises that interactions occur between cannabinoid and NRG1 signalling in the 
brain. Importantly, cannabinoid and neuregulin systems are both expressed in brain 
regions that mediate motor function and body temperature. For example both CB1 
and NRG1-ErbB4 are present in the basal ganglia where they modulate dopamine 
expression (Steiner et al., 1999, van der Stelt and Di Marzo, 2003, Yurek et al., 2004), 
and in the preoptic nucleus (Pinkas-Kramarski et al., 1994, Steiner et al., 1999, Rawls 
et al., 2002), a region involved in body temperature regulation (Ishiwata et al., 2005).  
PPI is the phenomenon whereby the pre-exposure to a weak acoustic stimulus 
reduces the startle response to a loud tone and is impaired in schizophrenia patients 
(Swerdlow et al., 1994). Unlike in our earlier study (Boucher et al., 2007a), here we 
replicated the finding of Stefansson et al. (2002) showing that on the first day of 
testing, acute VEH-treated Nrg1 HET mice display deficits in PPI. However, here we 
Chapter 4: Neurobehavioural effects of repeated CP 55,940 treatment on Nrg1 HET mice 
79 
observed that these Nrg1 HET mice present a concomitant impairment in the acoustic 
startle response to a loud 120 dB stimulus, highlighting that the deficit in PPI is likely 
confounded by a reduced startle responsivity. It is unclear why acute VEH-treated 
Nrg1 HET mice displayed a reduction in startle response and PPI in the present study 
but no reduction in startle response or PPI in Boucher et al. (2007a). One major 
difference between these two studies is the experimental design used. In Boucher et 
al. (2007a) a counterbalanced within-subjects design was implemented, such that most 
animals were previously exposed to the PPI testing chambers on 1 or 2 occasions 
whereas in the present study, acute VEH-treated Nrg1 HET mice were naïve to the 
test procedure. Therefore, we speculate that familiarity with the testing apparatus may 
determine whether deficits in acoustic startle and PPI are observed in VEH-treated 
Nrg1 HET mice on day 1. Reinforcing this view is the fact that Nrg1 HET mice only 
showed a deficit in startle response and PPI on day 1, which was not replicated on 
days 7 and 15 of testing using exactly the same PPI testing parameters. Thus the 
reduction of startle response and PPI in acute VEH-treated Nrg1 HET mice appears 
highly dependent on familiarity to the testing apparatus, so that only under relatively 
unfamiliar circumstances will this aspect of their phenotype be revealed.  
In the PPI paradigm, the first injection of CP 55,940 differentially affected the 
mice depending on their genotype. In WT mice, CP 55,940 promoted a PPI deficit 
that is consistent with prior research (Martin et al., 2003, Nagai et al., 2006). In 
contrast, CP 55,940 facilitated PPI in Nrg1 HET mice, an effect reversing the PPI 
deficit observed in VEH-treated Nrg1 HET mice. This is consistent with our previous 
study showing PPI facilitation in THC-treated Nrg1 HET mice, even in mice that 
showed no cannabinoid-induced reduction in acoustic startle response (Boucher et al., 
2007a). However in the present study the high dose of CP 55,940 suppressed the 
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acoustic startle response in both Nrg1 HET and WT mice, confounding the 
differential effect we observed on day 1 on PPI. As heavy cannabis abuse is more 
reliably associated with worsening of symptoms in patients with schizophrenia 
(Linszen et al., 1994) we expected that repeated administration of CP 55,940 might 
alter the profile of the Nrg1 HET mice in the PPI paradigm. However, no such effects 
were observed and by day 7 both genotypes became completely tolerant to the effects 
of CP 55,940 on acoustic startle and PPI. It is possible that dosing in adulthood, once 
the Nrg1 HET mice express their characteristic phenotype, does not provide the 
optimal period to assess the effects of chronic cannabinoids. One study showed that 
PPI deficits could be revealed in adult rats that received prior repeated cannabinoid 
injections during puberty, however no such effect was evident when rats were 
exposed to the same dosing regime during adulthood (Schneider and Koch, 2003). 
This suggests that puberty offers a unique period of vulnerability to the adverse 
effects of cannabis. This is especially significant given that human users commence 
cannabis use at ages that often coincide with puberty and the age of onset of 
schizophrenia (Gonzalez-Pinto et al., 2008). Further, as Nrg1 signalling is involved in 
the regulation of hormonal control during puberty, future studies could assess the 
administration of cannabinoids in Nrg1 HET mice in this critical age period (Ma et 
al., 1999).  
Another behavioural model that was investigated in the present study was SI. 
The acute administration of CP 55,940 decreased SI both in WT and Nrg1 HET mice 
similarly to our previous report using THC (Boucher et al., 2007a). After repeated 
treatment, little tolerance to CP 55,940-induced decreased SI was observed in Nrg1 
HET and WT mice. This is consistent with studies where, while tolerance was 
observed to the sedative effects of cannabinoids, the social behaviour was still 
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impaired by the drug (Frischknecht et al., 1982). Similarly, absence of tolerance to 
decreased sociability has been reported in humans (Haney et al., 1999). During the SI 
test, the animal’s exploration was also measured as the frequency of rearing. 
Interestingly, no tolerance to the effects of CP 55,940 on rearing were observed after 
15 days even though both WT and Nrg1 HET mice were tolerant to the locomotor 
suppressant effects of CP 55,940 by day 7. Therefore, our results are consistent with 
prior research in rats showing that rearing is more resistant to tolerance to THC than 
locomotor suppression (Miczek, 1976). This result reinforces that rearing and 
locomotor activity are mediated by distinct neurocircuits that are differentially 
susceptible to the development of tolerance induced by repeated cannabinoid 
exposure.  
In the LD test, the first administration of CP 55,940 decreased the time spent 
in the light compartment in both WT and Nrg1 HET mice. This is consistent with the 
equivalent decrease in SI promoted by CP 55,940 in Nrg1 HET and WT mice 
observed here and also the well-characterised anxiogenic-like effects of cannabinoids 
in rodents (Rutkowska et al., 2006). The anxiogenic effects of CP 55,940 on WT mice 
progressively decreased over days 7 and 15 indicative of cannabinoid tolerance. 
However, no such tolerance to the anxiogenic action of CP 55,940 was observed in 
Nrg1 HET mice that maintained a pronounced cannabinoid-induced aversion of the 
light compartment over days. Importantly, as the animals were tolerant to the 
locomotor suppressant effects of CP 55,940 on days 7 and 15, the persistent decreased 
time spent in the light of Nrg1 HET mice appears specific to increased anxiety-like 
behaviour and can not be accounted for cannabinoid-induced locomotor suppression. 
Reinforcing the observation that Nrg1 HET mice display no tolerance to cannabinoid-
induced anxiety-related behaviour is the finding that these animals showed a 
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consistent CP 55,940 promoted increase in time spent in the outer perimeter of the OF 
over days 1, 7 and 15 of dosing. Such thigmotaxic behaviour is also considered an 
index of anxiety as it is increased by anxiogenic agents and decreased by anxiolytic 
drugs (Simon et al., 1994). Taken together, these results demonstrate a long-term 
differential effect between Nrg1 HET mice and WT mice in their sensitivity to 
anxiety-related behaviour promoted by repeated cannabinoid treatment.  
The finding that CP 55,940 selectively increased thigmotaxis in Nrg1 HET 
mice but not WT mice on day 1 is consistent with our earlier study showing that the 
anxiogenic-like effects of acute THC in the LD test were only observed in Nrg1 HET 
mice but not in WT mice (Boucher et al., 2007a). However this effect was not 
reproduced in the OF test where both WT and Nrg1 HET mice displayed THC-
induced decreased time spent in the centre of the OF. In addition, in the present study, 
both Nrg1 HET and WT mice displayed an equivalent aversion to the light 
compartment of the LD test. This might be explained by subtle differences between 
the present study and the study of Boucher et al. (2007a). Here a between-subjects 
design was implemented, whereas Boucher et al. (2007a) utilised a within-subjects 
design. This difference may have altered the baseline level of exploration in the LD 
on day 1 due to variation in test experience between the two cohorts of mice. As such, 
VEH-treated WT and Nrg1 HET mice spent more time in the light compartment 
providing more room to reveal the anxiogenic effect of cannabinoids in both 
genotypes. Other differences between the present study and that of Boucher et al. 
(2007a) are that a different cannabinoid drug and dose was used here and that the 
animals used in the present study were approximately a month younger which may 
have decreased the time needed to develop a strong, drug-free anxiolytic-like 
phenotype in the Nrg1 HET mice (Karl et al., 2007). 
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Nrg1 HET mice showed a lack of tolerance to the cannabinoid-induced 
anxiety-like behaviour as measured in the time spent in the light compartment of the 
LD test and in the centre of the OF, while simultaneously showing more rapid 
tolerance to cannabinoid-induced locomotor suppression and hypothermia compared 
to WT mice. Such findings seem contradictory however they may be triggered by 
different alterations occurring in the discrete neurocircuits that underlie anxiety, 
motor behaviour and body temperature. As previously discussed, more rapid tolerance 
to the locomotor suppressant and hypothermic effects of CP 55,940 in Nrg1 HET 
mice might be explained by Nrg1’s contribution to processes that subserve 
cannabinoid tolerance in motor- or temperature-related regions of the brain. However, 
the lack of tolerance to the anxiogenic-like effects of CP 55,940 might be explained 
by selective, long-term neuroadaptive changes occurring in anxiety-related circuits of 
Nrg1 HET mice that are not observed in WT mice. Indeed, we report in the present 
study that, after 15 days repeated treatment with CP 55,940, Nrg1 HET mice display 
increased Fos B/∆Fos B expression in the LSV, unlike WT mice which showed no 
induction of this neuronal marker. 
This finding is extremely interesting given our previous data that acute THC 
treatment selectively increased c-Fos expression in the LSV of Nrg1 HET mice but 
not WT mice (Boucher et al., 2007b). Importantly, the selective enhancement in Fos 
B/∆Fos B expression in Nrg1 HET mice in the present study may not be simply a 
short-term response of the LSV to cannabinoid exposure as following chronic CP 
55,940 treatment no significant increase in c-Fos expression was observed in the LSV 
of Nrg1 HET mice. However, as our antibody does not discriminate between Fos B 
and ∆Fos B it cannot be ruled out that this effect is due to the shorter half-life of Fos 
B expression. In any case, this result further supports that the LSV is an important site 
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of cannabinoid-promoted dysregulation in Nrg1 HET mice which might subserve the 
maintenance of long-term anxiety/stress responses to chronic cannabinoid exposure in 
these mice. It is important to note that in our prior study (Boucher et al., 2007b), the 
acute effect of THC on c-Fos expression in the LSV was dependent on the stress of 
behavioural testing. It is possible the effect observed here with ∆Fos B could also be 
due to cannabinoid-stress interaction, however we did not test this hypothesis directly 
here. An interaction between neuregulin deficiency and cannabinoid exposure is 
likely to occur in the septum where both ErbB4 and CB1 receptors (Tsou et al., 1998, 
Steiner et al., 1999) are present, however the exact mechanism by which this 
interaction occurs in the LSV is unknown and further studies are required to 
understand the molecular processes underlying such a difference.  
An increased Fos B/∆Fos B expression was also observed in the CEA of both 
WT and Nrg1 HET mice, and this effect was not accompanied by an increased c-Fos 
expression. This suggests that long-term adaptive changes could have occurred in this 
stress-related region. As this area is interconnected with the lateral septum (Sheehan 
et al., 2004), it is surprising that the differential effect observed on Fos B/∆Fos B 
expression in the LSV is not associated with genotype difference in the CEA. 
Interestingly, acute cannabinoid treatment robustly increases c-Fos expression in the 
CEA (Boucher et al., 2007b), however with repeated cannabinoid treatment animals 
were clearly tolerant to this effect with no increased c-Fos expression being observed 
in this area following repeated CP 55,940 administration. Interestingly, such tolerance 
to cannabinoid-induced c-Fos expression does not necessarily follow for all regions. 
For example, independent of genotype, chronic CP 55,940 administration continued 
to increase c-Fos expression in the PVT to a level similar to that seen with acute THC 
administration. However in this area, Nrg1 HET mice tended to express less CP 
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55,940-induced c-Fos, which is consistent with these animals showing greater 
tolerance to cannabinoid-induced c-Fos expression than WT mice. Similarly, repeated 
CP 55,940 treatment significantly increased c-Fos expression in the PVN, albeit less 
markedly than in our acute THC-induced c-Fos study (Boucher et al., 2007b). 
Interestingly, tolerance does not occur to some of the neuroendocrine effects of 
cannabinoids, such as the decreased prolactin and luteinizing hormone secretion from 
the pituitary gland (de Miguel et al., 1998). Further, repeated cannabinoid exposure 
does not promote alterations in CB1 receptor binding and mRNA levels in the 
hypothalamus (de Miguel et al., 1998). The persistent effect of CP 55,940 on c-Fos 
expression in the PVT and PVN is consistent with such findings and underscores the 
concept that there exists regional diversity in the responsiveness of the brain to 
chronic cannabinoid exposure.  
These results show that Nrg1 HET mice adapt differently to repeated 
cannabinoid exposure compared to WT mice. Nrg1 HET mice displayed more rapid 
tolerance to the locomotor suppressant and hypothermic effects of cannabinoids. On 
the contrary, Nrg1 HET mice maintained a cannabinoid-induced anxiety-like 
responses with repeated cannabinoid dosing as seen in the LD test, unlike WT mice. 
Such a differential effect on anxiety-related behaviour correlated with a selective 
increase in Fos B/∆Fos B in the LSV of Nrg1 HET mice highlighting that a depletion 
of Nrg1 might enhance the neuroadaptive response to chronic cannabinoid exposure 
in this area which is involved in stress. It also underscores that the LSV may be an 
important region of dysregulation in Nrg1 HET mice exposed to cannabinoids. The 
present results further support that neuregulin and cannabinoid systems interact in the 
brain, which may provide a mechanism responsible for genetic vulnerability to 
cannabis-induced schizophrenia. 
Chapter 4: Neurobehavioural effects of repeated CP 55,940 treatment on Nrg1 HET mice 
86 
Summary of the main results at the end of Chapter 4 
 
 
Chapter 4 examined the behavioural and neurobiological effects of repeated CP 
55,940 exposure (0.4 mg/kg) on WT and Nrg1 HET mice. This dose is comparable to 
the dose of 10 mg/kg THC that could not be used in this study as THC was not 
available at the time of the experiment. Animals were tested for body temperature and 
locomotor activity every 2 days and for body temperature followed by locomotor 
activity, social interaction, light dark and prepulse inhibitions tests on days 1, 7 and 
15. The main results obtained from this experiment are summarised in Table 2 and 
show that Nrg1 HET mice developed tolerance to the hypothermic and locomotor 
suppressant effects of the drug faster than WT mice. In addition, while tolerance 
developed to the anxiety-like effects of CP 55,940 in WT mice, no tolerance was 
observed on this behaviour in Nrg1 HET mice. Fos B/ΔFos B expression was also 
measured as a marker of long term neuroadaptation and after 15 days repeated 
exposure CP 55,940 increased Fos B/ΔFos B expression in the ventrolateral septum 
(LSV) of Nrg1 HET mice but not WT mice.  
 
Table 2. Summary of main results form Chapter 2, 3 and 4. 
 
Test 
 
Chapter 2 
Effect of THC 
(10 mg/kg) 
Chapter 3 
Effects of THC  
(10 mg/kg) 
Chapter 4 
Repeated CP 55,940 
(0.4 mg/kg) 
 
 On day 1 Tolerance 
Locomotor activity in 
the open field 
 
Hypolocomotion 
more important 
in Nrg1 HET 
mice than WT 
mice  
 Strong 
hypolocomotio
n in both Nrg1 
HET and WT 
mice 
Nrg1 HET mice 
developed 
tolerance to the 
hypolocomotion 
faster than WT 
mice (similar 
results seen 
with 
hypothermia) 
Anxiety in the light 
dark  
 
 
Decreased time 
spent in the 
light 
compartment 
only in Nrg1 
HET mice 
 Decreased 
time spent in 
the light 
compartment 
in both Nrg1 
HET and WT 
mice 
Tolerance 
developed in WT 
mice but not in 
Nrg1 HET mice 
Social interaction Decreased social 
interaction in 
both WT and 
Nrg1 HET mice 
similarly 
 Decreased 
social 
interaction in 
both WT and 
Nrg1 HET mice  
No tolerance 
developed 
Prepulse inhibition 
 
Facilitation only 
in Nrg1 HET 
mice 
 Facilitation in 
Nrg1 HET 
mice, 
disruption in 
WT mice 
Tolerance 
developed in 
both Nrg1 HET 
and WT mice 
Immunohistochemistry 
 
 Increased c-Fos 
expression in the 
LSV of Nrg1 HET 
mice  
 Increased Fos 
B/ΔFos B 
expression in 
the LSV of Nrg1 
HET mice 
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1. Introduction  
Cannabis is the most widely used illicit drug in the world. Apart from its extensive 
recreational use, it also has some potential therapeutic relevance (Rog et al., 2005, 
Smith, 2005). One limitation of cannabis use is that its consumption induces cognitive 
impairments (Solowij et al., 1995, Fletcher et al., 1996), as well as structural and 
functional brain alterations (Jentsch et al., 1998, Kanayama et al., 2004, Yucel et al., 
2008). Thus, developing a better insight of the chronic effects of cannabinoids on 
cognition is of critical importance for understanding the adverse effects of this drug.  
Long-term cannabis users exhibit neuropsychological deficits such as 
impairments in memory and attention (Solowij et al., 2002, Messinis et al., 2006). In 
laboratory animals the acute administration of the main psychoactive constituent of 
cannabis, Δ9-tetrahydrocannabinol (THC), induces deficits in cognitive processes 
(Lichtman and Martin, 1996, Varvel et al., 2001, Da and Takahashi, 2002). While the 
acute effects of cannabinoids are well documented, the long term effects of the drug 
on learning and memory have received less attention (Nakamura et al., 1991, 
Hampson et al., 2003). With chronic treatment, many of the effects of cannabinoids 
are diminished – a phenomenon known as tolerance. Tolerance develops to the 
characteristic effects of cannabinoids at different rates, for example it develops more 
rapidly to cannabinoid-induced hypothermia than locomotor suppression (Whitlow et 
al., 2003, Gonzalez et al., 2005). Little is known about tolerance to the memory 
disruptive effects of cannabinoids, with a few human and animal studies suggesting 
that cannabinoid-induced memory impairment is more resistant to the development of 
tolerance (Nakamura et al., 1991, Haney et al., 1999, Nava et al., 2001, Solowij et al., 
2002). This difference in the time-course of the development of tolerance to the 
effects of cannabinoids is of particular interest in animal models of behaviour given 
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that it is often difficult to dissociate the specificity of learning perturbations from the 
confounding effects of these drugs on motor activity.  
The memory impairments promoted by cannabinoids appear to more strongly 
impact spatial memory. This hippocampus-mediated form of learning can be 
evaluated using animal models like the Morris water maze. Using this paradigm, 
different tasks can be examined to differentiate between reference and working 
memory (Varvel et al., 2001). Reference memory is evaluated in the place version of 
the water maze where the platform remains at a constant location, while working 
memory is usually studied by changing the location of the platform to assess 
behavioural flexibility, a process that is impaired with cannabinoid administration 
(Egerton et al., 2005, Hill et al., 2006). As memory is strongly regulated by the 
hippocampus, we also evaluated the chronic effects of THC on the brain by measuring 
zif268 expression. Zif268 (also known as krox-24, NGFI-A or egr-1) is an immediate 
early gene that is involved in learning and memory processes (Bozon et al., 2002). 
This transcription factor is abundant in the hippocampus where cannabinoids 
normally increase its expression (Derkinderen et al., 2003), an effect postulated to 
subserve the memory impairments promoted by these drugs (Lichtman et al., 1995, 
Egashira et al., 2002) 
The doses of THC used by previous mouse studies to promote deficits in 
working memory range between 3 and 10 mg/kg (Varvel et al., 2001, Da and 
Takahashi, 2002, Varvel et al., 2005, Niyuhire et al., 2007). Here we aimed to assess 
if deficits in reversal learning in mice also occur using a lower dose of THC (1 mg/kg) 
that is more relevant to those administered by humans. Furthermore, we aimed to 
evaluate whether the extended administration of THC induces memory deficits that 
persist even after the animals have developed tolerance to the locomotor suppressant 
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effects of the drug. In addition, we measured the underlying neuronal substrates that 
may be responsible for such effects by analysing zif268 expression in the brain. 
 
2. Methods 
2.1. Subjects 
Male adult C57BL/6J mice (weighing 23-28 g at the beginning of the experiment) 
were obtained from Charles River (Lyon, France). Animals were housed at 22-23°C 
under a 12 h light/dark cycle (7:00 a.m. on) with food and water available ad libitum. 
One week prior to the experiment, animals were separated into individual home cages 
and handled for 2–3 min/day during all the experiment to minimize non-specific 
stress. Experiments were performed in accordance with the guidelines on the ethical 
use of animals from the European Communities Council Directive of 24 November 
1986 (86/609/EEC).  
 
2.2. Drug treatments 
THC (25 mg/ml, Sigma, France) was dissolved at 5 mg/ml in ethanol. This 
preparation was emulsified in a solution at 2.5 mg of polysorbate 80 (Sigma, France) 
/ml of ethanol. Ethanol was then evaporated at room temperature using a rotary 
concentrator-evaporator (SpeedVac®System, ThermoSavant) for 20 min under a 
pressure of 5.1 bar. The residue was resuspended in NaCl (0.9 %) and sonicated for a 
final THC concentration of 0.1 mg/ml. The same protocol where ethanol was used in 
replacement of THC was used to prepare the vehicle (Veh) solution. THC (1 mg/kg) 
or Veh were administered intraperitoneally (i.p.) at a volume of 10 ml/kg. 
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2.3. Apparatus 
Learning in the Morris water maze was evaluated using a pool that measured 150 cm 
in diameter and 55 cm in height, and that was placed in a room maintained at 23-25 
◦C under constant lighting with many extra-maze cues posted on walls. It was filled 
with 21±1 ◦C water until 15 cm of the top and made opaque by addition of white non-
toxic paint. A hidden platform of 13 cm in diameter was submerged 5 mm below the 
surface. Its location could be indicated to the animals by placing a 15 cm height and 4 
cm of diameter intra-maze cue on the submerged platform. A video camera mounted 
above the pool was used to record swim trials. Swim speed, escape latency (time to 
reach the platform), time spent in the target quadrant (where the platform should be 
during the probe trial) and animal paths were recorded and analysed using an 
automated tracking system (Videotrack, France). 
A different set of animals were then tested for locomotor activity using an 
activity meter (Imetronic, France). Animals were placed individually in the boxes of 
the apparatus immediately after injection with THC or Veh, for 1 h under light 
exposure and without food or water available.  
 
2.4. Procedure of memory testing in the water maze 
For this experiment, mice were separated into 2 groups (see Fig. 1). Animals in the 
non pre-treated (NPT) group were treated with daily injections of THC (1 mg/kg) or 
Veh 30 min before testing in the water maze on days 1-11 (behavioural testing phase). 
Animals in the pre-treated (PT) group received 13 daily injections of THC (1 mg/kg) 
or Veh before the behavioural testing phase where, like NPT animals, these animals 
continued to receive THC or Veh on each day of testing. Therefore, such a design 
yielded 4 treatment groups: PT-Veh, PT-THC, NPT-Veh and NPT-THC.  
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On the first day of the behavioural testing phase, animals received a pre-
training session consisting of 2 cued trials where the hidden platform was indicated 
by a visual intra-maze cue. Then the acquisition started and mice were tested for 
spatial reference memory. Each animal was trained to find the hidden platform kept at 
the same location for 1 session of 4 trials per day for 9 days. Mice were released from 
a random location and were allowed to swim until they found and climbed on the 
platform or until a maximum of 90 s has elapsed. If a mouse did not find the platform, 
it was gently guided to the platform by hand where it was left for 20 s and then dried 
and returned to its home cage placed in a heating box. Mice were trained in groups of 
4 animals, allowing an intertrial interval of 15 min for each mouse. One hour after the 
end of the last session of the acquisition, mice were tested in a probe trial lasting 60 s 
where the platform was removed from the water maze.  
After 9 days of acquisition, mice were submitted to a reversal test where the 
platform location was moved in the opposite quadrant in order to evaluate the 
Behavioural testing phase  Pre-treatment phase (13 
PT - Veh or THC 
NPT - Veh or THC 
Day 
1         2          3        4       5        6        7          8 9         10       
11 
ACQUISITION  
P1 P2 
REVERSAL  
Figure 1. Protocol.  Animals were separated in 2 groups: non pre-treated (NPT) mice were treated 
with Veh or THC (1 mg/kg) during the behavioural testing phase in the water maze. Pre-treated (PT) 
animals were treated Veh or THC (1 mg/kg) for 13 days before the behavioural testing phase and, 
like the NPT group, until the end of the experiment. The behavioural testing phase consisted in 9 
days of acquisition of the spatial reference memory task where the location of the platform remained 
constant, followed by 2 days of reversal where the location of the platform was changed. Animals 
were also tested in the first probe trial (P1) at the end of the acquisition on day 9, and for the second 
probe trial (P2) at the end of the reversal on day 11.  
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behavioural and cognitive flexibility of the animals. Mice were tested in 2 sessions of 
4 trials separated by 24 h. One hour after the end of these reversal trials, mice were 
again submitted to a probe trial lasting 60 s where the platform was removed from the 
water maze.  
 
2.5. Immunohistochemistry 
Home cage control animals (Quiet cont group) did not receive any injection and were 
not behaviourally tested.  
Ninety minutes after the last probe trial, animals were anaesthetised with an 
i.p. injection of Tribromoethanol ( Avertin) and perfused transcardially with 0.9% 
saline followed by 100 ml of 4 % paraformaldehyde (PFA) in 0.1 M phosphate buffer 
(PB) at pH 7.4. Brains of animals kept in their home cages were also harvested as 
controls. The brains were removed and postfixed in PFA for 20 h. For cryoprotection, 
brains were placed in 30 % sucrose until they sunk. Brains were then sliced at 50 µm 
in a frozen microtome.  
Tissue sections were stored in cryoprotectant solution at – 20 °C until the 
staining was performed. For immunohistochemistry, free floating sections were 
washed 4 times for 10 min in PB before being incubated in 0.5 % hydrogen peroxide 
for 30 min. After 4 washes in 0.9 % NaCl, sections were incubated in 1 % bovine 
serum albumin, 0.2 % Triton X100 (PB-BSA-TX) for 30 min at room temperature. 
Sections were then stained with the zif268 primary antibody (Santa Cruz 
Biotechnology) diluted at 1:5,000 in PB-BSA-TX for 24 h at 4 °C while undergoing 
shaking. After 4 washes in PB containing 0.2 % Triton X-100 (PB-TX), sections were 
incubated in biotinylated anti-rabbit secondary antibody (Jackson ImmunoResearch) 
diluted at 1:2,000 in PB-BSA-TX for 2 h at room temperature while undergoing 
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shaking. Sections were washed again 4 times in PB-TX and transferred to an avidin-
biotin-peroxidase solution (Sigma, France) for 2 h at room temperature and protected 
from light. Sections were washed 4 times in PB and 3 times in 0.05 M Tris HCl (pH 
7.5), The peroxidase activity was visualised by placing the tissue in 0.037 % 
diaminobenzidine tetrahydrochloride diluted in Tris-HCl and 0.015 % hydrogen 
peroxidase for 5 to 15 min protected from light. The reaction was terminated by 4 
washes in 0.05 M Tris HCl and tissues were stored in PB containing 0.2 g/l Azide 
(Sigma). Sections were then mounted onto slides, air dried, dehydrated in toluene and 
coverslipped. Quantitative densitometry was performed on the images of digitized 
brain sections using Biocom Visiolab 2000 software. Each structure was counted 5 to 
8 times depending on the quality of the section. Results are indicated by number of 
reactive cells by unit of surface.  
 
2.6. Statistical analysis 
Data from the water maze were analysed using two-way repeated measures analysis 
of variance (ANOVA) where the between subjects factors were treatment (Veh or 
THC) and group (PT or NPT), and trial or session (day) as the repeated measure. 
When needed, data were examined for each day separately by two-way ANOVA and 
further analysed using Tukey’s post hoc test. Data from locomotor activity were 
analysed using one-way repeated measures ANOVA where the between subjects 
factor was treatment (Veh or THC), and day as the repeated measure. Data from 
immunohistochemistry were analysed using a Student t test. A significant level of P < 
0.05 was chosen for all comparisons.  
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3. Results 
3.1. Swim speed 
As cannabinoids have sedative effects, we analysed the swim speed of the animals 
during all phases of the water maze test to assess if motor impairment would persist 
when animals were placed in the water and forced to swim (data not shown). No 
overall effect of THC treatment was observed on swim speed over days of testing 
[F(1,44) = 1.32; P = 0.26] whether the animals were pre-treated or not. When 
analysing the different days separately, no effect of THC on swim speed was observed 
as measured on the first trial of each day. As observed during the tasks, all animals 
were able to swim and climb onto the platform. Taken together, these results show 
that THC treatment did not alter the swimming capability of the animals.   
 
3.2. Cued trials 
On the first day of behavioural testing before 
the beginning of the acquisition task, animals 
received a pre-training session consisting of 2 
cued trials where the platform was indicated 
by a visual cue (Fig. 2). A trend for THC 
treatment to increase escape latency was 
observed during the first cued trial [F(1,44) = 
2.88, P = 0.097]. Tukey’s post hoc test 
revealed that THC only reduced escape 
latency in NPT mice (P < 0.05). However, this effect was transient as it was not 
observed on the second trial and all animals were able to perform the task suggesting 
that THC did not impair visual ability and the procedural aspect of the experiment.   
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Figure 2. Escape latency in the 2 cued trials 
prior to the beginning of the acquisition on the 
first day of the behavioural testing phase in 
animals (n = 12 per group) pre-treated (PT) or 
non pre-treated (NPT) with either Veh or THC 
(1 mg/kg). Data are presented as means ± 
SEM. 
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3.3.   Acquisition of the spatial reference memory task 
Escape latencies for all sessions (average of the 4 trials per day) of acquisition and 
reversal are shown in Fig. 3. During acquisition, animals learnt where to find the 
platform as highlighted by a decreased escape latency over days [session: F(8, 352) = 
58.27, P < 0.001]. Interestingly, THC increased escape latency over days [treatment: 
F(1, 44) = 9.62, P < 0.01] and a treatment by session interaction was also observed 
[F(8, 352) = 2.29, P < 0.05]. To increase the accuracy of these results, we then 
analysed each session separately. We observed that THC impaired acquisition of the 
task on days 1 [F(1, 44) = 8.13, P < 0.01], 2 [F(1, 44) = 8.14, P < 0.01] and 3 [F(1, 
44) = 5.17, P < 0.05], with no difference observed on the other days. These results 
show that, independently of whether they received a pre-treatment or not, THC-
treated animals learnt the location of the platform slower than Veh-treated animals.  
 
 
 
 
 
 
 
 
 
3.4. Reversal of the spatial memory 
During the reversal phase (Fig. 3), the platform location was changed to assess 
learning flexibility of the animals. On the first session of the reversal on day 10, all 
animals showed an increased latency to reach the platform compared to the last 
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Figure 3. Escape latency for each session (4 trials per day) of acquisition of the 
spatial memory task (day 1-9) and reversal of the platform location (day 10-11) in 
animals (n = 12 per group) pre-treated (PT) or non pre-treated (NPT) with either Veh 
or THC (1 mg/kg). Data are presented as means ± SEM. 
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session of acquisition as they had to learn a new position of the platform. This is 
highlighted by a session effect between day 9 and 10 [F(1, 44) = 260.83, P < 0.001]. 
On the second session of reversal (day 11), the escape latency of all animals 
decreased compared to the first one, as shown by an effect of the session between 
days 10 and 11 [F(1, 44) = 27.34, P < 0.001]. This shows that the animals started to 
learn the new location of the platform. Interestingly, while no effect of THC was 
observed on the last days of acquisition, the reversal of the platform triggered a 
learning deficit in THC-treated animals during the reversal [treatment: F(1, 44) = 
5.93, P < 0.05]. When analysing the sessions of reversal separately, a treatment effect 
was observed on day 11 [F(1, 44) = 6.03, P < 0.05], showing that THC impaired 
performance in the reversal phase, reducing the ability of the animals to learn the new 
location of the platform. Similarly to the beginning of the acquisition, THC treatment 
impaired the escape latency whether the animals received a pre-treatment or not.  
 
 
 
 
 
 
 
 
To gain a more detailed insight into our results, we then analysed the different 
trials of the 2 sessions of reversal separately (Fig. 4). A trend for an effect of THC 
treatment was observed on the second trial of the first session of reversal [F(1, 44) = 
3.01, P = 0.09] but not on the first trial as animals had to find the new location of the 
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Figure 4. Detail of the 4 trials of the 2 sessions of reversal in animals (n = 
12 per group) pre-treated (PT) or non pre-treated (NPT) with either Veh or 
THC (1 mg/kg). Data are presented as means ± SEM. 
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platform. This THC-induced impairment in performance observed on the second trial 
of the first day of reversal was accentuated on the second day, as highlighted by an 
effect of THC treatment on trial 2 [F(1, 44) = 5.19, P < 0.05] and 4 [F(1, 44) = 5.31, P 
< 0.05] of the second session. These results are consistent with the interpretation that 
THC impaired working memory during the reversal. 
 
3.5. Probe trials 
The results from the probe trials are shown in Fig. 5. The first probe trial was done 1 
hour after the end of the acquisition on day 9. The platform was removed from the 
water maze and we measured the time spent in the target quadrant where the platform 
was formerly located during the acquisition. Consistent with results from escape 
latencies on the last days of acquisition, all animals spent the same time in the target 
quadrant as shown by the absence of treatment effect [F(1, 44) = 0.12, P = 0.73]. In 
addition, all animals were above chance level in the time spent exploring the target 
quadrant (P < 0.001), showing that all animals had learnt the location of the platform 
at the end of the acquisition (Fig. 5A; P1 TQ1). We also measured the latency for the 
first platform location crossing (Fig. 5B). In the first probe test, we observed that 
THC-treated mice exhibited a significant increased latency to cross the platform 
compared to Veh-treated animals [F(1, 44) = 5.3, P < 0.05] and this effect was 
independent of the treatment condition [F(1, 44) = 2.53, P = 0.12].  
One hour after the end of the second session of reversal on day 11, a second 
probe trial was done to compare whether animals swam in the new target quadrant or 
in the old one where the platform was located during the acquisition. No effect of 
THC was observed on the time spent in the old target quadrant [F(1, 44) = 0.47, P = 
0.49] that all animals explored at chance level (Fig. 5A; P2 TQ1). This shows that all 
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mice stopped exploring the quadrant where the platform was located during the 
acquisition. In the new target quadrant, THC increased the latency to first cross the 
location of the platform [F(1, 44) = 4.8, P < 0.05] (Fig. 5B; probe test 2). Supporting 
this result, a trend for THC to decrease the time spent in the new target quadrant was 
observed [F(1, 44) = 3.38, P = 0.07] (Fig. 5A; P2 newTQ). Importantly, Veh-treated 
animals spent more time 
(above chance level) in the 
new target quadrant than in the 
old one [F(1, 22) = 6.09, P < 
0.05], showing that they have 
started to learn the new 
location of the platform. 
However, THC-treated animals 
were at chance level in both the 
new and the old quadrants. 
Taken together, these results 
show that THC impaired 
reversal learning in the water 
maze.   
 
3.6. Locomotor activity 
We also measured locomotor activity using another set of animals (Fig. 6). No 
difference was observed between the animals on day 0 prior to the beginning of the 
drug administration. Using one-way repeated measure ANOVA, we showed that THC 
treatment promoted an overall decreased locomotor activity over days [F(1, 54) = 
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Figure 5. A) Time spent in the different target quadrants (TQ) 
during the 2 probe trials. The first probe (P1) occurred 1 h after 
the end of the acquisition (i.e. on day 9) and the second probe 
(P2) occurred 1 h after the end of the reversal (i.e. on day 11). 
B) Latency to cross the platform location for the first time in 
animals (n = 12) pre-treated (PT) or non pre-treated (NPT) with 
either Veh or THC (1 mg/kg). Data are presented as means ± 
SEM. (Means ± SEM). Significant effects are indicated by Ë (P 
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5.48, P < 0.05]. The analysis of each days separately showed that THC reduced 
locomotor activity on days 2 [F(1,9) = 14.84, P < 0.01], 3 [F(1,9) = 5.94, P < 0.05] 
and 4 [F(1,9) = 6.84, P < 0.05]. From the fifth day of treatment, no difference was 
seen between Veh- and THC-treated mice, showing that animals became tolerant to 
the locomotor suppressant effect of THC.  
 
 
 
 
 
 
 
 
 
 
3.7. Immunohistochemistry 
The number of zif268 immunoreactive cells for the different regions are shown in Fig. 
7. Analysis with Student’s t-test showed that in animals that were not pre-treated 
(NPT-Veh compared to NPT-THC), THC decreased zif268 expression in the CA3 of 
the hippocampus (P < 0.001), in the dorsomedial (P < 0.01) and dorsolateral (P < 
0.05) part of the caudate putamen and in the prefrontal cortex (P < 0.05). No effect of 
THC was observed in animals that received pre-treatment with THC (PT-Veh 
compared to PT-THC).  
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Figure 6. Tolerance to locomotor activity in animals (n = 5-6) treated with Veh or 
THC (1 mg/kg). Data are presented as means ± SEM. Significant effects are 
indicated by Ë (P < 0.05) and ËË (P < 0.01). 
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4. Discussion 
The main results from the present study indicate that animals treated with a low dose 
of THC, whether they were pre-treated or not, showed a reduced learning of the 
spatial reference memory task. However, they eventually acquired the task like 
control animals. During the reversal phase, while both NPT and PT animals were 
tolerant to the locomotor suppressant effects of THC, the drug impaired cognitive 
Figure 7. Number of zif268 immunopositive cells in (A) CA1 and (B) CA3 of 
the hippocampus, (C) the prefrontal cortex (PFCx) and (D) the dorsomedial 
(DM) and (E) the dorsolateral (DL) caudate putamen (CPU) in animals (n = 6 
per group) that were pre-treated (PT) or non pre-treated (NPT) with either 
Veh or THC (1 mg/kg). Animals from “Quiet cont” group did not receive any 
injection and were not trained. Data are presented as means ± SEM. 
Significant effects are indicated by Ë (P < 0.05), ËË (P < 0.01) and ËËË 
(P < 0.001). 
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flexibility of the animals as they did not learn the new location of the platform 
compared to control. This highlights a long-lasting cognitive deficit in these animals, 
as even after 24 days of exposure to the drug, PT mice still had not developed 
tolerance to this effect. Immunohistochemical analysis revealed that THC decreased 
zif268 expression in the CA3 of the hippocampus, in the prefrontal cortex and in the 
dorsomedial and dorsolateral caudate putamen only in animals that did not received a 
pre-treatment, with no effect seen in PT animals.   
 At the beginning of the acquisition, animals were trained in 2 cued trials 
where the location of the platform was indicated by a visual cue. No significant 
difference between Veh- and THC-treated animals was observed, showing that all 
animals were able to find the platform. This result, together with the absence of 
difference in swim speed in animals treated with THC compared to Veh, suggests that 
THC did not induce any visual or locomotor impairment in mice exploring the water 
maze. These results are consistent with studies showing that, while cannabinoids 
impair learning in the place version of the water maze, no deficit was observed in the 
cued version of the water maze task using the visible platform (Ferrari et al., 1999, 
Niyuhire et al., 2007).  
Following the 2 cued trials, acquisition of the reference memory task began. 
Animals received 4 trials per session over 9 consecutive days where the hidden 
platform remained in a fixed position. We observed a slower acquisition of spatial 
memory performance in animals treated with THC, irrespective of whether these 
animals were pre-treated with THC for 13 days or not. Cannabinoids agonist like HU 
210 (Ferrari et al., 1999)and THC (Da and Takahashi, 2002) have previously been 
shown to impair learning in the place version of the water maze task. By the ninth 
day, no difference was observed between Veh- and THC-treated groups, showing that 
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all animals had learnt the task. These results demonstrate that THC impaired the 
acquisition of spatial reference memory, and this effect was overcome with repeated 
learning sessions.   
For the reversal testing, the location of the platform was changed but the 
procedural component of the task (to swim to the platform to escape) remained 
unmodified. Thus animals had to extinguish the original spatial response and learn a 
new one by making new associations between the novel platform location and the 
surrounding spatial cues (Rossato et al., 2006). On the first trial of the first day of 
reversal (day 11) an increased time to reach the platform was observed for all animals, 
as they had to find the new location of the platform. Interestingly on the second trial 
of this day, THC-treated animals were delayed in finding the platform compared to 
Veh-treated animals, and this effect was accentuated on the second day of reversal 
(see Fig. 4). This is consistent with a deficit in working memory, as it is usually 
evaluated with the repeated learning of a new location of the platform. Research 
evaluating the effects of cannabinoids on working memory has widely reported 
deficits in this form of learning. In C57BL/6 mice, 3 mg/kg THC impaired working 
memory (Varvel et al., 2001), and this effect was reversed by the cannabinoid 
receptor antagonist SR141716A. In a similar paradigm to ours, THC decreased spatial 
working memory on the second trial of the delayed-matching-to-place in the water 
maze when administered at 2 and 5 mg/kg (Fadda et al., 2004). Impairment of 
working memory with THC (6 mg/kg) was also observed in the radial arm maze, 
another model that can be used to measure working memory (Lichtman and Martin, 
1996). In the present study, using a relatively low dose of THC which is more 
comparable to human dosing, we observed a reversal deficit which suggests that THC 
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impaired the re-actualization of the information, this capacity of flexibility being one 
of the properties of working memory.  
One hour following the last trial of acquisition on day 9, animals were tested 
in a probe trial where the platform was removed from the pool. We observed that all 
mice explored the target quadrant where the platform was localized during the 
acquisition above chance level, confirming that they successfully learnt the spatial 
reference memory task. However, although the difference between Veh- and THC-
treated animals is quite moderate, the significantly higher latency to the first platform 
crossing implies a less accurate spatial response in mice that were treated with THC. 
On the second probe trial at the end of the reversal on day 11, Veh-treated animals 
spent more time in the new target quadrant than THC-treated animals, and above 
chance level. This illustrates that Veh-treated animals were again learning the new 
location of the platform faster than THC-treated mice. This further strengthens our 
interpretation that THC impaired behavioural flexibility in this model. As THC-
treated animals did not learn the new platform location this deficit in reversal might 
be due to an increased perseverance of the animals in returning to the previously 
learnt platform location. However our results showed that THC-treated animals, that 
spent less time in the new target quadrant, did not spend more time in the former 
target quadrant where the platform was located during the acquisition, that they 
explored at chance level. Therefore, THC-induced deficits in reversal learning are 
unlikely due to perseverance and most likely explained by a specific deficit in 
learning the new platform location.  
Interestingly during both the reference memory and the reversal tasks, no 
differences were observed between THC-treated PT and NPT animals, showing no 
differential effect of the pre-treatment on learning. With repeated administration, 
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tolerance to the effects of cannabinoids such as locomotor suppression, analgesia or 
hypothermia develop rapidly (Oliva et al., 2003), however effects on social or 
memory impairment appear to be more resistant to the development of tolerance (for a 
review, see Gonzalez et al., 2005). We analysed the effect of repeated THC exposure 
on locomotor activity and observed that animals developed tolerance to the locomotor 
suppressant effects of 1 mg/kg THC with no difference observed between Veh- and 
THC-treated animals after 5 days of treatment. Thus, THC-induced deficits on 
reference memory cannot be related to the sedative effects of cannabinoids, as NPT 
animals that received the drug for the first time exhibited the same level of 
performance as PT animals on day 1. Further, PT animals that received 13 days of 
pre-treatment were already tolerant to the locomotor suppressant effect of THC at the 
beginning of the acquisition. In conjunction with the absence of effects of the drug on 
swim speed, this strengthens the interpretation that this low dose of THC promoted a 
specific memory deficit. 
While the acute effects of cannabinoids on memory are widely reported, the 
effects of long term cannabinoid exposure have received less attention. Interestingly, 
the memory deficits observed during the reversal phase were independent of whether 
the animals received 13 days of pre-treatment prior to the beginning of the acquisition 
or not. This suggests that even after 24 days of treatment for the PT group and 11 days 
of treatment for the NPT group, THC was still effective in impairing memory. In 
human studies persistent cognitive deficits were observed after repeated use of 
cannabis (Solowij et al., 2002, Messinis et al., 2006). Animal studies have also 
reported the lack of development of tolerance to cannabinoid-induced working 
memory impairment (Nakamura et al., 1991, Nava et al., 2001). These studies used 5 
mg/kg THC, a dose higher than the one used here. Thus, results from the present 
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study show that memory impairments promoted by THC, even at such a low dose, are 
resistant to the development of tolerance.  
In NPT mice, THC decreased zif268 expression in hippocampal CA3 and to a 
lesser extent in the CA1, which is consistent with the view that the hippocampus 
mediates the memory impairing effects of cannabinoids (Lichtman et al., 1995, 
Misner and Sullivan, 1999, Hampson and Deadwyler, 2000, Egashira et al., 2002). 
Interestingly, THC exposure also reduced the expression of zif268 in the prefrontal 
cortex. This region is another site thought to participate in cannabinoid-induced 
spatial memory impairment in previous studies. For example, direct administration of 
THC into the medial prefrontal cortex has been shown to disrupt spatial working 
memory (Silva de Melo et al., 2005). Further, repeated THC administration in rats 
caused a persistent reduction in medial prefrontal cortical dopamine turnover which 
was assumed to subserve in part the cognitive dysfunction observed in these animals 
(Verrico et al., 2003). Because memory processes are dependent on synaptic plasticity 
in the hippocampus and prefrontal cortex (Laroche et al., 2000, Riedel and Davies, 
2005), these results suggest that the THC-induced impairment of working memory 
observed here could be mediated by a decreased neuronal activity in both the 
hippocampus and prefrontal cortex as measured by zif268. 
The decreased zif268 expression in the hippocampus we observed here was 
more dramatically observed in NPT than in PT animals, although the latter did exhibit 
cognitive impairments which were sometimes even more marked as assessed by the 
probe tests (Fig. 5). These results suggest that between 11 and 24 days of treatment, 
some cellular and molecular determinants of tolerance began developing which are 
dissociable from the mnemonic effect of THC. Interestingly, a 2-week chronic THC 
treatment did not produce tolerance to CB1-mediated inhibition of extracellular 
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hippocampal acetylcholine and working memory, but there was a time-course 
difference between these two phenomena suggesting they might be dissociated (Nava 
et al., 2001). Similar to the effects of THC on the hippocampus, THC also decreased 
zif268 expression in the dorsomedial and dorsolateral caudate putamen only in NPT 
animals. The dorsal striatum is not reported to be implicated in spatial memory 
(Egashira et al., 2002), but recent reports have emphasized a role of the medial 
striatum in behavioural flexibility (McDonald et al., 2008). The behavioural effects of 
THC on striatal function seem to fit better with this interpretation as the PT animals 
were tolerant to the locomotor suppressant effect of THC at the time of testing and no 
deficits were observed in the cued trials of the water maze task, a task supposed to be 
mediated by the caudate putamen (Packard and Teather, 1998).  
The present study examined for the first time the effects of repeated 
cannabinoid exposure on zif268 expression in the mouse forebrain. In prior in situ 
hybridisation studies, acute cannabinoid receptor agonist exposure increased the 
expression of zif268 mRNA in the CA1 and CA3 regions of the hippocampus 
(Derkinderen et al., 2003), cingulate cortex, fronto-parietal cortex and the caudate-
putamen (Mailleux et al., 1994). Consistent with this, (Glass and Dragunow, 
1995)showed in an immunohistochemical study that acute administration of a high 
dose of CP 55,940 (2.5 mg/kg) significantly increased zif268 in the striatum (CP 
55,940 is approximately 30 times as potent as THC, see (Arnold et al., 2001a, Arnold 
et al., 2001b). Given that acutely cannabinoids induce zif268 expression, the 
decreased zif268-labelled cells we observed here indicates that zif268 expression is 
inversely regulated by repeated cannabinoid exposure. Indeed, such a phenomenon 
has been reported for the psychostimulant drug, cocaine. Acute cocaine increased 
zif268 expression in the rat forebrain, however with repeated administration it 
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decreased basal zif268 expression (Bhat et al., 1992). We hypothesise that the 
diminished zif268 expression observed here following repeated THC exposure may 
promote changes in the zif268-regulated target genes which subserve the long-term 
memory impairing actions of cannabinoids. 
The present study shows that THC delayed the acquisition of a reference 
memory task in the water maze even in animals tolerant to the locomotor suppressant 
effects of the drug. When submitted to the reversal of the platform, THC impaired 
reversal learning suggesting deficits in behavioural flexibility consistent with 
dysfunction in working memory. This effect was still present in animals that received 
up to 24 days of treatment, showing that the memory disruptive effects of THC are 
particularly resistant to the development of tolerance even when using a low dose 
more consistent with human consumption. In the selected brain regions, THC 
decreased zif268 immunoreactivity only in animals that did not receive a pre-
treatment, suggesting that tolerance to the neuronal effects of the drug may have 
appeared between 11 and 24 days of treatment. In conclusion, this study showed that 
repeated cannabinoid exposure induced persistent memory deficits which are resistant 
to tolerance and may be, at least initially, regulated by diminished expression of the 
transcription factor zif268.  
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Summary of the main results at the end of Chapter 5 
 
 
Chapter 5 examined the behavioural effects of repeated THC exposure (1 mg/kg) on 
WT mice using the water maze. The main results obtained from this experiment are 
summarised in Table 1 and show that THC delayed learning of a spatial reference task 
and importantly, after 24 days repeated exposure, THC impaired reversal learning in 
animal that were already tolerant to the effects of the drug on locomotor activity. 
 
Table 1. Summary of main results form Chapter 2, 3, 4 and 5. 
Test 
 
Chapter 2 
Effect of THC  
(10 mg/kg) 
Chapter 3 
Effects of THC  
(10 mg/kg) 
Chapter 4 
Repeated CP 55,940  
(0.4 mg/kg) 
 
Chapter 5 
Chronic THC  
(1 mg/kg)  
WT only 
 On day 1 Tolerance  
Locomotor 
activity in the 
open field 
 
Hypo- 
locomotion 
more 
important in 
Nrg1 HET mice 
than WT mice  
 Strong 
hypo- 
locomotion 
in both Nrg1 
HET and WT 
mice 
Nrg1 HET 
mice 
developed 
tolerance to 
the hypo- 
locomotion 
faster than 
WT mice  
Tolerance to 
the decreased 
locomotor 
activity 
developed 
after 5 days 
Anxiety in the 
light dark  
 
 
Decreased 
time spent in 
the light 
compartment 
only in Nrg1 
HET mice 
 Decreased 
time spent 
in the light 
compartmen
t in both 
Nrg1 HET 
and WT 
mice 
Tolerance 
developed in 
WT mice but 
not in Nrg1 
HET mice 
 
Social 
interaction 
Decreased 
social 
interaction in 
both WT and 
Nrg1 HET mice 
similarly 
 Decreased 
social 
interaction 
in both WT 
and Nrg1 
HET mice  
No tolerance 
developed 
 
Prepulse 
inhibition 
 
Facilitation 
only in Nrg1 
HET mice 
 Facilitation 
in Nrg1 HET 
mice, 
disruption in 
WT mice 
Tolerance 
developed in 
both Nrg1 
HET and WT 
mice 
 
Immunohisto- 
chemistry 
 
 Increased c-Fos 
expression in the 
LSV of Nrg1 HET 
mice  
 Increased 
Fos B/ΔFos 
B expression 
in the LSV of 
Nrg1 HET 
mice 
Decreased 
zif268 
expression in 
CA3, PFC and 
CPU only in 
NPT mice 
Memory in the 
water maze 
 
    Delayed 
learning of 
spatial 
memory 
Impaired 
reversal 
learning 
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1. Significance of key findings and future directions 
While human population studies indicate that a gene-environment interaction is likely 
required for the development of schizophrenia, they are restricted in the mechanistic 
detail they can provide in improving the understanding of this phenomenon. Indeed 
epidemiologists have made a call to basic scientists to assist in the quest to delineate 
the exact genetic and neuropharmacological basis for cannabis-induced schizophrenia 
(Henquet et al., 2005). The research presented in this thesis provides the first attempt 
to create an animal model of genetic vulnerability to cannabinoid-induced 
schizophrenia. This was achieved using mice heterozygous for the schizophrenia 
susceptibility gene Nrg1 that display many schizophrenia-like endophenotypes. These 
animals were exposed to acute and chronically administered cannabinoid drugs, 
including the main psychoactive constituent of cannabis, THC, and their 
neurobehavioural responses were compared to that of WT mice. Further, an animal 
model of chronic cannabinoid-induced impairments in spatial working memory was 
also developed that might be applied to the Nrg1 HET mice in future studies. 
The results from this thesis further reinforce the nature of the Nrg1 HET 
mouse phenotype and that it provides a compelling animal model of schizophrenia. 
For example, Nrg1 HET mice show a hyperactive phenotype (Chapter 2) that is 
resistant to habituation compared to WT animals (Chapter 4). The Nrg1 HET mice 
display a moderate anxiolytic-like phenotype that is task-specific as it was only 
observed in the LD but not in the SI test (Chapter 2). However, the locomotor 
hyperactivity of these mice reduces the impact of such a conclusion as it confounds 
anxiogenic measurement in exploration-based models like the LD task. Nrg1 HET 
mice also displayed PPI deficits (Chapter 4); however, this effect was not observed in 
Chapter 2. A change in PPI testing parameters in Chapter 4 was necessary to reveal 
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the PPI deficit of Nrg1 HET mice. Therefore, the consistency of such a phenotype is 
questionable and requires further research to identify the exact conditions required to 
reliably uncover this aspect of the Nrg1 HET mice phenotype. On a neurobiological 
level we reported for the first time in Chapter 3 that Nrg1 HET mice show enhanced 
c-Fos expression in schizophrenia-relevant areas of the CNS, i.e. the LSV (Sheehan et 
al., 2004), and the NAS (van der Stelt and Di Marzo, 2003).  This is consistent with 
these animals having a schizophrenia phenotype, especially with respect to the 
increased c-Fos expression in the NAS which might be caused by increased dopamine 
levels in this region.  
SI was measured in Chapter 2 and 4 of the present thesis but did not reveal 
drug-free differences between Nrg1 HET mice and WT mice. Social withdrawal is 
generally observed in schizophrenia, but the absence of a social deficit in Nrg1 HET 
mice suggests that this behaviour may not involve Nrg1 processes. O’Tuathaigh and 
colleagues (2008) reported increased aggressive behaviours of Nrg1 HET mice in the 
resident intruder test where the opponent is placed in the home cage of the tested 
animals. Here mice were tested in a novel environment, thus context differences could 
account for the absence of SI between our studies and O’Tuathaigh’s, as aggressive 
behaviour is more robust in a territorial context. This suggests that a more 
confrontational environment should be used to evaluate SI in the future. In addition, 
O’Tuathaigh et al. (2008) reported a selective impairment of Nrg1 HET mice in 
recognising social novelty. Cannabinoid treatment impairs social recognition in 
rodents (Schneider and Koch, 2002). Therefore it would be of high interest to evaluate 
if the effects of cannabinoids on social recognition would be intensified in Nrg1 HET 
mice. 
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The data reported in Chapter 2 were the first supporting that Nrg1 HET mice 
exhibit an increased sensitivity to cannabinoids in behavioural domains associated 
with schizophrenia-like symptoms in animals. This key finding is a breakthrough in 
understanding the genetic basis for cannabis-induced psychosis as it demonstrates that 
alteration in Nrg1 modulates the acute actions of cannabinoids. The most striking 
result from Chapter 2 was that Nrg1 HET mice expressed a greater THC-induced 
enhancement in PPI compared to WT mice. It is tempting to speculate that these data 
are consistent with the self-medication hypothesis of schizophrenia as acute THC 
treatment enhanced attentional function in the Nrg1 HET mice as measured in the PPI 
model. To assess the neurobiological correlates of such an increased behavioural 
sensitivity of Nrg1 HET mice, Chapter 3 measured neuronal activation following 
acute THC exposure. An increased THC-induced c-Fos expression was observed 
selectively in the LSV of Nrg1 HET but not in WT mice. Taken together, these two 
chapters demonstrate that cannabinoid and neuregulin systems interact to modulate 
the sensitivity of Nrg1 HET mice to the acute neurobehavioural effects of 
cannabinoids.  
The increased sensitivity of Nrg1 HET mice to the acute effects of THC might 
be explained by the establishment of compensatory mechanisms that might have 
developed during neurodevelopment in Nrg1 HET mice. Nrg1 and its receptor ErbB4 
play essential roles in neuronal migration, neurotransmitter receptor expression and 
myelination (Corfas et al., 2004) and are highly expressed in the developing brain 
suggesting that in humans like in animals, Nrg1 is involved in neuronal maturation 
(Pinkas-Kramarski et al., 1994, Bernstein et al., 2006). Interestingly, the presence of 
such compensatory mechanism was suggested in mutant mice null for the Nrg1 
receptor ErbB4 (Thuret et al., 2004). Therefore, the partial deficiency of Nrg1 could 
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have engendered a reorganisation of the brain during development that could have 
affected the expression or efficacy of different neurotransmitter systems including 
CB1 receptors, explaining the different sensitivity of Nrg1 HET mice after acute THC 
treatment in Chapter 2 and 3. Indeed our group has preliminary data suggesting that 
the levels of CB1 and NMDA receptors binding show altered expression in Nrg1 HET 
mice as measured by autoradiography (unpublished observations). 
As human studies showed that it is more consistently the chronic use of 
cannabis that precipitates schizophrenia in vulnerable individuals, Chapter 4 
examined the effect of repeated administration of cannabinoids. As THC could not be 
used in this experiment as it was unavailable at this time, the effects of the synthetic 
analogue of THC, CP 55,940, were evaluated on Nrg1 HET mice. Upon repeated 
administration, we were expecting that chronic administration of CP 55,940 would 
precipitate PPI deficits in Nrg1 HET mice. However no long-term effect of the drug 
was observed in PPI, wether it is facilitation or perturbation. These results show that, 
in the limitation of animal research, the PPI model may not be able to discriminate 
long term effects of cannabinoids in terms of psychotic-related symptoms. However 
other models revealed interesting genotype differences after repeated cannabinoid 
treatment. Tolerance to CP 55,940-induced locomotor suppression and hypothermia 
developed more rapidly in Nrg1 HET mice than in WT mice. By contrast, while 
tolerance developed to the anxiogenic-like effects of CP 55,940 in WT animals, no 
tolerance to this anxiogenic-like effect could be observed in Nrg1 HET mice, even 
after 15 days exposure to the drug. In addition, this effect was associated with an 
increased Fos B/∆Fos B expression in the LSV of Nrg1 HET mice, with no 
corresponding effect observed in WT mice. These results provide new insight into 
Nrg1-cannabinoid interactions and show that repeated cannabinoid exposure promotes 
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differential behavioural effects on Nrg1 HET and WT mice and reaffirm that the LSV 
may be an important site for cannabinoid-induced neuronal dysregulation in the brain 
of Nrg1 HET mice.  
Nrg1 and ErbB4 are also expressed in the adult brain (Steiner et al., 1999, Law 
et al., 2004), and neuregulins are involved in regenerative processes in the mature 
brain (Kerber et al., 2003). As observed in Chapter 4, Nrg1 depletion may confer a 
distinct neuroadapative response to repeated treatment with CP 55,940 observed in 
adulthood. Interestingly, the neurobehavioural response of the Nrg1 HET mice to 
repeated cannabinoid exposure varied depending on the measure being taken. The 
neuroadaptive processes underlying these effects are likely distinct and involve partly 
disparate brain circuitry. For example, an enhanced rate of CB1 receptor down-
regulation or desensitisation in the substantia nigra and hypothalamus could explain 
why Nrg1 HET mice develop tolerance more rapidly to the locomotor suppressant and 
hypothermic effects of CP 55,940 respectively. Alternatively, the sustained 
anxiogenic response of Nrg1 HET mice with repeated testing might be subserved by 
induction of the long-term neuronal marker Fos B/∆Fos B in the LSV, an area 
involved in anxiety-related behaviour (Sheehan et al., 2004, Sotomayor et al., 2005, 
Calfa et al., 2007). Future studies are required to clearly delineate the mechanisms 
subserving these altered neuroadaptive responses to repeated CP 55,940 in Nrg1 HET 
mice. For example, analysing CB1 receptor function using autoradiography would 
help to further understand the neuronal changes that occur in the different brain 
regions of these animals following a repeated treatment with cannabinoids.  
Neurodevelopmental processes underlying brain maturation are also critical 
during adolescence (Schneider, 2008) - the age coinciding with the onset of 
schizophrenia. Indeed, adolescence is also the age-period at which people often start 
Chapter 6: General discussion 
116 
experimenting with cannabis. Human studies have shown that earlier cannabis use 
confers greater risks for developing schizophrenia than later cannabis use (Arseneault 
et al., 2002). Thus, adolescence may offer a period of particular vulnerability to the 
adverse effects of cannabis. Consistent with this, studies have shown that cannabinoid 
exposure in adolescence may induce subtle but lasting neurobiological changes in 
adult brain circuits underlying higher thought functions (Quinn et al., 2008, Rubino 
and Parolaro, 2008, Schneider, 2008). A previous study by Karl and colleagues (2007) 
indicated that Nrg1 HET mice have an age-dependent phenotype, with symptoms like 
hyperactivity being evident after 5 months of age. Therefore, it would be of particular 
interest to observe whether cannabinoid exposure in adolescent Nrg1 HET mice 
facilitates the earlier development of the “schizophrenia-like” phenotype paralleling 
human evidence showing that cannabis use might precipitate schizophrenia earlier in 
people with vulnerability to the disorder (Barnes et al., 2006, Mauri et al., 2006).  
The results from Chapter 3 and 4 of this thesis highlight that the LSV may be a 
particular site of dysregulation in Nrg1 HET mice which responds aberrantly to 
cannabinoid exposure. It is surprising that this particular region is the recurring brain 
area discerning genotype-cannabinoids interaction, given that schizophrenia is most 
generally associated with dysfunctions in the cingulate and prefrontal corteces or the 
hippocampus (Mitchell et al., 2001), regions where we did not find any interactions. 
However, the lateral septum is involved in the integration of cognitive processes by 
receiving inputs from the hippocampus, as well as from the PFC and the entorhinal 
cortex (Sheehan et al., 2004). It also shares reciprocal projections with the 
hypothalamus, the amygdala and the BNST that indicate a role in relaying affective 
information. Further, its role in incentive motivation and schizophrenia is highlighted 
by its connections with the mesocorticolimbic dopaminergic system (Sheehan et al., 
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2004). In addition to the modulation of these diverse functions, the lateral septum has 
widely been reported to be involved in the stress response. It receives vasopressin 
innervations from the amygdala and the BNST that are involved in social response to 
stress and anxiety-provoking environments (Koolhaas et al., 1998). When directly 
injected in the lateral septum, nicotine and serotonin receptor agonists induced 
anxiogenic effects in rats (Cheeta et al., 2000).  
In Chapter 3, the increased sensitivity of Nrg1 HET mice to the effects of 
THC on c-Fos expression in the LSV was dependent on whether the animals had been 
behaviourally tested, indicating that one possible reason for this effect could be that 
the stress associated with the procedure would be necessary to reveal this effect. 
Interestingly, infusion of a corticotrophin-releasing factor 2 receptor agonist directly 
into the lateral septum increased anxiety-related behaviour at lower doses in a high 
stress environment that in a low stress environment (Henry et al., 2006). This suggests 
that modulation of anxiety by the lateral septum is dependent on the background 
stress level of the animal. Thus increasing the magnitude of stress could exaggerate 
the effects of cannabinoids in Nrg1 HET mice. Importantly, schizophrenia patients 
have an increased reactivity to psychosocial stress, and this effect has been associated 
with NRG1 polymorphism (Keri et al., 2008). Taken together, these data suggest a 
three-way interaction between cannabinoid exposure, depletion of Nrg1 and stress 
which uncovers increased schizophrenia-related neurobehavioural responses. 
The persistent Fos B/∆Fos B expression promoted by CP 55,940 in the LSV 
might suggest that it is a key region in the regulation of drug-induced psychosis. 
Evidence that the lateral septum might be involved in schizophrenia processes is 
supported by the observations that most antipsychotic drugs increase c-Fos expression 
in the LSV (Pinna et al., 1999). Interesting, after repeated exposure to haloperidol no 
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tolerance developed to the induction of c-Fos expression in the LSV (Sebens et al., 
1995). In addition, the chronic administration of clozapine increases cytochrome c 
oxidase expression in the septum (Prince et al., 1998). In contrast, PCP and 
methamphetamine that are known for inducing psychotic symptoms decrease 
cytochrome c oxidase activity in the septum, an effect reversed by antipsychotic drugs 
(Prince et al., 1997). Cytochrome c oxidase is a pivotal enzyme from mitochondria 
that is involved in oxidative metabolism to generate ATP by cell respiration and has a 
role in apoptosis (Kadenbach et al., 2000, Ow et al., 2008). Inhibited neuronal 
functional activity, as a consequence of reduced energy metabolism mediated by 
altered mitochondrial function and decreased cytochrome oxidase levels, has been 
proposed to influence the symptomatology of schizophrenia (Marchbanks et al., 
1995). Interestingly, both cannabinoid and Nrg1-ErbB signalling have been 
implicated in inducing apoptosis by releasing cytochrome c (Downer et al., 2001, 
Rohrbach et al., 2005). In conclusion, these results suggest that cannabinoids could 
influence the response of the LSV of Nrg1 deficient mice by interacting with 
cytochrome c oxidative processes.  
The lateral septum expresses various substances to support neurotransmission. 
The rostral region of the lateral septum expresses neurotensin and enkephalin and 
caudal parts show high levels of somatostatin. However the ventral component of the 
lateral septum appears to predominantly express estrogen (Sheehan et al., 2004). 
Estrogens act on an interconnected network of hypothalamic and limbic areas, and 
especially on the lateral septum, where they modulate aggressive behaviour (Trainor 
et al., 2006). Interestingly, estrogens also regulate cannabinoid-induced presynaptic 
inhibition of glutamate and GABA release in the hypothalamus (Nguyen and Wagner, 
2006), and stimulate interaction between estrogen receptors and the neuregulin 
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receptor ErbB4 as shown in breast cancer cells (Zhu et al., 2006). Variation in the 
estrogen receptor gene has been associated to schizophrenia and estrogens have been 
suggested to provide a potential treatment for schizophrenia due to their 
neuromodulatory and neuroprotective activities (Kulkarni et al., 2008, Weickert et al., 
2008). All together these studies suggest that the interaction between cannabinoids 
and NRG1-ErbB4 signalling in the LSV might involve estrogen receptors.   
Chapter 4 highlighted that tolerance develops at different rates dependent on 
the behaviour tested, however memory processes were not evaluated as it requires 
more elaborated protocols. Thus Chapter 5 evaluated the chronic effects of 
cannabinoids in a model of reversal learning in the water maze using a low dose of 
THC (1 mg/kg) in C57Bl/6 wild-type mice (the background strain of our Nrg1 HET 
mice). In addition, an effect of 13 days pre-treatment with the drug was evaluated to 
observe whether memory deficits would persist after tolerance had developed to the 
locomotor suppressant of the drug. This allowed testing of a cognitive-specific effect 
of THC without locomotor confounds promoted by the sedative effects of the drug. 
The data reported in Chapter 5 showed that THC promoted a deficit in reversal 
learning which was observed even after 24 days of treatment, suggesting that 
tolerance did not develop to the cognitive impairing effects of THC.  
There has been expanding interest in recent years of the involvement of 
cannabinoids in executive functions, as they modulate diverse higher-order cognitive 
processes including attention, inhibitory control and decision-making, time 
estimation, working memory and behavioural flexibility (Pattij et al., 2008). The latter 
represent the capacity to adapt to the environment by adjusting behavioural strategies 
- that is to suppress old responses and replace them with new ones. This process is 
impaired in cannabis users (Lamers et al., 2006) and animal models reported 
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impairments in attentional set shifting tasks (Egerton et al., 2005, Hill et al., 2006). To 
our knowledge only one study previously showed that modulation of the cannabinoid 
system impairs behavioural flexibility in reversal learning in the water maze (Varvel 
and Lichtman, 2002), thus the results from Chapter 5 provide the first evidence for a 
persistent deficit in reversal learning following chronic cannabinoid treatment. The 
protocol outlined in Chapter 5 could also provide a model of high interest to evaluate 
if cannabinoids trigger increased memory deficits in Nrg1 HET mice compared to WT 
mice. O’Tuathaigh and colleagues (2007) reported intact spatial learning of Nrg1 
HET mice in the Barnes maze and intact spatial working memory using a spontaneous 
alternation task however spatial memory performance of Nrg1 HET mice has never 
been evaluated in the water maze. Association of NRG1 gene with working memory 
deficits have been shown in healthy individuals (Krug et al., 2008), thus it is also 
possible that Nrg1 HET mice might display altered working memory compared to WT 
mice using the water maze and the effects of cannabinoids might be exaggerated in 
Nrg1 HET mice in such a task.  
While behavioural studies can give a profound insight into modelling 
psychiatric diseases in animals, the main limitation of these tests include the absence 
of consistency between experiments. Behavioural models are strongly dependent upon 
the procedure used, for example a change in the PPI paradigm in Chapter 4 compared 
to Chapter 2 revealed a PPI deficit in VEH-treated Nrg1 HET mice. In addition, other 
factors can influence the outcome of behavioural testings, especially when measuring 
anxiety-related behaviours. We observed an increased time spent in the light 
compartment of the LD and in the time spent in SI of baseline VEH-treated WT and 
Nrg1 HET mice on the 1st day of administration in Chapter 4 compared to Chapter 2. 
Such variations can be accounted for the difference in familiarity to the apparatus 
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(repeated testing in Chapter 2 using within-subjects comparison versus use of naïve 
animals in Chapter 4 using a between-subjects comparison) or the age of the animals 
(22-25 weeks in Chapter 4 versus 26-30 weeks in Chapter 2). Another limitation of 
these behavioural models is the interpretation of the effects observed. The increased 
locomotor activity of Nrg1 HET mice confounded the specificity of the anxiety-like 
effect in the LD in Chapter 2, and the decreased startle response also confounds the 
PPI deficit observed in VEH-treated Nrg1 HET mice. Thus a careful investigation of 
the test parameters associated with the evaluation of several models is required to 
increase the strength of the results. Future studies of biological correlates such as 
corticosterone levels measurements could be helpful to further characterize the 
specificity of the increased sensitivity of Nrg1 HET mice to cannabinoid-induced 
anxiety-like behaviour. 
When taken together, the results from the present thesis support that gene-
environment interactions increase vulnerability to developing schizophrenia-like 
symptoms. Consistent with the main theory of the association between cannabis and 
schizophrenia considered in Chapter 1, cannabis would increasing psychosis in 
vulnerable individuals, as supported by the increased sensitivity of Nrg1 HET mice to 
the neurobehavioural effects of cannabinoids observed in this thesis. This work raises 
the need for future investigations on gene-environment interactions, and other studies 
exploring other environmental causes such as pregnancy or early life stress would be 
of high interest to try to further understand the basis of the development of 
schizophrenia.   
While the use of Nrg1 HET mice provides a very promising model for 
schizophrenia, other genetic animal models are on offer to explore the genetic basis of 
cannabis-induced psychosis. One of the most interesting are those involving genetic 
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manipulation of the DISC1 gene. Collectively, these mice have enlarged ventricles 
and exhibit behavioural impairments such as hyperactivity, abnormal spatial working 
memory and sociability, and an anhedonia/depression-like deficit. Further, these mice 
show deficits in LI and PPI that were reversed by antipsychotic treatment (Koike et 
al., 2006, Clapcote et al., 2007, Hikida et al., 2007, Li et al., 2007, Pletnikov et al., 
2008). Other schizophrenia susceptibility genes have also been investigated, for 
example PRODH that induced PPI impairments (Gogos et al., 1999) and deficits in 
associative learning and exaggerated stress and amphetamine responses (Paterlini et 
al., 2005). Therefore, the use of mutant mice for schizophrenia susceptibility genes is 
a new and exciting tool in understanding psychiatric diseases and it would be of 
interest to replicate the effects of cannabinoids with other susceptibility genes. To 
model the polygenetic aetiology of schizophrenia, the use of mutant mice exhibiting 
mutation for several susceptibility genes would represent the future of genetic 
modelling of psychiatric disorder. 
 
2. Conclusion 
In conclusion, the present thesis provides the first evidence that partial 
deletion of the schizophrenia susceptibility gene Nrg1 modulates the 
neurobehavioural actions of acutely and chronically administered cannabinoids. Nrg1 
HET mice appear more sensitive to the acute neurobehavioural effects of 
cannabinoids. Acutely THC exposure had a beneficial action on attentional function 
by promoting PPI facilitation in Nrg1 HET mice. However, with repeated 
cannabinoid administration such an acute benefit disappeared and the Nrg1 HET mice 
displayed a long-lasting anxiogenic profile that was resistant to tolerance. Conversely, 
Nrg1 HET mice developed tolerance to the locomotor suppressant and hypothermic 
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effects of cannabinoids more rapidly than WT mice, indicating a distorted 
neuroadaptive response in these animals. Another major finding of the current thesis 
is that the lateral septum appears to be an important brain region of cannabinoid-
induced dysregulation in Nrg1 HET mice. Setting up animal models that parallel 
human disorders as complex as schizophrenia is necessary in understanding the exact 
nature of the underlying neuronal mechanisms. This research enhances our 
understanding of the neurobehavioural consequences of interactions between 
neuregulin 1 and cannabinoid systems that may provide a model for genetic 
vulnerability to cannabis-induced schizophrenia. These data might ultimately assist in 
helping to inform why individuals with genetic irregularities in the NRG1 gene should 
avoid using cannabis. 
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ABSTRACT  
Few studies have investigated the effects of chronic cannabinoid exposure on memory 
performance and whether tolerance occurs to cannabinoid-induced memory 
impairment. Here we studied the effects of repeated exposure to ∆9-
tetrahydrocannabinol (THC: 1 mg/kg) on spatial memory and zif268 expression in 
mice. One group of animals were not pre-treated with THC while another group was 
injected with 13 daily injections of THC prior to memory testing in the Morris water 
maze. Both groups were administered THC throughout the memory testing phase of 
the experiment. THC decreased spatial memory and reversal learning, even in animals 
that received the THC pre-treatment and were tolerant to the locomotor suppressant 
effects of the drug. Zif268 immunoreactivity was reduced in the CA3 of the 
hippocampus and in the prefrontal cortex only in non pre-treated animals, indicating 
that while tolerance to the effects of cannabinoids on neuronal activity were evident, 
cannabinoid-promoted memory impairment in these animals persisted even after 24 
days of exposure. Taken together this study demonstrates that following extended 
administration of THC its spatial memory impairing effects are resistant to tolerance.  
 
Key words: cannabinoid; memory; zif268; chronic; tolerance; hippocampus 
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INTRODUCTION 
Cannabis is the most widely used illicit drug in the world. Apart from its extensive 
recreational use, it also has some potential therapeutic relevance (Rog et al., 2005, 
Smith, 2005). One limitation of cannabis use is that its consumption induces cognitive 
impairments (Solowij et al., 1995, Fletcher et al., 1996), as well as structural and 
functional brain alterations (Jentsch et al., 1998, Kanayama et al., 2004, Yucel et al., 
2008). Thus, developing a better insight of the chronic effects of cannabinoids on 
cognition is of critical importance for understanding the adverse effects of this drug.  
Long-term cannabis users exhibit neuropsychological deficits such as 
impairments in memory and attention (Solowij et al., 2002, Messinis et al., 2006). In 
laboratory animals the acute administration of the main psychoactive constituent of 
cannabis, Δ9-tetrahydrocannabinol (THC), induces deficits in cognitive processes 
(Lichtman and Martin, 1996, Varvel et al., 2001, Da and Takahashi, 2002). While the 
acute effects of cannabinoids are well documented, the long term effects of the drug 
on learning and memory have received less attention. With chronic treatment, many 
of the effects of cannabinoids are diminished – a phenomenon known as tolerance. 
Tolerance develops to the characteristic effects of cannabinoids at different rates, for 
example it develops more rapidly to cannabinoid-induced hypothermia than 
locomotor suppression (Whitlow et al., 2003, Gonzalez et al., 2005). Little is known 
about tolerance to the memory disruptive effects of cannabinoids, with a few human 
and animal studies suggesting that cannabinoid-induced memory impairment is more 
resistant to the development of tolerance (Nakamura et al., 1991, Deadwyler et al., 
1995, Nava et al., 2001, Solowij et al., 2002, Hampson et al., 2003). This difference in 
the time-course of the development of tolerance to the effects of cannabinoids is of 
particular interest in animal models of behaviour given that it is often difficult to 
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dissociate the specificity of learning perturbations from the confounding effects of 
these drugs on motor activity.  
The memory impairments promoted by cannabinoids appear to more strongly 
impact spatial memory (Ferrari et al., 1999, Varvel et al., 2001, Da and Takahashi, 
2002, Fadda et al., 2004). This hippocampus-mediated form of learning can be 
evaluated in animals using the Morris water maze. Using this paradigm, different 
tasks can be examined to differentiate between reference and working memory 
(Varvel et al., 2001). Reference memory is evaluated in the place version of the water 
maze where the platform remains at a constant location, while working memory is 
usually studied by changing the location of the platform to assess behavioural 
flexibility, a process that is impaired with cannabinoid administration (Egerton et al., 
2005, Hill et al., 2006). As memory is strongly regulated by the hippocampus, we also 
aimed to evaluate the chronic effects of THC on the brain by measuring zif268 
expression. Zif268 (also known as krox-24, NGFI-A or egr-1) is an immediate early 
gene that is involved in learning and memory processes (Bozon et al., 2002). This 
transcription factor is abundant in the hippocampus where cannabinoids normally 
increase its expression (Derkinderen et al., 2003), an effect postulated to subserve the 
memory impairments promoted by these drugs (Lichtman et al., 1995, Egashira et al., 
2002). 
The doses of THC used by previous mouse studies to promote deficits in 
working memory range between 3 and 10 mg/kg (Varvel et al., 2001, Da and 
Takahashi, 2002, Varvel et al., 2005, Niyuhire et al., 2007). Here we aimed to assess 
if deficits in reversal learning in mice also occur using a lower dose of THC (1 mg/kg) 
that is more relevant to those administered by humans. Furthermore, we aimed to 
evaluate whether the extended administration of THC induces memory deficits that 
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persist even after the animals have developed tolerance to the locomotor suppressant 
effects of the drug. In addition, we measured the underlying neuronal substrates that 
may be responsible for such effects by analysing zif268 expression in the brain. 
 
METHODS 
Subjects 
Male adult C57BL/6J mice (weighting 23-28g at the beginning of the experiment) 
were obtained from Charles River (Lyon, France). Animals were housed at 22-23°C 
under a 12 h light/dark cycle (7:00 a.m. on) with food and water available ad libitum. 
One week prior to the experiment, animals were separated into individual home cages 
and handled for 2–3 min/day during all the experiment to minimize non-specific 
stress. Experiments were performed in accordance with the guidelines on the ethical 
use of animals from the European Communities Council Directive of 24 November 
1986 (86/609/EEC).  
 
Drug treatment 
THC (25 mg/ml, Sigma, France) was dissolved at 5 mg/ml in ethanol. This 
preparation was emulsified in a solution at 2.5 mg of polysorbate 80 (Sigma, France) 
/ml of ethanol. Ethanol was then evaporated at room temperature using a rotary 
concentrator-evaporator (SpeedVac®System, ThermoSavant) for 20 min under a 
pressure of 5.1 bars. The residue was resuspended in NaCl (0.9 %) and sonicated for a 
final THC concentration of 0.1 mg/ml. The same protocol where ethanol was used in 
replacement of THC was used to prepare the vehicle (Veh) solution. THC (1 mg/kg) 
or Veh were administered intraperitoneally (i.p.) at a volume of 10 ml/kg. 
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Apparatus 
Learning in the Morris water maze was evaluated using a pool that measured 150 cm 
in diameter and 55 cm in height, and that was placed in a room maintained at 23-25 
◦C under constant lighting with many extra-maze cues posted on walls. It was filled 
with 21±1 ◦C water until 15 cm of the top and made opaque by addition of white non-
toxic paint. A hidden platform of 13 cm in diameter was submerged 5 mm below the 
surface. Its location could be indicated to the animals by placing a 15 cm height and 4 
cm of diameter intra-maze cue on the submerged platform. A video camera mounted 
above the pool was used to record swim trials. Swim speed, escape latency (time to 
reach the platform), time spent in the target quadrant (where the platform should be 
during the probe trial) and animals paths were recorded and analysed using an 
automated tracking system (Videotrack, France). 
A different set of animals were then tested for locomotor activity using an 
activity meter (Imetronic, France). Animals were placed individually in the boxes of 
the apparatus immediately after injection with THC or Veh, for 1 hour under light 
exposure and without food or water available.  
 
Procedure of memory testing in the water maze 
For this experiment, mice were separated in 2 groups (see Fig. 1). Animals in the non 
pre-treated (NPT) group were administered daily injections of THC (1 mg/kg) or Veh 
30 min before testing in the water maze on days 1-11 (behavioural testing phase). 
Animals in the pre-treated (PT) group received 13 daily injections of THC (1 mg/kg) 
or Veh before the behavioural testing phase where, like NPT animals, these animals 
continued to receive THC or Veh on each day of testing. Therefore, such a design 
yields 4 treatment groups: PT-Veh, PT-THC, NPT-Veh and NPT-THC.  
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On this first day of the behavioural testing phase, animals received a pre-
training session consisting of 2 cued trials where the hidden platform was indicated 
by a visual intra-maze cue. Then the acquisition started and mice were tested for 
spatial reference memory. Each animal was trained to find the hidden platform kept at 
the same location for 1 session of 4 trials per day for 9 days. Mice were released from 
random location and were allowed to swim until they found and climbed on the 
platform or until a maximum of 90 s has elapsed. If a mouse did not find the platform, 
it was gently guided to the platform by hand where it was left for 20 s and then dried 
and returned to its home cage placed in a heating box. Mice were trained in groups of 
4 animals, allowing an intertrial interval of 15 min for each mouse. One hour after the 
end of the last session of the acquisition, mice were tested in a probe trial during 60 s 
where the platform was removed from the water maze.  
After 9 days of acquisition, mice were submitted to a reversal test where the 
platform location was moved to the opposite quadrant in order to evaluate the 
behavioural and cognitive flexibility of the animals. Mice were tested in 2 sessions of 
4 trials separated by 24 h. One hour after the end of these reversal trials, mice were 
again submitted to a probe trial during 60 s where the platform was removed from the 
water maze.  
 
Immunohistochemistry 
Home cage control animals (Quiet cont group) did not receive any injection and were 
not behaviourally tested.  
Ninety minutes after the last probe trial, animals were anaesthetised with an 
i.p. injection of Avertin and perfused transcardially with 100 ml of 4 % 
paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB) at pH 7.4. Brains of animals 
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kept in their home cages were also harvested as controls. The brains were removed 
and postfixed in PFA for 20 h. For cryoprotection, brains were placed in 30 % sucrose 
until they sunk. Brains were then sliced at 50 µm in a frozen microtome.  
Tissues were stored in cryoconservation solution at – 20 °C until the staining 
was performed. For immunohistochemistry, free floating sections were washed 4 
times for 10 min in PB before being incubated in 0.5 % hydrogen peroxide for 30 
min. After 4 washes in 0.9 % NaCl, sections were incubated in 1 % bovine serum 
albumin, 0.2 % Triton X100 (PB-BSA-TX) for 30 min at room temperature. Sections 
were then stained with the zif268 primary antibody (Santa Cruz Biotechnology) 
diluted at 1:5,000 in PB-BSA-TX for 24 h at 4 °C under shaking. After 4 washes in 
PB containing 0.2 % Triton X100 (PB-TX), sections were incubated in biotinylated 
anti-rabbit secondary antibody (Jackson ImmunoResearch) diluted at 1:2,000 in PB-
BSA-TX for 2 h at room temperature while undergoing shaking. Sections were 
washed again 4 times in PB-TX and transferred to an avidin-biotin-peroxydase 
solution (Sigma, France) for 2 h at room temperature and protected from the light. 
Sections were washed 4 times in PB and 3 times in 0.05 M Tris HCL (pH 7.5). The 
peroxidase activity was visualised by placing the tissue in 0.037 % diaminobenzidine 
tetrahydrochloride diluted in Tris-HCl and 0.015 % hydrogen peroxidase for 5 to 15 
min protected from light. The reaction was terminated by 4 washes in 0.05 M Tris 
HCl and tissues were stored in PB containing 0.2 g/l Azide (Sigma). Sections were 
then mounted onto slides, air dried, dehydrated in toluene and coverslipped. 
Quantitative densitometry was performed on the images of digitized brain sections 
using Biocom Visiolab 2000 software. Each structure was counted 5 to 8 times 
depending on the quality of the section. Results are indicated by number of reactive 
cells by unit of surface.  
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Statistical analysis 
Data from the water maze were analysed using two-way repeated measures analysis 
of variance (ANOVA) where the between subjects factors were treatment (Veh or 
THC) and group (PT or NPT), and trial or session (day) as the repeated measure. 
When needed, data were examined for each day separately by two-way ANOVA and 
further analysed using Tukey’s post hoc test. Data from locomotor activity were 
analysed using one-way repeated measures ANOVA where the between subjects 
factor was treatment (Veh or THC), and day as the repeated measure. Data from 
immunohistochemistry were analysed using a student t test. A significant level of P < 
0.05 was chosen for all comparisons.  
 
RESULTS 
Swim speed 
As cannabinoids have sedative effects, we analysed the swim speed of the animals 
during all phases of the water maze test to assess if motor impairment would persist 
when animals were placed in the water and forced to swim (data not shown). No 
overall effect of THC treatment was observed on swim speed over days of testing 
[F(1,44) = 1.32; P = 0.26] whether the animals were pre-treated or not. When 
analysing the different days separately, no effect of THC on swim speed was observed 
as measured on the first trial of each day. As observed during the tasks, all animals 
were able to swim and climb onto the platform. Taken together, these results show 
that THC treatment did not alter the swimming capability of the animals.   
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Cued trials 
On the first day of behavioural testing before the beginning of the acquisition task, 
animals received a pre-training session consisting of 2 cued trials where the platform 
was indicated by a visual cue (Fig. 2). A trend for THC treatment to increase escape 
latency was observed during the first cued trial [F(1,44) = 2.88, P = 0.097]. Tukey’s 
post hoc test revealed that THC only reduced escape latency in NPT mice (P < 0.05). 
However, this effect was transient as it was not observed on the second trial and all 
animals were able to perform the task suggesting that THC did not impair visual 
ability and the procedural aspect of the experiment.     
 
Acquisition of the spatial reference memory task 
Escape latencies for all sessions (average of the 4 trials per day) of acquisition and 
reversal are shown in Fig. 3. During acquisition, animals learnt where to find the 
platform as highlighted by a decreased escape latency over days [session: F(8, 352) = 
58.27, P < 0.001]. Interestingly, THC increased escape latency over days [treatment: 
F(1, 44) = 9.62, P < 0.01] and a treatment by session interaction was also observed 
[F(8, 352) = 2.29, P < 0.05]. To increase the accuracy of these results, we then 
analysed each session separately. We observed that THC impaired acquisition of the 
task on days 1 [F(1, 44) = 8.13, P < 0.01], 2 [F(1, 44) = 8.14, P < 0.01] and 3 [F(1, 
44) = 5.17, P < 0.05], with no difference observed on the other days. These results 
show that, independently of whether they received a pre-treatment or not, THC-
treated animals learnt the location of the platform slower than Veh-treated animals.  
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Reversal of the spatial memory 
During the reversal phase (Fig. 3), the platform location was changed to assess 
learning flexibility of the animals. On the first session of the reversal on day 10, all 
animals showed an increased latency to reach the platform compared to the last 
session of acquisition as they had to learn a new position of the platform. This is 
highlighted by a session effect between day 9 and 10 [F(1, 44) = 260.83, P < 0.001]. 
On the second session of reversal (day 11), the escape latency of all animals decreased 
compared to the first one, as shown by an effect of the session between days 10 and 
11 [F(1, 44) = 27.34, P < 0.001]. This shows that the animals started to learn the new 
location of the platform. Interestingly, while no effect of THC was observed on the 
last days of acquisition, the reversal of the platform triggered a learning deficit in 
THC-treated animals during the reversal [treatment: F(1, 44) = 5.93, P < 0.05]. When 
analysing the sessions of reversal separately, a treatment effect was observed on day 
11 [F(1, 44) = 6.03, P < 0.05], showing that THC impaired performance in the 
reversal phase, reducing the ability of the animals to learn the new location of the 
platform. Similarly to the beginning of the acquisition, THC treatment impaired the 
escape latency whether the animals received a pre-treatment or not.  
To gain a more detailed insight into our results, we then analysed the different 
trials of the 2 sessions of reversal separately (Fig. 4). A trend for an effect of THC 
treatment was observed on the second trial of the first session of reversal [F(1, 44) = 
3.01, P = 0.09] but not on the first trial as animals had to find the new location of the 
platform. This THC-induced impairment in performance observed on the second trial 
of the first day of reversal was accentuated on the second day, as highlighted by an 
effect of THC treatment on trial 2 [F(1, 44) = 5.19, P < 0.05] and 4 [F(1, 44) = 5.31, P 
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< 0.05] of the second session. These results are consistent with the interpretation that 
THC impaired working memory during the reversal. 
 
Probe trials 
The results from the probe trials are shown in Fig. 5. The first probe trial was done 1 
hour after the end of the acquisition on day 9. The platform was removed from the 
water maze and we measured the time spent in the target quadrant where the platform 
was formerly located during the acquisition. Consistent with results from escape 
latencies on the last days of acquisition, all animals spent the same time in the target 
quadrant as shown by the absence of treatment effect [F(1, 44) = 0.12, P = 0.73]. In 
addition, all animals were above chance level in the time spent exploring the target 
quadrant (P < 0.001), showing that all animals had learnt the location of the platform 
at the end of the acquisition (Fig.5A; P1 TQ1). We also measured the latency for the 
first platform location crossing (Fig. 5B). In the first probe test, we observed that 
THC-treated mice exhibited a significant increased latency to cross the platform 
compared to Veh-treated animals [F(1, 44) = 5.3, P < 0.05] and this effect was 
independent of the treatment condition [F(1, 44) = 2.53, P = 0.12].  
One hour after the end of the second session of reversal on day 11, a second 
probe trial was done to compare whether animals swam in the new target quadrant or 
in the old one where the platform was during the acquisition. No effect of THC was 
observed on the time spent in the old target quadrant [F(1, 44) = 0.47, P = 0.49]. In 
addition, as shown in Fig.5A (P2 TQ1) all animals irrespective of treatment group 
explored this quadrant below chance level. This shows that all mice stopped exploring 
the quadrant where the platform was located during the acquisition. In the new target 
quadrant, THC increased the latency to first cross the location of the platform [F(1, 
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44) = 4.8, P < 0.05] (Fig 5B; probe test 2). Supporting this result, a trend for THC to 
decrease the time spent in the new target quadrant was observed [F(1, 44) = 3.38, P = 
0.07] (Fig.5A; P2 newTQ). Importantly, Veh-treated animals spent more time (above 
chance level) in the new target quadrant than in the old one [F(1, 22) = 6.09, P < 
0.05], showing that they have started to learn the new location of the platform. 
However, THC-treated animals were at chance level in both the new and the old 
quadrants. Taken together, these results show that THC impaired reversal learning in 
the water maze.   
 
Locomotor activity 
We also measured locomotor activity using another set of animals (Fig. 6). No 
difference was observed between the animals on day 0 prior to the beginning of the 
drug administration. Using one-way repeated measure ANOVA, we showed that THC 
treatment promoted an overall decreased locomotor activity over days [F(1, 54) = 
5.48, P < 0.05]. The analysis of each days separately showed that THC reduced 
locomotor activity on days 2 [F(1,9) = 14.84, P < 0.01], 3 [F(1,9) = 5.94, P < 0.05] 
and 4 [F(1,9) = 6.84, P < 0.05]. From the fifth day of treatment, no difference was 
seen between Veh- and THC-treated mice, showing that animals became tolerant to 
the locomotor suppressant effect of THC.  
 
Immunohistochemistry 
The number of zif268 immunoreactive cells for the different regions are shown in Fig. 
7. Analysis with student’s t-test showed that in animals that were not pre-treated 
(NPT-Veh compared to NPT-THC), THC decreased zif268 expression in the CA3 of 
the hippocampus (P < 0.001), in the dorsomedial (P < 0.01) and dorsolateral (P < 
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0.05) part of the caudate putamen and in the prefrontal cortex (P < 0.05). No effect of 
THC was observed in animals that received pre-treatment with THC (PT-Veh 
compared to PT-THC).  
 
DISCUSSION 
The main results from the present study are that animals treated with a relatively low 
dose of THC, whether they have been pre-treated or not, had a reduced learning of the 
spatial reference memory task. However, they eventually acquired the task like 
control animals. During the reversal phase, while both NPT and PT animals were 
tolerant to the locomotor suppressant effects of THC, the drug impaired cognitive 
flexibility of the animals as they did not learn the new location of the platform 
compared to control. This highlights a long-lasting cognitive deficit in these animals, 
as even after 24 days of exposure to the drug, PT mice still had not developed 
tolerance to this effect. Immunohistochemical analysis revealed that THC decreased 
zif268 expression in the CA3 of the hippocampus, in the prefrontal cortex and in the 
dorsomedial and dorsolateral caudate putamen only in animals that did not received a 
pre-treatment, with no effect seen in PT animals.   
At the beginning of the acquisition, animals were trained in 2 cued trials where 
the location of the platform was indicated by a visual cue. No significant difference 
between Veh- and THC-treated animals was observed, showing that all animals were 
able to find the platform. This result, together with the absence of difference in swim 
speed in animals treated with THC compared to Veh, suggests that THC did not 
induce any visual or locomotor impairment in mice exploring the water maze. These 
results are consistent with studies showing that, while cannabinoids impair learning in 
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the place version of the water maze, no deficit was observed in the cued version of the 
water maze task using the visible platform (Ferrari et al., 1999, Niyuhire et al., 2007).  
Following the 2 cued trials, acquisition of the reference memory task began. 
Animals received 4 trials per session over 9 consecutive days where the hidden 
platform remained in a fixed position. We observed a slower acquisition of spatial 
memory performance in animals treated with THC, irrespective of whether these 
animals were pre-treated with THC for 13 days or not. Cannabinoids like HU 210 
(Ferrari et al., 1999) and THC (Da and Takahashi, 2002) have previously been shown 
to impair learning in the place version of the water maze task. By the ninth day, no 
difference was observed between Veh- and THC-treated groups, showing that all 
animals had learnt the task. These results demonstrate that THC impaired the 
acquisition of the spatial reference memory, which was overcome with repeated 
learning sessions.   
For the reversal testing, the location of the platform was changed but the 
procedural component of the task (to swim to the platform to escape) remained 
unmodified. Thus animals had to extinguish the original spatial response and learn a 
new one by making new associations between the novel platform location and the 
surrounding spatial cues (Rossato et al., 2006). On the first trial of the first day of 
reversal (day 11) an increased time to reach the platform was observed for all animals, 
as they had to find the new location of the platform. Interestingly on the second trial 
of this day, THC-treated animals were delayed in finding the platform compared to 
Veh-treated animals, and this effect was accentuated on the second day of reversal 
(see Fig. 4). Using acute doses of THC higher than in the present study, working 
memory deficits have been reported both in rats and mice (Lichtman and Martin, 
1996, Varvel et al., 2001). In a similar paradigm to ours, THC decreased spatial 
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working memory on the second trial of the delayed-matching-to-place paradigm in the 
water maze when administered at 2 and 5 mg/kg (Fadda et al., 2004). In line with 
these data, our own study, by using a relatively low dose of THC more comparable to 
human dosing, demonstrated working memory impairment as evidenced by reversal 
deficit. Indeed, as illustrated by our data, instead of promoting perseveration 
responses (see below) THC appeared to alter the re-actualization of the information, 
this capacity of flexibility being one of the properties of working memory. 
The first probe trial carried out one hour after the last acquisition trial showed 
that all mice explored the target quadrant above chance level, confirming that they 
successfully learnt the spatial reference memory task. However, although the 
difference between Veh- and THC-treated animals is quite moderate, the significantly 
higher latency to the first platform crossing implies a less accurate spatial response in 
THC-treated mice. On the second probe trial at the end of the reversal on day 11, 
Veh-treated animals spent more time in the new target quadrant than THC-treated 
animals, and above chance level. This illustrates that Veh-treated animals were again 
learning the new location of the platform faster than THC-treated mice. This further 
strengthens our interpretation that THC impaired behavioural flexibility in this model. 
As THC-treated animals did not learn the new platform location this deficit in reversal 
might be due to an increased perseverance of the animals in returning to the 
previously learnt platform location. However our results showed that THC-treated 
animals that spent less time in the new target quadrant did not spend more time in the 
former target quadrant. Therefore, THC-induced deficits in reversal learning are most 
likely explained by a specific deficit in learning the new platform location.  
Interestingly during both the reference memory and the reversal tasks, no 
difference was observed between THC-treated PT and NPT animals, showing no 
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differential effect of the pre-treatment on learning. With repeated administration, 
tolerance to the effects of cannabinoids such as locomotor suppression or hypothermia 
develops rapidly (Oliva et al., 2003), however effects on memory impairment appear 
to be more resistant to the development of tolerance (for a review see Gonzalez et al., 
2005). We analysed the effect of repeated THC exposure on locomotor activity and 
observed that animals developed, tolerance to the locomotor suppressant effects of 
1mg/kg THC after 5 days of treatment. Thus, THC-induced deficits on reference 
memory cannot be related to the sedative effects of cannabinoids, as NPT and PT 
animals exhibited the same level of performance on day 1 of acquisition. In 
conjunction with the absence of effects of the drug on swim speed, this strengthens 
the interpretation that this relatively low dose of THC promoted a specific memory 
deficit. 
While the acute effects of cannabinoids on memory are widely reported, the 
effects of long term cannabinoid exposure have received less attention. Interestingly, 
the memory deficits observed during the reversal phase were independent of whether 
the animals received 13 days of pre-treatment prior to the beginning of the acquisition 
or not. This suggests that even after 24 days of treatment for the PT group and 11 days 
of treatment for the NPT group, THC was still effective in impairing memory. To our 
knowledge, the present study is the first to report the absence of development of 
tolerance to cannabinoid-induced working memory impairments in mice. These 
results are consistent with studies using rats reporting that THC administered at 5 
mg/kg impaired working memory in the radial arm maze even after 90 days of 
administration 6 days per week (Nakamura et al., 1991). A 2-weeks pre-treatment 
with the same dose of THC injected twice daily did not modify the effect of a 
challenging dose of 2.5 mg/kg THC on impairment of correct alternation task in the 
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T-maze showing that animals did not develop tolerance to working memory deficits 
(Nava et al., 2001). The spatial working memory impairments observed with 2 and 5 
mg/kg THC-rich extracts were also observed over months of dosing with brief periods 
of washout (Fadda et al., 2004). When tolerance was observed, it only appeared after 
30 days of exposure to relatively high doses of both THC (10 mg/kg) and the 
cannabinoid receptor agonist WIN 55,212-2 in delayed-match-to-sample and delayed-
non match-to-sample tasks, respectively (Deadwyler et al., 1995, Hampson et al., 
2003). Thus consistent with previous studies, the results from the present study show 
that memory impairments promoted by THC, even at such a relatively low dose, are 
resistant to the development of tolerance. It would be interesting to examine if 
tolerance could be observed to the memory impairing effects with such a low dose of 
THC and how many days of administration beyond the 24 days examined here, would 
be required. 
In NPT mice, THC decreased zif268 expression in hippocampal CA3 and to a 
lesser extent in the CA1, which is consistent with the view that the hippocampus 
mediates the memory impairing effects of cannabinoids (Lichtman et al., 1995, 
Misner and Sullivan, 1999, Hampson and Deadwyler, 2000, Egashira et al., 2002). 
Interestingly, THC exposure also reduced the expression of zif268 in the prefrontal 
cortex. This region is another site thought to participate in cannabinoid-induced 
spatial memory impairment. For example, direct administration of THC into the 
medial prefrontal cortex has been shown to disrupt spatial working memory (Silva de 
Melo et al., 2005). Further, repeated THC administration in rats caused a persistent 
reduction in medial prefrontal cortical dopamine turnover which was assumed to 
subserve in part the cognitive dysfunction observed in these animals (Verrico et al., 
2003). Because memory processes are dependent on synaptic plasticity in the 
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hippocampus and prefrontal cortex (Laroche et al., 2000, Riedel and Davies, 2005), 
these results suggest that the THC-induced impairment of working memory observed 
here could be mediated by a decreased neuronal plasticity in both the hippocampus 
and prefrontal cortex as measured by zif268. 
The decreased zif268 expression in the hippocampus and prefrontal cortex in 
NPT animals vanished in PT animals, although the latter did exhibit cognitive 
impairments which were sometimes even more marked as assessed by the probe tests 
(Fig. 5). These results suggest that between 11 and 24 days of treatment, some cellular 
and molecular determinants of tolerance began developing which are dissociable from 
the memory impairing effect of THC. Interestingly, 2 week chronic THC treatment 
did not produce tolerance to CB1-mediated inhibition of extracellular hippocampal 
acetylcholine and working memory, but there was a time-course difference between 
these two phenomena suggesting they might be dissociated (Nava et al., 2001).  
Similar to the effects of THC on the hippocampus and prefrontal cortex, THC 
also decreased zif268 expression in the dorsomedial and dorsolateral caudate putamen 
only in NPT animals. The dorsal striatum is not reported to be implicated in spatial 
memory (Egashira et al., 2002), but recent reports have emphasized a role of the 
medial striatum in behavioural flexibility (McDonald et al., 2008). The behavioural 
effects of THC on striatal function seem to fit better with this interpretation as the PT 
animals were tolerant to the locomotor suppressant effect of THC at the time of 
testing and no deficits were observed in the cued trials of the water maze task, a task 
supposed to be mediated by the caudate putamen (Packard and Teather, 1998).  
The present study examined for the first time the effects of repeated 
cannabinoid exposure on zif268 expression in the mouse forebrain. In prior in situ 
hybridisation studies, acute cannabinoid receptor agonist exposure increased the 
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expression of zif268 mRNA in the CA1 and CA3 regions of the hippocampus 
(Derkinderen et al., 2003), cingulate cortex, fronto-parietal cortex and the caudate-
putamen (Mailleux et al., 1994). Consistent with this, (Glass and Dragunow, 1995) 
showed in an immunohistochemical study that acute administration of a high dose of 
CP 55,940 (2.5 mg/kg) significantly increased zif268 in the striatum (CP 55,940 is 
approximately 30 times as potent as THC, see (Arnold et al., 2001a, Arnold et al., 
2001b). Given that acutely cannabinoids induce zif268 expression, the decreased 
zif268-labelled cells we observed here indicates that zif268 expression is inversely 
regulated by repeated cannabinoid exposure. Indeed, such a phenomenon has been 
reported for the psychostimulant drug, cocaine. Acutely cocaine increased zif268 
expression in the rat forebrain, however with repeated administration it decreased 
basal zif268 expression (Bhat et al., 1992).  
In conclusion, this study showed that repeated cannabinoid exposure induced 
persistent memory deficits which are resistant to tolerance and may be, at least 
initially, regulated by diminished expression of the transcription factor zif268.  
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FIGURES AND LEGENDS 
 
Figure 1. Protocol 
 
 
 
 
Figure 2. Cued trials. 
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Figure 3. Spatial memory. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Reversal. 
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Figure 5. Probe trials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Locomotor activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
P2 TQ1 P2 newTQ
0
5
10
15
20
25
30
35
Ti
m
e 
in
 Q
ua
dr
an
t (
s)
P1 TQ1
PT THC
NPT THC
PT Veh
NPT Veh
*
Ti
m
e 
in
 Q
ua
dr
an
t (
s)
B 
Fi
rs
t p
la
tfo
rm
cr
os
si
ng
(s
)
0
10
20
30
40
50
Probe test 1 Probe test 2
*
*
Fi
rs
t p
la
tfo
rm
cr
os
si
ng
(s
)
Fi
rs
t p
la
tfo
rm
cr
os
si
ng
(s
)
0
50
100
150
200
250
300
Day
Lo
co
m
ot
or
ac
tiv
ity
un
its
1 2 3 4 5 6 70
Veh
THC
no treatment
**
*
*
Lo
co
m
ot
or
ac
tiv
ity
un
its
Lo
co
m
ot
or
ac
tiv
ity
un
its
Chapter 8: Appendix 
 
180 
Figure 7. Zif268 immunohistochemistry. 
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LEGENDS. 
 
Figure 1. Animals were separated in 2 groups: non pre-treated (NPT) mice were 
administered with Veh or THC (1 mg/kg) during the behavioural testing phase in the 
water maze (n = 12 per group). Pre-treated (PT) animals were administered Veh or 
THC (1 mg/kg) for 13 days before the behavioural testing phase and, like the NPT 
group, until the end of the experiment (n = 12 per group). The behavioural testing 
phase consisted in 9 days of acquisition of the spatial reference memory task where 
the location of the platform remained constant, followed by 2 days of reversal where 
the location of the platform was changed. Animals were also tested in the first probe 
trial (P1) at the end of the acquisition on day 9, and for the second probe trial (P2) at 
the end of the reversal on day 11.  
 
Figure 2. Escape latency in the 2 cued trials prior to the beginning of the acquisition 
on the first day of the behavioural testing phase in animals (n = 12 per group) pre-
treated (PT) or non pre-treated (NPT) with either Veh or THC (1 mg/kg). Data are 
presented as means ± SEM. 
 
Fig. 3. Escape latency for each session (4 trials per day) of acquisition of the spatial 
memory task (day 1-9) and reversal of the platform location (day 10-11) in animals (n 
= 12 per group) pre-treated (PT) or non pre-treated (NPT) with either Veh or THC (1 
mg/kg). Data are presented as means ± SEM. 
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Figure 4. Detail of the 4 trials of the 2 sessions of reversal in animals (n = 12 per 
group) pre-treated (PT) or non pre-treated (NPT) with either Veh or THC (1 mg/kg). 
Data are presented as means ± SEM. 
 
Figure 5. A) Time spent in the different target quadrants (TQ) during the 2 probe 
trials. The first probe (P1) occurred 1h after the end of the acquisition (i.e. on day 9) 
and the second probe (P2) occurred 1h after the end of the reversal (i.e. on day 11). B) 
Latency to cross the platform location for the first time in animals (n = 12) pre-treated 
(PT) or non pre-treated (NPT) with either Veh or THC (1 mg/kg). Data are presented 
as means ± SEM. (Means ± SEM). Significant effects are indicated by Ë (P < 0.05). 
The doted line represents chance level. 
 
Figure 6. Tolerance to locomotor activity in animals (n = 5-6) treated with Veh or 
THC (1 mg/kg). Data are presented as means ± SEM. Significant effects are indicated 
by Ë (P < 0.05) and ËË (P < 0.01). 
 
Figure 7. Number of zif268 immunopositive cells in (A) CA1 and (B) CA3 of the 
hippocampus, (C) the prefrontal cortex (PFCx) and (D) the dorsomedial (DM) and (E) 
the dorsolateral (DL) caudate putamen (CPU) in animals (n = 6 per group) were pre-
treated (PT) or non pre-treated (NPT) with either Veh or THC (1 mg/kg). Animals 
from “Quiet cont” group did not receive any injection and were not trained (n = 6). 
Data are presented as means ± SEM. Significant effects are indicated by Ë (P < 0.05), 
ËË (P < 0.01) and ËËË (P < 0.001). 
 
  
 
 
